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ABSTRACT 
 
In hypertrophic cardiomyopathy (HCM), an autosomal dominant disorder, hypertrophy is variable 
within and between families carrying the same causal mutation, suggesting a role for modifier genes. 
Associations between left ventricular hypertrophy and left ventricular pressure overload suggested 
that sequence variants in genes involved in the Renin-Angiotensin Aldosterone System (RAAS) may 
act as hypertrophy modifiers in HCM, but some of these studies may have been confounded by, 
amongst other things, lack of adjustment for hypertrophy covariates. 
 
To investigate this hypothesis, twenty one polymorphic loci spread across six genes (ACE1, AGT, 
AGTR1, CYP11B2, CMA and ACE2) of the RAAS were genotyped in 353 subjects from 22 South 
African HCM-families, in which founder mutations segregate. Genotypes were compared to 17 
echocardiographically-derived hypertrophic indices of left ventricular wall thickness at 16 segments 
covering three longitudinal levels. Family-based association was performed by quantitative 
transmission disequilibrium testing (QTDT), and mixed effects models to analyse the X-linked gene 
ACE2, with concurrent adjustment for hypertrophy covariates (age, sex, systolic blood pressure (BP), 
diastolic BP, body surface area, heart rate and mutation status). 
 
Strong evidence of linkage in the absence of association was detected between polymorphisms at 
ACE1 and posterior and anterior wall thickness (PW and AW, respectively) at the papillary muscle 
level (pap) and apex level (apx). In single-locus analysis, statistically significant associations were 
generated between the CYP11B2 rs3097 polymorphism and PW at the mitral valve level (mit) and 
both PWpap and inferior wall thickness (IW)pap. Statistically significant associations were 
generated at three AGTR1 polymorphisms, namely, between rs2640539 and AWmit, rs 3772627 and 
anterior interventricular septum thickness at pap and rs5182 and both IWpap and AWapx. 
Furthermore, mixed effects model detected statistically significant association between the ACE2 
rs879922 polymorphism and both posterior interventricular septum thickness and lateral wall 
thickness at mit in females only. 
 
These data indicate a role for RAAS gene variants, independent of hypertrophy covariates, in 
modifying the phenotypic expression of hypertrophy in HCM-affected individuals. 
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OPSOMMING 
Hipertrofiese kardiomiopatie (HCM), ‘n autosomale dominante afwyking, toon hoogs variërende 
hipertrofie binne en tussen families wat dieselfde siekte-veroorsakende mutasie het, hierdie dui op 
die moontlike betrokkenheid van geassosieerde modifiserende gene. Assosiasies tussen linker 
ventrikulêre hipertrofie en linker ventrikulêre druk-oorlading stel voor dat volgorde variasies in gene 
betrokke in die Renin-Angiotensin Aldosteroon Sisteem (RAAS) mag optree as hipertrofie 
modifiseerders in HCM. Sommige van hierdie soort studies is egter beperk omdat hulle nie 
gekompenseer het vir kovariante van hipertrofie nie. 
 
Om hierdie hipotese te ondersoek, is die genotipe bepaal by een-en-twintig polimorfiese lokusse, 
verspreid regoor ses RAAS gene (ACE1, AGT, AGTR1, CYP11B2, CMA and ACE2), in 353 
kandidate vanuit 22 Suid-Afrikaanse HCM-families in wie stigter mutasies segregeer. Genotipes was 
vergelyk met 17 eggokardiografies afgeleide hipertrofiese indekse van linker ventrikulêre wanddikte 
by 16 segmente wat oor drie longitudinale vlakke strek. Familie-gebaseerde assosiasies was 
bestudeer deur kwantitatiewe transmissie disequilibrium toetsing (QTDT) en gemengde effek 
modelle om die X-gekoppelde geen ACE2 te analiseer, met gelyktydige kompensasie vir hipertrofie 
kovariate (ouderdom, geslag, sistoliese bloed druk (BP), diastoliese BP, liggaamsoppervlak area, 
hartritme en mutasie-status).  
 
Sterk indikasies van koppeling in die afwesigheid van assosiasie is waargeneem tussen ACE1 
lokusse en posterior wanddikte (PW) asook anterior wanddikte (AW) by die papillêre spier vlak 
(pap) en die apeks vlak (apx). In enkel-lokus analises is statisties-betekenisvolle assosiasies gevind 
tussen die CYP11B2 rs3097 polimorfisme en PW by die mitraalklep vlak (mit) en beide die PWpap 
en inferior wanddikte (IW)pap. Statisties-betekenisvolle assosiasies was verder gevind by drie 
AGTR1 polimorfismes, naamlik, tussen rs2640539 polimorfisme en AWmit, rs3772627 en die 
anterior interventrikulêre septumdikte (aIVS) by die pap en rs5182 by beide die IWpap en AWapx. 
Gemengde-effek modelle het verder assosiasies aangetoon tussen die ACE2 rs879922 polimorfisme 
en die posterior interventrikulêre septumdikte en die laterale wanddikte by die mit, slegs in vrouens. 
 
Hierdie data dui op ‘n kovariaat-onafhanklike rol vir RAAS genetiese variante in die modifisering 
van die fenotipiese uitdrukking van hipertrofie in HCM-geaffekteerde individue.      
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CHAPTER 1 
1. Introduction: 
1.1. Left ventricular hypertrophy (LVH) 
Left ventricular hypertrophy (LVH) is a condition recognised echocardiographically by 
an increase in left ventricle mass, marked thickening of the interventricular septum (IVS) 
and the posterior wall of the left ventricle (LV) (figure 1.1) (Czubryt and Olson, 2004). 
Heart muscle overgrowth is considered to be the major predictor of morbidity and 
mortality, secondary to age (Levy et al., 1990). Levy et al., (1988) and Koren et al., 
(1991) implicated LVH as being a precursor of morbidity and mortality, and noted its 
frequent occurrence in older people and individuals with hypertension, obesity, 
myocardial infarction (MI) and valve diseases. Furthermore, it has been shown that LVH 
acts independently of other cardiovascular risk factors such as smoking and 
hypercholesterolaemia (Koren et al., 1991; Ghali et al., 1992).  
 
Left ventricular hypertrophy is associated with many common complex and some rarer 
inherited disease states. Previous tenets suggested that LVH is a result of left ventricular 
pressure overload (Grossman et al., 1975; Ganau et al., 1992). However, it has been 
observed that the degree of LVH and blood pressure (BP) do not show a positive 
correlation (Grossman et al., 1975; Drayer et al., 1983). In addition, it has been 
demonstrated that some individuals with LVH have normal BP, suggesting that factors 
other than haemodynamic overload may play a role in hypertrophy development (Levy et 
al., 1988). Additionally, not all hypertrophy is harmful and two forms have been 
recognised, pathological hypertrophy and physiological hypertrophy, such as occurs in 
“athlete’s heart” in response to exercise, and these conditions have been shown to differ 
from one another (Granger et al., 1985). 
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Figure 1.1: Cross section through a hypertrophied heart showing the relationship between 
interventricular septum thickness and left ventricle size. Reproduced from http://www-
medlib.med.utah.edu/WebPath/CVHTML/CV169.html 
 
1.2 Hypertrophic cardiomyopathy (HCM) 
One of the inherited heart diseases in which LVH occurs, is hypertrophic cardiomyopathy 
(HCM), an inherited heart muscle disease; in turn, HCM serves as a model to elucidate 
the molecular mechanisms involved in hypertrophy development within susceptible 
individuals (Moolman et al., 1997). At the molecular level, HCM is considered to be a 
disease of the sarcomere (Moolman-Smook et al., 2003). The hypertrophy which is the 
hallmark of HCM mostly affects the IVS and the LV, although right ventricular 
hypertrophy also occurs (Wigle et al., 2001). At the clinical level, the disease is 
characterised by arrhythmias, impaired exercise tolerance and sudden cardiac death 
(SCD) in young individuals under the age of 35 years old (Denfield and Garson, 1990).  
 
The pathological hypertrophy observed in HCM is associated with decreased muscle 
compliance due to defective sarcomere functioning and/or structure (Wigle et al., 1995). 
Additionally, the tissue pathology of hypertrophied hearts differs between HCM and 
exercise-induced hearts (Gregory et al., 1983; Brink et al., 1996). HCM is classified at 
histological level by myofibrillar disarray and interstitial fibrosis (Davies et al., 1984; 
Tanaka et al., 1986).  
 
Left ventricle 
Interventricular septum  
Interventricular septum 
wall thickness ≥ 13mm 
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The patterns of LVH found in HCM patients are either concentric or asymmetric and vary 
in extent from apical to basal regions of the LV (Wigle et al., 1985). Typical (classical) 
HCM, characterised by asymmetrical hypertrophy, occurs more frequently in HCM 
patients than apical hypertrophy and most often affects the IVS and, to some extent, the 
posterior walls of the LV, resulting in a narrow outflow tract (Wigle et al., 1995). Apical 
HCM is characterised by a spade-shaped ventricular cavity and is said to be a genetically 
and clinically different form of HCM because familial occurrence of apical HCM is rare 
and it is associated with a good clinical prognosis (Wigle et al., 1995). Hypertrophy in 
HCM in general varies in a range from none or minimal (less than 11mm in adults being 
termed normal), to massive hypertrophy (the latter defined as maximum ventricular wall 
thickness of 35mm or more in adults), which is adjusted for age in children (Spirito et al., 
1997).  
 
The physical examination for HCM may or may not reveal physical signs of cardiac 
hypertrophy (e.g., pressure loaded apex beat, fourth heart sound) nor  signs of obstruction 
(e.g., jerky pulse, ejection systolic murmur which varies on squatting or Valsalva 
manoeuvre), if hypertrophic obstructive cardiomyopathy is present (in ~ 20% of cases). 
The electrocardiographic and echocardiographic abnormalities are found on a special 
examination for electrical changes in the heart rhythm and measurement of the extent and 
localisation of hypertrophy by means of a two-dimensional echocardiography (2D-echo). 
Both techniques are considered compulsory for effective diagnosis, with each procedure 
having its own advantages and disadvantages. For diagnosis of HCM in adults, an 2D-
echo measurement of the left ventricular wall thickness (LVWT) having a value of equal 
or greater than 13mm is considered clinically affected, while values of LVWT between 
11mm and 13mm are considered clinically equivocal (Maron et al., 1981). According to 
Spirito et al., (1994) and Maron et al., (1995), a value of 13mm is a good indicator of 
HCM, considering endurance athletes rarely exceed this level. However, 2D-echo is 
unable to detect HCM in pre-pubescent children and at all ages misdiagnosis is a 
possibility because hypertrophy could be acquired due to other causes (Bachinski and 
Roberts, 1996). 
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To accurately capture the extent and localisation of hypertrophy within the myocardium, 
three composite hypertrophy-score measures have been advocated. The first scoring 
system used for quantitative evaluation of the extent of LVH is the semi-quantitative 
point score method (ranges 0 to 10) developed by Wigle et al., (1985), because maximum 
left ventricular wall thickness measured by 2D-echo may not truly reflect the extent of 
hypertrophy, or involvement of the distal (apical) half of the septum or lateral walls. A 
maximum of 10 points is given; 1 to 4 points for septal hypertrophy based on magnitude 
of thickness, 2 points for extension of hypertrophy beyond the level of the papillary 
muscles (basal two thirds of the septum), 2 points for extension of hypertrophy to the 
apex (total septal involvement), and 2 points for extension of hypertrophy into the lateral 
wall.  
 
The extent of hypertrophy is quantified by a second score method the Spirito-Maron 
score (Spirito and Maron et al., 1990). This is calculated by dividing the LV into four 
regions, the anterior and posterior ventricular septum with the anterolateral and posterior 
left ventricular walls. The Spirito-Maron score is calculated by adding the measurements 
of maximum wall thickness (MWT) obtained in each of the four left ventricular regions. 
Maximal wall thickness is defined as the sum of the greatest wall thickness observed in 
the mitral valve level or papillary level of the short-axis planes in any of the four 
segments. 
  
The third quantitative hypertrophy score more recently proposed by Forissier et al., 
(2005) is the two-dimensional left ventricular hypertrophy score (2-DLVH), a 
determination of the sum of the MWT obtained in the four regions of the LV. The 
segments correspond to the anterior, posterior ventricular septum and the anterolateral 
and posterior left ventricular free walls. Additionally, Forissier et al., (2005) validated the 
2-DLVH score as having a higher diagnostic value for familial HCM screening than the 
conventional criteria of MWT suggested by Charron et al., (1997), particularly in young 
adolescents. Even though, the 2-DLVH score was measured, it was not considered a 
parameter in the present study, because it has not been verified in hypertrophy score-
derived studies. 
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1.2.1. Molecular genetics of HCM 
The prevalence of HCM within the population of the United States of America (USA) is 
estimated to be 1 in 500 individuals (Maron et al., 1984) but its prevalence has not been 
reported in the South African population. Numerous investigations have indicated that 
HCM may be either sporadic or inherited and it appears that each form represents 
approximately 50% of the cases (Maron et al., 1984). Familial hypertrophic 
cardiomyopathy (FHCM) is a genetically heterogeneous disease, inherited in an 
autosomal dominant pattern. However, a proportion of the HCM cases are probably 
caused by de novo germline mutations and thus affected individuals could transmit the 
disease to their offspring (i.e. FHCM) (reviewed by Maron et al., 2002). Presently, more 
than 400 different HCM-causative mutations have been identified in 14 different genes, 
11 of the genes encoding sarcomeric proteins (figure 1.2) (Ho and Seidman et al, 2006).  
 
A hallmark of HCM is clinical heterogeneity, a phenomenon manifesting amongst 
individuals of both the same and/or different families (intrafamilial and interfamilial 
variability), respectively (Epstein et al., 1992a; Epstein et al., 1992b; Fananapazir and 
Epstein, 1994; Posen et al., 1995; Moolman et al., 1997). This clinical variability ranges 
from asymptomatic to severe forms of hypertrophy with a high risk of SCD, and is 
associated with different symptoms such as shortness of breath, angina, presyncope, 
syncope, mitral valve regurgitation and arrhythmias (Brachfeld and Gorlin et al., 1959; 
Brent et al., 1960).  
 
Molecular genetic studies have facilitated the identification of four prevalent FHC-
causative genes, which code for β-myosin heavy chain (MYH7) on chromosome 14q12, 
cardiac troponin T (TNNT2) on chromosome 1q32, α-tropomyosin (TPM1) on 
chromosome 15q2 and cardiac myosin binding protein C (cardiac MYBPC3) on 
chromosome 11q11 (Geisterfer-Lowrance et al., 1990; Thierfelder et al., 1994; Bonne et 
al., 1995; Watkins et al., 1995). 
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Figure 1.2: Diagrammatic representation of the sarcomere showing sarcomeric proteins in which 
the majority of HCM-causing mutations have been described (the myosin light chain is present 
but not indicated is its two forms, namely, myosin essential light chain and myosin regulatory 
light chain and not indicated is α-myosin heavy chain and titin). Taken from Spirito et al., 1997.  
 
In 1995, Marian and Roberts suggested that a small proportion of unknown genes, in 
which mutations could cause HCM, excluding the known genes with mutations that 
account for 50-70% of all FHCM related cases, may still exist. Other less prevalent 
HCM-causative genes identified to date are ACTC, TNNI3, MYL3, MYL2, MYH6, TNNC1 
and TTN. These genes encode the sarcomeric proteins cardiac actin, troponin I, myosin 
essential light chain (MELC), myosin regulatory light chain (MRLC), α-myosin heavy 
chain, cardiac troponin C and titin, respectively (Poetter et al., 1996; Kimura et al., 1997; 
Mogensen et al., 1999; Satoh et al., 1999). Additionally, the PRKAG2 that encodes the 
2–subunit of a non-sarcomeric protein, 5’-AMP-activated protein kinase (AMPK), was 
found to cause HCM associated with Wolf-Parkinson-White syndrome (WPW) (Gollob 
et al., 2001; Arad et al., 2002). Subsequently, two additional non-sarcomeric proteins, 
namely, muscle LIM protein and X-linked lysosome-associated membrane protein, 
encoded by CRP3 and LAMP2, respectively, were identified as containing HCM-
causative mutations (Schmitt et al., 2003b). Listed in table 1.1 are the known sarcomeric 
and non-sarcomeric genes in which HCM-causative mutations have been described. 
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Table 1.1: HCM-causative genes, chromosomal loci and their sub-cellular localisation. 
Causative gene Locus Sub-cellular localisation Reference 
MYH7 14q12 sarcomere 1 
MYH6 14q13 sarcomere 2 
MYBPC3 11p11 sarcomere 3 
TNNT2 1q32 sarcomere 4 
TNNI3 19q13 sarcomere 5 
TNNC1 3p21 sarcomere 6 
TPM1 15q22 sarcomere 4 
MYL2 12q23-q24 sarcomere 7 
MYL3 3p21 sarcomere 7 
ACTC 15q14 sarcomere 8 
TTN 2q31 sarcomere 9 
CRP3 11p15 non-sarcomere 10 
PRKAG2 7q36 non-sarcomere 11 
LAMP2 X non-sarcomere 12 
Abbreviations:   MYH7- cardiac β-myosin heavy chain gene; MYH6 - cardiac α-myosin heavy 
chain gene; MYBPC3 - cardiac myosin binding protein C gene; TNNT2 - cardiac troponin T 
gene; TNNI3 - cardiac troponin I; TNNC1 - cardiac troponin C; TPM1 - cardiac tropomyosin 
gene; MYL2 - ventricular myosin regulatory light chain; MYL3 – myosin essential light chain; 
ACTC - cardiac actin; TTN - titin; CRP3 - cardiac muscle lim protein gene; PRKAG2 - 5’-AMP-
activated protein kinase, gamma-2 subunit gene; LAMP2 - linked lysosome-associated membrane 
protein. References: 1) Geisterfer-Lowrance et al., 1990, Vikstrom and Leinwand, 1996; 2) 
Niimura et al., 2002; 3) Bonne et al., 1995, Watkins et al., 1995; 4) Thierfelder et al., 1994; 5) 
Kimura et al., 1997; 6) Hoffmann et al., 2001; 7) Poetter et al., 1996; 8) Olson et al., 2000; 9) 
Satoh et al., 1999; 10) Geier et al., 2003; 11) Blair et al., 2001, Gollob et al., 2001 and Arad et al., 
2002; 12) Arad et al., 2005. 
 
 
Worldwide, it has been calculated that three predominant FHC-causing genes, MYH7, 
MYBPC3 and TNNT2, account for ~70 % of FHC cases, subdivided into ~35% caused by 
mutations in  MYH7, ~20% caused by mutations in MYBPC3, ~15% caused by mutations 
in TNNT2, an additional ~3% is due to mutations in TPM1 (Watkins et al., 1995). In 
South Africa (SA), unlike the rest of the world, where unique private mutations, each 
having an independent origin, are the “rule”, molecular genetic studies identified unique 
founder mutations, two in MYH7 (Ala797Thr and Arg403Trp) and one in TNNT2 
(Arg92Trp), each accounting for 25%, 5% and 11% of HCM cases, respectively 
(Moolman-Smook et al., 2000). The identical-by-descent (IBD) origin of these HCM 
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mutations, indicating that individuals harbour the same disease-causing mutation 
inherited from a common ancestor, was confirmed by haplotype analysis (Moolman-
Smook et al., 1999). 
 
1.2.2. Clinical variability in HCM 
Initially, Watkins et al., (1992) and Fananapazir et al., (1994) reported a correlation 
between phenotypic expression of HCM and specific mutations in MYH7. It has also been 
demonstrated that mutations in MYH7, TNNT2 and MYBPC3 are associated with varying 
degrees of penetrance, in terms of the extent and distribution of hypertrophy and the 
occurrence of SCD, which is variable amongst HCM-mutation carriers (Posen et al., 
1995; Watkins et al., 1995; Moolman et al., 1997). Furthermore, Watkins et al., (1995) 
and Moolman et al., (1997) suggested that the position of the mutation within a gene 
affects the phenotype, as discussed in the following paragraphs.  
 
Missense mutations in MYH7 such as Arg403Gln, Arg453Cys and Arg719Trp are 
associated with variable risk of SCD and overt hypertrophy, while a missense mutation in 
TNNT2 (Arg92Trp) is associated with a high frequency of SCD with subtle to 
undetectable hypertrophy (see figures 1.3 and 1.4). In contrast, several protein truncation 
mutations in MYBPC3 (intervening sequence intron (IVS7) +1G>A, IVS20 -2A>G and 
IVS27 +1G>A) is associated with a broad spectrum of HCM phenotypes, including life-
threatening arrhythmias present in affected individuals (Erdmann et al., 2001). Missense 
mutations, insertion/deletion and splice junction mutations in MYBPC3 account for 
approximately 20% to 25% of all HCM cases (Erdmann et al., 2001). For individuals 
with MYBPC3 missense mutations, the prognosis is favourable with a late onset of 
disease (Charron et al., 1998; Niimura et al., 1998), while individuals with frameshifts 
and deletion mutations present a more severe phenotype with a high risk of SCD 
(Erdmann et al., 2001). 
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Figure 1.3: Comparison of the degree of hypertrophy (left ventricular wall thickness) in family 
members with single distinct HCM-causing mutations in different sarcomeric protein coding 
genes (compiled from the data of Watkins et al., 1995 and Moolman et al., 1997). Abbreviations 
used: LVWT - left ventricular wall thickness, mm - millimetres, TnT - troponin T, βMHC - β-
myosin heavy chain and MYBPC - myosin binding protein C. The clinical diagnostic criteria for 
HCM mutation carriers was measured for a maximum left ventricular wall thickness (MLVWT) ≥ 
13mm [indicated by bold red line]. Above and on the line were considered as clinically affected 
and below unaffected. 
 
Previous views recognised TNNT2 mutations as being associated with relatively mild 
hypertrophy in diseased individuals with high SCD (Watkins et al., 1995; Moolman et al., 
1997). However, the TNNT2 missense mutation Phe110Glu segregating in Japanese 
families is associated with a benign form of hypertrophy with no incidence of SCD 
(Watkins et al., 1995; Anan et al., 1998). Furthermore, the supporting evidence of 
molecular genetic studies revealed that, in some cases, a quarter of genetically-positive 
individuals showed no clinical symptoms of disease (Dausse et al., 1993; Carrier et al., 
1997). These findings suggest that the variability of phenotype within and amongst HCM 
families harbouring the same mutation is indicative of possible multifactorial contributors 
to disease presentation and that the inheritance pattern in HCM is not purely a monogenic 
disease. 
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Figure 1.4: Kaplan-Meier survival curves 
These curves demonstrate the probability of a male or female person, belonging to a family in 
which a distinct HCM-causing founder mutation is segregating, being alive at a given age. 
Abbreviations used: m - male, f - female, R403W - Arg403Trp in MYH7, R92W - Arg92Trp in 
TNNT2, A797T - Ala797Thr in MYH7. 
 
 
1.3. Candidate gene modifiers        
1.3.1. Establishing the role of genetic modifiers of clinical phenotypes 
As discussed in the preceding sections, phenotypic variability is a prominent feature of 
HCM, even among individuals of the same family harboring the same disease-causative 
mutation (Watkins et al., 1995; Moolman et al., 1997). It has been suggested that 
phenotypic variability is caused by genetic background and/or environmental factors, 
which together, or separately, may influence disease expression (Patel et al., 2000). For 
example, Fananapazir and Epstein et al., (1994) demonstrated that the MYH7 Arg403Gln 
mutation, that is generally associated with malignant HCM, exhibited a benign outcome 
in one Korean family. Similarly, two related individuals harboring the same TNNI3 
Lys183 deletion mutation exhibited two distinct forms of HCM, namely, apical HCM and 
typical (classical) HCM (Kimura et al., 1997). Investigations of the heritability of cardiac 
size in monozygotic and dizygotic twin studies indicated that genetic background 
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contributes to the variability in cardiac size irrespective of other influences (Adams et al., 
1985). Subsequently, Schunkert et al., (1999a) used echocardiographic measurements to 
demonstrate that siblings of LVH subjects had a higher risk for LVH development than 
subjects who did not have a LVH-affected sibling.  
 
Genetic background has been shown to be a contributor to HCM phenotype demonstrated 
in transgenic animal models (Sebkhi et al., 1999; Semsarian et al., 2001). Moreover, the 
same group of Sebkhi and colleagues (1999) performed a whole genome linkage scan and 
identified regions on chromosome 3 in rats that independently co-segregate with LV 
weight (termed quantitative trait loci (QTL)) and which affect differences in LV mass 
(LVM) in two inbred normotensive rat strains. Additionally, Semsarian et al., (2001) 
illustrated that the variability in cardiac hypertrophy can be influenced by genetic 
background in α-MHC403/+ knockout inbred and outbred mouse models. The α-MHC403/+ 
missense mutation in mice is equivalent to the human MYH7 Arg403Trp mutation. They 
observed strain dependent differences in the degree of variability in cardiac hypertrophy 
and SCD irrespective of body weight and exercise (Semsarian et al., 2001). On the basis 
of these findings it can therefore be suggested that similar, unknown, QTLs could play a 
role in hypertrophy development in humans, either independently, or by influencing the 
phenotypic response to mutationally altered sarcomere proteins. 
 
1.3.2. Candidate gene modifiers of HCM phenotype 
Numerous studies performed in Caucasian individuals with HCM have assessed the role 
of several candidate genes as hypertrophy modifiers of the condition HCM (Table 1.2) 
(Ishanov et al., 1997). Many of these genes encode proteins that are components of the 
renin-angiotensin aldosterone system (RAAS), including angiotensin-1 converting 
enzyme encoded by ACE1, angiotensinogen encoded by AGT, angiotensin II type I 
receptor encoded by AGTR1, cardiac chymase encoded by CMA,  bradykinin B2 receptor 
encoded by BDKRB2 and aldosterone synthase encoded by CYP11B2 (Marian et al., 
1993; Pfeufer et al., 1996; Brugada et al., 1997; Yamada et al., 1997; Erdmann et al., 
1998; Patel et al., 2000). Other implicated genes include those that encode trophic factors, 
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namely, endothelin 1 (EDN1), tumor necrosis factor α (TNF-α) and insulin-like growth 
factor 2 (IGF2) (Brugada et al., 1997; Patel et al., 2000).  
 
Although some of the genes (ACE1, TNF-α, BDKRB2 and AGTR1) reported to be 
associated with hypertrophy maintained significant association in replication studies, only 
a minority account for the variability in the HCM phenotype (Marian et al., 2002). For 
example, in one study only the uncommon A-allele of the functional promoter region 
TNF-α-308 G/A polymorphism was found to be associated with increased LVH in HCM 
patients when compared to other functional variants of the candidate modifier genes 
transforming growth factor-β1 (TGFβ1), CYP11B2, interleukin-6 (IL6) and IGF-2 (Patel 
et al., 2000). These results suggests a role for TNF-α as a potential modifier gene for 
HCM (Patel et al., 2000). 
 
Previously, many of the candidate genes were considered as hypertrophy modifiers 
because of their regulatory role in control of BP and involvement in cell growth (Brugada 
et al., 1997; Patel et al., 2000). Additionally, ACE1 has been implicated as a potential 
modifier of HCM. The insertion/deletion (I/D) polymorphism has also been shown to be 
associated with various other cardiovascular diseases (CVD) (Perkins et al., 2005), and 
higher plasma ACE1 levels have been observed in HCM or hypertensive patients (Rigat 
et al., 1990; Lechin et al., 1995). The first observation was made by Marian et al., (1993), 
when they illustrated an association between the I/D polymorphism of ACE1 and the risk 
of SCD in HCM patients. Moreover, they observed that the DD genotype was more 
common in HCM families with a high incidence of SCD compared to other families with 
the II genotype (Marian et al., 1993). Subsequently, (Tesson et al., 1997) reported an 
association found between the DD genotype and cardiac hypertrophy expression, 
specifically in French and South African HCM individuals harbouring the MYH7 
Arg403Gln gene mutation.  
 
In summary, these data presented above only implicate ACE1 and TNF-α as genetic 
modifiers in replication studies in the development of inherited HCM. In the next section 
the RAAS will be discussed in more detail. 
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Table 1.2: Candidate modifier genes for hypertrophic cardiomyopathy (HCM). 
Gene Variants Study population Type of study Covariates Results References 
Tumour Necrosis Factor α -308 G/A HCM-affectees Case-only None -308A associated with LVH 1 
Insulin-like Growth Factor 2 820G/A HCM-affectees Case-only None No association found 1 
Transforming Growth Factor β -509C/T HCM-affectees Case-only None No association found 1 
HCM-affectees Case-only None 
Interleukin 6 -174G/C HCM-affectees Case-only None No association found 1 
Angiotensinogen M235T, T174M  and -6G/A HCM-affectees Case-only None -6 G/A no association 2 
Angiotensinogen M235T and T174M  HCM-affectees Case-control None No association found 3 
Endothelin 1 G8002A HCM-affectees Case-only None 8002A associated with LVH 2 
Aldosterone synthase -344C/T HCM-affectees Case-only None No association found 1 
Angiotensin II receptor 1 1166A/C HCM-affectees Case-only 
age, gender, two 
polymorphisms, peak 
LV outflow tract 
gradient and plasma 
renin concentration 
1166C associated with LVH 4 
Chymase A 1625G/A and -1903G/A HCM-affectees Case-control age and gender No association found 5 
Angiotensin-1 Converting Enzyme I/D HCM-affectees Case-only 
age, sex, weight, height, 
BSA, BMI and ACE1 
genotypes 
DD associated with LVH 6 
Angiotensin-1 Converting Enzyme I/D HCM-affectees family-based study None DD associated with LVH 7 
Bradykinin B2 receptor T21M and -412C/G CVD Case-control None 21M associated with HCM  8 
The genes underlined are involved in hypertension and hypertrophy. Reproduced and adapted from Marian et al., 2002. Abbreviation used: CVD – 
cardiovascular disease, I/D – insertion/deletion. References: 1) Patel et al., 2000; 2) Brugada et al., 1997; 3) Yamada et al., 1997; 4) Osterop et al., 
1998; 5) Pfeufer et al., 1996; 6) Lechin et al., 1995; 7) Tesson et al., 1997; 8) Erdmann et al., 1998.  
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1.4. Renin-Angiotensin Aldosterone System (RAAS) 
1.4.1. What is RAAS?  
The renin-angiotensin aldosterone system (RAAS) was previously considered to be an 
endocrine system that played an important role in regulation of BP, fluid balance and 
electrolyte homeostasis within the vasculature (Catt et al., 1970; Vane et al., 1974). 
However, subsequent evidence demonstrated that the RAAS is present and functional in a 
vast number of tissues such as the brain (Ganten et al., 1984), kidney (Deschepper et al., 
1986) and heart (Schelling et al., 1991). Thus, the concept of tissue-based RAAS 
emerged (Dzau et al., 1993). Two forms of the RAAS occur in the human body, namely, 
plasma and tissue, with both involved at multiple levels of synthesis  of angiotensin II 
(ANGII) (endocrine, autocrine and paracrine), which come into play during increased BP 
levels. One of the most important actions of the RAAS is its role in adaptive processes 
related to cardiac hypertrophy and angiogenesis (Dzau et al., 1993). The main effector 
peptide of this system is ANGII, which functions both as an autocrine and paracrine 
substance having vast effects on various glands and tissues. The two-enzyme cascade 
system regulated by angiotensin-converting enzyme (ACE1) and renin has been shown to 
play a substantial role in the pathogenesis of CVD (Campbell et al., 1987; Dzau et al., 
1993).  
 
In the first step of the system, angiotensin I (ANGI), an inactive decapeptide, is cleaved 
from the precursor substrate angiotensinogen (AGT) by renin. The second step involves 
the cleavage of ANGI by both ACE1 and cardiac chymase (CMA) to generate ANGII, an 
active vasoconstrictor peptide, and aldosterone-stimulating peptide via its binding to 
angiotensin II type 1 receptor (AGTRI); these interactions mediate downstream effects of 
ANGII (figure 1.5) (Urata et al., 1996).  
 
In the following paragraphs the key components involved in the RAAS cascade, namely, 
renin, AGT, ACE1, CMA, angiotensin converting enzyme 2 (ACE2) and aldosterone 
synthase (CYP11B2) will be discussed. 
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A critical component of the RAAS is AGT, an α-2 globulin produced in the liver that is 
the substrate involved in first step of the RAAS cascade (figure 1.5). AGT is also 
expressed in the brain, kidney, heart, vascular wall and adipose tissue (Campbell et al., 
1986 and 1987; Dzau et al., 1987 and 1989; de Mello and Danser et al., 2000). This 
substrate ultimately determines the amount of ANGII produced, irrespective of both renin 
concentration and/or ACE1 activity (Reid et al., 1978).  
 
In the second step of the cascade, renin, an aspartyl protease localised within the smooth 
muscle cell layer (in the vasculature) is biosynthesised in, and released from, the 
juxtaglomerular (JG) cells of the renal afferent arterioles (figure 1.5) (Higashimori et al., 
1991; Carey and Siragy, 2003). Renin is encoded by a single gene that translates renin 
mRNA into preprorenin that is subsequently cleaved and processed in the Golgi-
apparatus to active renin and released from JG cells. At the same time prorenin is 
released from the cell membrane and converted to active renin by a trypsin-like activating 
enzyme (Hsueh et al., 1991). Renin, the initiating enzyme of the tightly regulated RAAS 
cascade is involved in a rate-limiting step in the production of ANGI from AGT.  
 
A cascade enzyme, the dipeptidyl-carboxypeptidaseI/kinase II ecto-enzyme ACE1, has 
been found to be synthesised by adipose, cardiac and vascular tissue (figure 1.5) (Cooper 
et al., 1997; Baker et al., 1992). In humans, two forms of ACE1 are expressed, a somatic 
and germinal form. The somatic form is synthesised by adipose, cardiac and vascular 
tissue expressed on the surface of endothelial cells of lung vessels and various other cell 
types (monocytes, T lymphocytes and adipocytes); the germinal form is found 
exclusively in the testes (Fleming et al., 2006). ACE1, similar to renin, is a rate-limiting 
enzyme in the RAAS pathway, and hydrolyses ANGI to generate the effector peptide 
ANGII (figure 1.5) (Danser et al., 1992; Muller et al., 1998). 
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Another enzyme involved in the generation of ANGII, is CMA, a serine protease (figure 
1.5). CMA belongs to the chymotrypsin family of enzymes that are located within mast 
cells of various tissues of both human and animal species (Fleming et al., 2006). It is 
suggested that CMA is responsible for >80% of human heart and >60% of human artery 
ANGII formation (Petrie et al., 2001; Borland et al., 2005). ANGII has been implicated in 
the development of CVDs, particularly in cardiac hypertrophy and heart failure (Takai et 
al., 2004). Interestingly, ANG1-7, a heptapeptide fragment of ANGI generated by ACE2, 
a monocarboxypeptidase, antagonises the actions of ANGII (Schiavone et al., 1988; 
Tipnis et al., 2000). Moreover, ANGII is able to increase BP, while ANG1-7 decreases 
BP in hypertensive animals and reduces vascular cell wall growth (Benter et al., 1995; 
Freeman et al., 1996).  
 
Aldosterone, a mineralocorticoid, is synthesised in the adrenal glomerulosa cells from 
cholesterol and occurs via the actions of four cytochrome P450 enzymes; cholesterol 
desmolase (CYP11A), 21-hydroxylase (CYP21), CYP11B2 (18-oxidase) and 3β-
hydroxysteroid dehydrogenase (3β-HSD) (figure 1.5) (Silvestre et al., 1998). Even 
though it is known that most of the circulating aldosterone is manufactured from 
cholesterol in the adrenal gland, the cardiac tissue in humans and rats has been shown to 
contain the molecular machinery for aldosterone synthesis and response, producing both 
the co-expressed receptors and 11-β-hydroxysteriod dehydrogenase enzyme (Lombes et 
al., 1995, Silvestre et al., 1998). Further evidence exists for aldosterone synthesis and 
release from cardiac tissue from the infarcted hearts of rats (Silvestre et al., 1999). 
Additionally, an experiment in cultured rat aortic smooth muscle cells demonstrated 
inhibition of vascular smooth muscle cell proliferation when aldosterone receptor 
antagonists were present, thus providing evidence for the role of aldosterone in 
controlling vasculature structure and function (Xiao et al., 2000).  
 
In summary, the RAAS which produces ANGII has been identified in cardiomyocytes, 
endothelial cells, as well as vascular smooth muscle cells (Fleming et al., 2006). Koch-
Weser et al., (1964) illustrated that both circulating and locally generated ANGII are able 
to induce vasoconstriction and chronotropic actions on the heart. Local RAAS, or tissue-
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based RAAS, has been found to be involved in both the maintenance of cardiovascular 
structure and repair. Evidence for this comes from experiments of in vivo gene transfer of 
ACE1 into uninjured rat carotid arteries (Morishita et al., 1994). The investigators 
observed vascular remodeling resulting in vascular hypertrophy independent of 
systematic and haemodynamic effects (Morishita et al., 1994). In addition, other reports 
demonstrated that overexpression of ACE1 results in morphological changes associated 
with atrial arrhythmias and sudden death (Xiao et al., 2004).  
 
1.4.2. RAAS and the cardiovascular system 
The role of RAAS components in the pathogenesis of CVD will be discussed in this 
section.  
 
ANGII 
The RAAS has become the focus of many cardiovascular studies, largely due to the 
trophic factor ANGII’s involvement in CVD. Schelling and colleagues (1991) observed 
that this effector peptide of the RAAS may be a potential growth factor triggering the 
chronic cardiovascular hypertrophy process. The effects exerted by ANGII are enhanced 
by the facilitation of noradrenaline release from the sympathetic nerve endings. ANGII 
induces various pathologies such as cardiac hypertrophy, inflammation and fibrosis in the 
heart by increasing endothelin-1, transforming growth factor (TGF-β), oxidative stress 
and cytokines (Bader et al., 2004).  
 
Additionally, using transgenic animal models, Schelling et al., (1991) demonstrated that 
mouse fibroblasts grew in a dosage-related manner promoted by ANGII. Several studies 
have shown trophic effects of ANGII in both vascular smooth muscle cells and cardiac 
myocytes (Naftilan 1989a and 1989b; Taubman et al., 1989). Several researchers have 
also shown that blocking the endothelin receptor with receptor specific antagonists 
reduces the release of ANGII and endothelin-1 in rat hearts in which hypertrophy would 
normally be induced due to haemodynamic overload and in mechanical stretch-induced 
cultured cardiomyocytes of neonatal rats pretreated with endothelin-1 receptor 
antagonists (Ito et al., 1994; Arai et al., 1995; Yamazaki et al., 1996). The 
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cardiomyocytes were stretched by plating them on culture dishes with stretch frames 
attached to a silicone dish. The stretch frame is designed to mechanically expand by 
turning a horizontal thumb screw, thus increasing the length of the dish (Komuro et al., 
1990). From Schelling and colleagues’ (1991) observations, it has been suggested that the 
next step forward will be to develop transgenic and knockout animal models to study the 
aberrant expression of local RAAS components (Stec et al., 1998; Bader et al., 2000; Lim 
et al., 2001; Patel et al., 2001). The above findings reveal the role of ANGII in promoting 
CVD in animal models. 
 
ACE1 and AGT transgenic animal models 
Schunkert et al., (1990) demonstrated a correlation between ACE1-activity and elevated 
mRNA levels in a study done in rats that developed LVH due to long term experimental 
aortic stenosis, generated by placing a metal clip on the ascending aorta via thoracic 
incision (termed aortic banding). Prior to the study of Schunkert et al., (1990), Linz and 
colleagues (1989) demonstrated that ACE1 inhibition induced the regression of cardiac 
hypertrophy in rats (Linz et al., 1989). Transgenic rat models created to overexpress 
ACE1 demonstrated no change in cardiac morphology unless they were subjected to 
pressure overload due to aortic banding (Tian et al., 2004). However, mice that 
exclusively overexpressed AGT, maintained normal BP levels but still developed 
hypertrophy (Mazzolai 1998).  
 
Summary of studies of the role of RAAS in CVD 
In summary, from these studies, it was evident that the RAAS plays an important role in 
the development of cardiac hypertrophy, prompting numerous investigations to identify 
new drug targets to interfere with ANGII formation and possibly other components of the 
system (Shirani et al., 2000; Spirito et al., 2000; Marian et al., 2002). 
 
1.4.3. Role of RAAS in Hypertension and LVH 
1.4.3.1 RAAS and Hypertension 
The RAAS is an important system known to be associated with the development of 
abnormally high BP in humans. Evidence to support its role in the development of high 
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BP is the excessive amounts of aldosterone production observed in hypertensive patients 
with adrenal hyperplasia and adenomas (Stowasser et al., 2001). Additional evidence for 
its pathophysiology is the active release of renin in renovascular hypertension (Laragh et 
al., 1986). However, it has been observed that within many hypertensive individuals the 
plasma renin activity (PRA) is normal (Folkow et al., 1982). Similarly, in essential 
hypertension (EHT) (which is defined as an increased BP of which the cause is unknown 
or undefined) of subjects who have a normal aldosterone concentration, the renin levels 
have also been shown to be normal, thus suggesting a downstream abnormality in the 
RAAS pathway, somewhere from AGT to aldosterone formation (Fisher et al., 1999).  
 
Conversely, hypertensive subjects of African ancestry showed a decreased PRA without 
changes in plasma aldosterone concentrations (Cohen et al., 1982). To determine if the 
low PRA was due to genetic variation within CYP11B2, three polymorphisms, -344C/T, 
Arg173Lys and an intron 2 conversion (IC), were investigated and found not to be 
associated with EHT in black Afro-Caribbean origin subjects from South-West London 
(Zhu et al., 2003). 
 
In both hypertensive parents and their offspring, increased plasma AGT concentrations 
have been observed (Watt et al., 1992). According to several investigators, BP often 
correlates with plasma AGT concentrations (Walker et al., 1979; Bennett et al., 1993; 
Bloem et al., 1995). Harrap et al., (1996) suggested that an elevated ANGII concentration 
predisposes an individual to develop hypertension. 
 
A substantial amount of evidence favours the role of the RAAS in hypertension. 
However, no single gene is considered to control the activity of this RAAS. This is 
supported by various studies using animal models each implicating a RAAS gene 
involved in control of BP (Rapp et al., 1989; Kim et al., 1995; Yu et al., 1998). For 
example, it has been found that in mice a reduction in BP was observed when the two 
isoforms of the ACE1 gene were totally inactivated by an insertional mutation within 
exon 14 (Krege et al., 1995). Although to date no monogenic form of hypertension exists 
that influences other components of the RAAS, investigators hypothesise that RAAS 
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gene variants might be important in the development of EHT (Tiago et al., 2002 and 
2003).  
 
In summary, the RAAS is involved at multiple molecular levels to regulate BP, however, 
gene variants that moderate RAAS activity are likely to affect BP and left ventricular 
wall size, which in turn, could have effects on phenotypic risk factors for CVD (Tiago et 
al., 2002). 
 
1.4.3.2. RAAS and LVH 
LVH is considered a major independent risk factor for CVD (Koren et al., 1991). The 
assumption was made on the basis of certain clinical characteristics observed in LVH 
patients, which included the presence of various pathologies such as cardiac fibrosis 
(Weber et al., 1994), apoptosis (Sharov et al., 1996) and impaired coronary 
haemodynamics (Marcus et al., 1981). However, the mechanisms that generate LVH in 
CVD patients are unclear, even though there remains a direct relationship between 
regression of LVH during treatment and reduction in cardiac events (Liebson and Serry, 
2000). According to Korner and Jennings (1998), LVH is due to increased BP, whereby 
the heart muscle compensates for increased cardiac load. However, there is a poor 
correlation between BP and cardiac mass (Korner and Jennings, 1998). Additionally, in 
patients undergoing antihypertensive treatment decreased BP does not always result in a 
similar reduction in left ventricle mass (LVM), although the prognosis is suggested to be 
better within these patients (Liebson and Serry, 2000). Several investigators observed 
unfavourable effects of regressing LVH within animal and human models, by failing to 
reduce LVM when treated with the antihypertensive drug, hydralazine (Fogari et al., 
1995; Norton et al., 1997; Yamazaki et al., 1999; Tsotetsi et al., 2001). 
 
These observations implied the presence of variability in LVM in hypertensive patients 
(Liebson and Serry, 2000) and indicate that factors independent of haemodynamic effects 
(BP) should also be examined as potential hypertrophy determinants.  
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As shown in cultured cells stimulated by ANGII, the RAAS mediates its effects on 
cardiac growth independently of its actions on BP and induces cardiomyocyte 
hypertrophy (Sadoshima and Izumo, 1993) through both reactive oxygen species 
(Takemoto et al., 2001) and calcineurin-dependent pathways (Olson and Molkentin, 
1999). In 11 patients (6 males and 5 females) with HCM and 8 healthy asymptomatic 
individuals, a 4.5-fold increased myocardial aldosterone level was observed in HCM 
patients versus controls and increased CYP11B2 mRNA levels was also seen in the 
subjects with HCM, while the cAMP level was normal in both cases and controls 
(Tsybouleva et al., 2004). 
 
In a study by Schmitt et al., (2003a), the effects of transverse aortic banding on two 
strains of transgenic mice with and without the cardiac MYH6 Arg403Gln missense 
mutation (equivalent to the human MYH7 Arg403Gln mutation) were assessed. They 
found that in transverse aortic banded mice that were not subjected to treatment with the 
calcineurin-inhibitor cyclosporin A, the hypertrophic response to hypertrophy was 
uniform. When cyclosporin A (an agent that is known to amplify hypertrophy induced by 
this sarcomere mutation [Arg403Gln]) (Fatkin et al., 2000) was added to banded mice 
harbouring either the wild type (WT) (+/+) or the missense (+/-) mutation, it resulted in 
an augmented hypertrophic response in both groups (Schmitt et al., 2003a). 
Consequently, the authors predicted that both hypertension and HCM act independently 
of one another and not synergistically.  
 
In cultured rat cardiac myocytes and fibroblasts, CYP11B2 provoked expression of 
hypertrophic and profibrotic effects via activation of protein kinase D (PKD) and 
upregulation of phosphoinositide 3-kinase (PI3K) (Tsybouleva et al., 2004). Additionally, 
Tsybouleva et al., (2004) demonstrated that in a cardiac troponin T (cTnT)-Q92 
transgenic mouse model of human HCM (in humans, TNNT2 Arg92Trp mutation), 
blockade with mineralocorticoid receptor (MR) antagonist spironolactone inhibited PKD 
(a mediator of hypertrophic effect of aldosterone) and PI3K (a mediator of profibrotic 
effects). This resulted in aldosterone normalised myocardial collagen content and 
attenuated myocyte disarray phenotypes. The myocytic disarray phenotypes were similar 
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to those shown by Varnava et al., (2001) and Silvestre et al., (1998) to associate with 
SCD and heart failure in humans and mouse models of HCM. These studies implicate 
aldosterone as a molecular link between sarcomeric gene mutations and cardiac 
phenotypes as demonstrated in human hearts, cultured cells and a genetic animal model 
of HCM. 
 
Direct role for RAAS in LVH 
Thus, there is mounting evidence for the RAAS’s role in LVH, the first being an 
independent relationship between plasma ACE levels and aldosterone concentrations with 
either LVH or indices of cardiac growth (Schunkert et al., 1996, 1997). The second line 
of evidence was the finding by Harrap et al., (1996), which indicated a relationship 
between plasma ANGII concentrations and LVM in healthy young adults. Numerous data 
implicate the RAAS as a mediator of LVM by having either direct cellular effect on 
cardiac growth (Olson and Molkelin, 1999; Takemoto et al., 2001) and/or indirect effects 
via circulating components of the RAAS on LVM (Harrap et al., 1996; Schunkert et al., 
1996, 1997). This evidence has prompted researchers to investigate the role of RAAS 
gene variants on the development of LVH.  
 
Mechanism of RAAS inducing LVH 
The mechanism of RAAS’s effects on LVH occurs via an interaction between direct 
cellular/molecular pathways and indirect haemodynamic changes (Sadoshima and Izumo, 
1993; Harrap et al., 1996). Both these effects are considered interdependent and 
synergistically induce marked LVM changes. Thus, one change is not sufficient to 
modify LVM as shown in previous preclinical studies (Sen et al., 1974; Sen and Tarazi, 
1983; Frohlich and Sasaki, 1990). It is assumed that genetic polymorphisms within the 
RAAS system could potentially modify RAAS activity in the presence of hypertension 
and thus produce marked effects on LVM (Tiago et al., 2002). If the RAAS is not the 
primary cause then it might be a contributor to LVH, a characteristic often associated 
with HCM. The potential effects of RAAS activation in cardiac hypertrophy include 
myocardial fibrosis, diastolic dysfunction (Weber et al., 1994), myocyte necrosis (Tan et 
al., 1991; Ollivier and Bouchet, 1992), myocyte slippage, cardiac dilatation (Mann and 
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Spinale, 1998) and vasoconstriction (Hall et al., 1986; Hall et al., 1990; Hall and Gayton, 
1996).  
 
Some of the risk factors involved in CVD development are known and the RAAS is 
considered a mediator of these factors leading up to LVH (Tiago et al., 2002). Other 
studies have sought to determine the genetic factors involved in the development of 
hypertension and LVH, using genetic approaches. 
 
The following sections will introduce the concept of genetic association studies, linkage 
disequilibrium (LD), population stratification and using family members as controls in 
genetic studies, because of their relevance to the present case-control association study in 
which the role of RAAS as a modifier of the hypertrophic phenotype in HCM was 
investigated. 
 
Genetic association analyses/ Case-control association studies  
Association studies aim to demonstrate a statistical difference in the distribution of allelic 
variants of selected genes within affected (cases) and unaffected (control) individuals. 
The studied individuals are included irrespective of their family members’ disease status 
in these studies. Genetic association analyses are usually conducted in a population-based 
setting using larger sample sizes to gain adequate power (Silverman and Palmer, 2000).  
 
For association studies one of two approaches can be used. The first approach is based on 
an “a priori” candidate gene hypothesis whereby variants within a specific gene are 
investigated based on known physiological, biochemical or pharmacological evidence. 
These studies offer increased power to detect genes of moderate effect, while taking into 
account the current information known about the tissues, proteins and potential genes 
involved in the pathogenesis of a condition. The second approach, known as a genome-
wide association analysis, involves screening the entire genome in search of the causal 
genetic variant(s), without prior consideration of pathophysiological mechanisms.  This 
systematic approach is regarded as being unbiased because it also involves no prior 
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assumptions regarding the localisation of possible susceptibility variants (Hirschhorn and 
Daly, 2005). 
 
The success of both methods relies on the association found between the selected marker 
and the susceptibility allele due to a phenomenon known as linkage disequilibrium (LD). 
 
Linkage disequilibrium (LD) 
LD is the non-random statistical association of alleles at single linked loci, which co-
segregate with a high frequency across a population. LD can be used to investigate 
human evolution and genetic aetiology of complex disorders (Jorde et al., 1995; Kidd et 
al., 1998) and can aid in the identification of susceptibility loci, for example, in a group 
of affected individuals that are descended from a single founder individual. It is 
considered that, over a restricted period of time, in a group descended from a common 
ancestor, or single founder individual, a low fraction of meiotic recombination events will 
have occurred, thereby defining a commonly inherited DNA-region that possesses the 
susceptibility alleles. In case-control association studies, LD patterns give information on 
the genetic distance over which signals of causation may be generated. Risch and 
Merikangas, (1996) regarded LD as a tool to identify the neighborhood surrounding the 
susceptibility allele. However, there are several caveats that should be considered when 
performing an association study, one being population stratification (see below). 
 
Population stratification 
A study is said to have population stratification, if the allele frequencies between cases 
and controls differ due to diversity in background of the population (Cardon and Palmer, 
2003). Population stratification normally occurs when there are differences in disease 
prevalence between cases and controls and variation in allele frequencies between 
population groups (Cardon and Palmer, 2003). In case-control association studies, false 
positives may occur due to even the slightest differences in genetic ancestry between 
cases and controls. This is because the source population under investigation might 
comprise of different clusters of subpopulations resulting in spurious associations. For 
example any allele which by chance has a higher frequency in the subpopulation that 
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possesses a larger disease risk than in the control group might appear to have an 
association with the disease (Wacholder et al., 2002). Alternatively, population 
stratification may result in a false negative finding: if the frequency of the associated 
allele is by chance, low in a subgroup of people in which the disease is more prevalent, 
than in the control group the association with the disease may be masked (Deng et al., 
2001). However, population stratification can be avoided by using family members as 
controls (Thomas and White, 2002); this rationale was implemented in the present study. 
 
Using family members as controls 
Transmission disequilibrium test analysis (TDT) makes use of parents and siblings as 
family-based controls. TDT allows the transmission pattern of selected marker alleles 
from heterozygous parents to affected offspring to be followed. If transmission frequency 
of the marker allele exceeds that which is expected by chance alone, the allele is assumed 
to be associated with the disorder in some way.   
 
The approaches mentioned above have been used in several genetic association studies to 
determine the influence of genetic factors of the RAAS on the phenotypic expression of 
hypertension and LVH; as will be discussed in further detail in the following section. 
  
1.4.4. RAAS genes in hypertension and LVH 
As discussed in section 1.4.1, the RAAS is a complex integrated system mediating both 
cellular/molecular and haemodynamic effects on tissues and organs. Several studies have 
implicated RAAS gene variants as having independent effects on cardiac growth. 
Previously, polymorphisms within the RAAS genes have been extensively investigated 
for involvement in hypertension and a variety of other CVD’s in case-control association 
studies (Bonnardeaux et al., 1994; Staessen et al., 1997). These polymorphisms include 
the ACE1 insertion/deletion (I/D), AGT M235T, AGTR1 A/C1166 (an A/C transversion at 
nucleotide position 1166), CMA A/G exchange at position -1903 and CYP11B2 C/T 
exchange at position -344 (Rigat et al., 1990; Jeunemaitre et al., 1992; Bonnardeaux et 
al., 1994; Pfeufer et al., 1996; Kupari et al 1998) (Table 1.2). Subsequently, several other 
polymorphisms located in the promoter, exonic or untranslated region (UTR) of ACE1, 
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AGT and AGTR1 were identified, which were also examined for association with CVD’s 
(Villard et al., 1996; Inoue et al., 1997; Ishigami et al., 1997; Sato et al., 1997). 
Concomitantly, researchers were prompted to investigate additional variants in other 
components/genes of the RAAS for possible associations.  
 
The following section will provide more detail on the aforementioned genes investigated 
in previous association studies arranged chronologically in support of the present study.  
 
1.4.4.1. ACE1  
The ACE1 gene located on chromosome 17q23.3 comprises 25 exons, 24 introns and a 
promoter region (figure 1.6). The 287 base pair (bp) I/D polymorphism in intron 16 is 
associated with approximately half of the plasma ACE1 level variability between 
individuals, as well as in variation with tissues (Rigat et al., 1990; Danser et al 1995). 
Other studies have confirmed a positive correlation between the D-allele of ACE1 and 
increased enzyme activity (Watt et al., 1992; Nakai et al., 1994; Dessi-Fulgheri et al., 
1995; Bloem et al., 1996; Fornage et al 1998).  
 
ACE1 and Blood pressure 
Various studies performed to determine if ACE1 is involved in human hypertension 
development have yielded conflicting results. However, some studies have shown 
positive results for a plausible role of the ACE1 in gender-specific hypertension. Using a 
large population-based sample of 1445 men and 1650 women from the Framingham heart 
study, O’Donnell et al., (1998) confirmed a relationship between the D-allele of ACE1 
and both a diagnosis of EHT and increased BP in males. An additional case-control study 
supported a gender-based association between microsatellite markers in ACE1 and EHT 
again in male subjects only (Fornage et al., 1998). The study recruited 1488 Caucasian 
siblings consisting of 814 males and 674 females subdivided into hypertensives (systolic 
BP (SBP) > 160 and diastolic BP (DBP) > 95mmHg) and normotensives (SBP ≤ 140 and 
DBP ≤ 90mmHg) (Fornage et al., 1998). Subsequently, a larger gender-specific study 
conducted in 5014 Japanese EHT patients (2340 men and 2674 women) confirmed 
Fornage and colleague’s (1998) results (Higaki et al., 2000b).  
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In a study of 3596 Finnish children aged 6 to 8 years who had hypertensive parents, 
results suggested that polymorphisms in ACE1 are associated with BP in offspring 
belonging to parents who had a positive history of hypertension, while AGT 
polymorphism(s) were not associated with BP (Tian et al., 1997). However, two other 
studies failed to demonstrate a relationship between ACE1 genotypes and severity of BP 
changes in EHT in 343 Caucasian German subjects (Beige et al., 1997) and 50 untreated 
hypertensive subjects (Gharavi et al., 1997). Similarly, in French hypertensive patients 
(453 men and 326 women) the ACE1 I/D variant were found not to be associated with 
hypertension (Tiret et al., 1998). The lack of association mentioned in the latter three 
studies could be due to small sample sizes used for analysis.  
 
 
Figure 1.6: Genomic organisation of the human angiotensin-converting enzyme gene (ACE1) 
showing variants investigated in association studies. The locations of various polymorphisms 
being investigated for possible association with LVH (indicated by vertical black arrows). The 
markers highlighted in red indicate variants investigated in previous association studies and the 
blue highlighted markers indicate variants that have not yet been investigated (Table 1.2 section 
1.3.2). Abbreviations: I/D – insertion/deletion; rs – SNP identification number in NCBI database.  
 
 
In 5014 human Japanese hypertensive subjects, the D-allele was significantly associated 
with hypertension in men but not in women, even after adjustment for the effect of 
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confounding variables such as age, body mass index (BMI), smoking and drinking habits, 
total cholesterol, triglycerides, HDL-cholesterol, fasting plasma glucose and creatine 
(Higaki et al., 2000b). A case-control association study by Agachan and colleagues 
(2003) found a positive association between the ACE1 I/D variant and EHT in 109 
hypertensive subjects (SBP > 140 and DBP > 90mmHg) compared to 86 normotensives 
(SBP < 140 and DBP < 90mmHg) from Turkey. 
 
ACE1 and LVH per se 
The literature is filled with conflicting results, because associations have been reported 
for the ACE1 D-allele with electrocardiographic or echocardiographic LVH per se 
(Schunkert et al., 1994; Gharavi et al., 1996), while other studies report no significant 
association of the D-allele with these conditions (as referred to below). The Schunkert et 
al’s., (1994) study, which found an association between the ACE1 D-allele and 
electrocardiographic LVH, recruited Caucasian subjects of Western European descent, 
consisting of 717 men and 711 women between the ages of 45 and 59 years, with LVH 
and a similar number of healthy controls matched for age, sex and BP status.  
 
Additionally, in a population-based case-control association study of 430 randomly 
selected hypertensive and 426 control subjects, no association was found between the 
ACE1 I/D polymorphism and LVM in subjects from Oula, Finland (Kauma et al 1998). 
The epidemiological study by Kauma et al., (1998) included hypertensive subjects who 
had age and sex-matched controls with statistical analysis performed by adjusting for the 
influence of covariates of hypertrophy such as age, BMI, SBP, gender, fasting insulin and 
physical activity.  
 
Similarly, in a group of 87 Japanese patients (48 men and 39 women) randomly selected 
from the population, the DD genotype of the ACE1 I/D variant was associated with 
hypertensive LVH in the concentric hypertrophy group (increased LVMI and relative 
wall thickness) (Ueno et al., 1999).   
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In 2000, a meta-analysis study found no association for the ACE1 I/D polymorphism with 
either electrocardiographic or echocardiographic LVH (Kuznetsova et al., 2000). 
However, when other studies were performed in untreated hypertensive patients, a 
significant association was observed between DD typed homozygotes and LVMI (Iwai et 
al., 1994; Gharavi et al., 1996; Perticone et al., 1997). But in continuing association 
studies, Ortlepp et al., (2001) enrolled 105 patients with aortic stenosis and genotyped 
them for five RAAS polymorphisms, namely, ACE1 I/D, AGT M235T, AGTR1 A/C1166, 
CMA -1905A/G and CYP11B2 -344C/T. However, none of the investigated variants 
showed significant association with LVH in patients with aortic stenosis (Ortlepp et al., 
2001). In contrast, Hernandez et al., (2003) genotyped 61 Caucasian male endurance 
athletes from the Canary Islands for the ACE1 I/D polymorphism and found that DD-
genotyped athletes had greater LVMI than II and ID athletes. The statistically significant 
association remained even after adjusting for the influence of confounding variables such 
as age, BMI, haemoglobin levels, years of training and BP.  
 
An ensuing association study by Kuznetsova et al., (2004) recruited 221 nuclear 
Caucasian families (384 parents and 431 offspring) from Poland and Italy. Using a 
population and family-based approach, Kuznetsova and colleagues (2004) demonstrated 
by statistical analysis, adjusting for the effects of covariates, that the ACE1 I/D and 
AGTR2 1675G/A variants independently influence LVM in men and are modulated by 
sodium intake.  
 
A retrospective, case-control study recruited 180 Emiratus nationals consisting of 50 
LVH patients and 130 controls between the ages of 43-72 years old, who were all non-
alcohol users and non-smokers; thus reducing environmental confounders (Saeed et al., 
2005). The two genotyped polymorphisms in ACE1 I/D and 2350G/A, demonstrated an 
independent association with LVH in normotensive LVH patients (Saeed et al., 2005). 
However, the association was lost after adjusting for age and gender, but was regained 
when performing haplotype analyses, with the combined two polymorphisms yielding 
haplotype I/G that was significantly associated with LVH (Saeed et al., 2005).  Similarly, 
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reports on association between the ACE1 I/D polymorphism and hypertrophic or survival 
phenotypes in HCM are conflicting (Marian et al., 1993).  
 
In population-based association studies, Yoneya et al., (1995) demonstrated in Japanese 
subjects that the D-allele was more common in family members of 80 HCM patients that 
had a high incidence of SCD compared to 88 of their unaffected children and their 
siblings. These results are discordant with those generated in a case-control study using 
71 unrelated patients with nonfamilial HCM and 88 patients with nonfamilial DCM and 
122 healthy control subjects from Japan (Yamada et al., 1997). Genotyping these cases 
and controls for ACE1 I/D, AGT M235T and T174M polymorphisms failed to confirm 
any association between either of the polymorphisms and LVH (Yamada et al., 1997). 
 
Lechin and colleagues (1995) enrolled 183 Caucasian patients with HCM, of whom 87 
had the sporadic form, while the other 96 had FHCM. Lechin et al., (1995) found a 
statistically significant association between ACE1 DD genotyped individuals, and left 
ventricle mass index (LVMI) as well as LVH score, in 108 genetically independent 
patients (sporadic cases combined and one randomly chosen individual per family), 
independent of the effect of confounding variables.  
 
Additionally, in 62 patients with HCM, the DD genotype of the ACE1 I/D variant was 
associated with a greater progression of LVH compared to II and ID genotypes, 
independent of age, body mass and resting BP (Doolan et al., 2004). 
 
Perkins and colleagues (2005) illustrated in 389 unrelated patients with HCM that the 
ACE1 DD genotype is associated with increased LVWT in MYBPC3 carriers, but not in 
ACE1 DD genotyped individuals harbouring the MYH7 mutation.  
 
Functionality of ACE I/D polymorphism  
The following subsection will discuss the possible role and mechanism of the ACE1 I/D 
polymorphism in general CVD development.  
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The genetic localisation of the ACE1 I/D polymorphism, within intron 16, makes it an 
unlikely candidate to affect ACE activity and therefore to affect function of the protein. 
However, it is suggested that alleles at a locus or marker in LD with this ACE1 I/D 
polymorphism and located in a functionally conserved region may have a role in direct 
effects on ACE activity (Tiret et al., 1992; Tiret et al., 1994; Villard et al., 1996). In an 
attempt to identify possible variants that are in complete LD with the I/D polymorphism, 
Keavney et al., (1998) analysed nine polymorphisms, including the I/D polymorphism, 
that spanned 26kb of ACE1 in Caucasian British families. Measured haplotype analysis 
revealed that the major variant influencing ACE levels is located 3’ of a putative 
ancestral breakpoint which signifies an ancestral recombination event near position 6435 
(Keavney et al., 1998). After refinement of the putative ancestral breakpoint by Farrall et 
al., (1999), McKenzie and colleagues (2001) examined ten ACE1 polymorphisms in 
Afro-Carribean families and compared the results to the study done by Keavney et al., 
(1998). The results of McKenzie et al., (2001) suggested that the major ACE1-linked 
QTL is likely to lie in close proximity to the 2350G/A polymorphism (see page 29). They 
concluded that further investigations of polymorphisms 5’ and 3’ of this 2350G/A 
polymorphism were warranted.    
 
The peptide by which increased AGT expression and ACE enzyme activity influence 
cardiac tissue structure and function is through ANGII production (Schunkert et al., 1990; 
Arnal et al., 1994; Muller et al., 1997). An additional mechanism of action that should be 
considered is the role of gene-gene interactions in the development of CVD, which is 
assumed to have a multi-factorial etiology (Wang et al., 2000). The first evidence comes 
from studies done by Tiret et al., (1994), Alvarez et al., (1998) and Fatini et al., (2000), 
where they observed a synergistic relationship between the ACE1 I/D and AGTR1 
A/C1166 polymorphisms in determining risk for coronary heart disease development. The 
second line of evidence is from a study that investigated the synergistic effects of the 
ACE1 I/D and α-adducin (αADD) Gly460Trp polymorphisms on BP responses to sodium 
loading (Barlassina et al., 2000). Barlassina et al., (2000) found similar BP levels across 
ACE1 I/D genotypes and for αADD Gly/Gly homozygotes, whereas a positive correlation 
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and linear association was observed for all αADD Trp-allele carriers who also harboured 
the ACE1 D-allele. 
 
In summary, several case-control association studies provide evidence for a relationship 
between the ACE1 I/D polymorphism and LVM in normotensive and hypertensive groups 
(Iwai et al., 1994; Schunkert et al., 1994; Perticone et al., 1997). More importantly, LVM 
measurements indicate a relationship between the ACE1 I/D polymorphism and LVM 
(Nakahara et al., 2000).  
 
1.4.4.2. AGT  
The gene encoding AGT comprises five exons, four introns and a promoter region 
located on chromosome 1q42-43 (figure 1.7). AGT is highly polymorphic with nearly 20 
variants indexed in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/). The 
AGT exon 2 variant 704T→C results in a methionine being substituted for a threonine in 
position 235 of the amino-acid sequence (M235T). It has been suggested that the M235T 
polymorphism is a marker determining the amount of plasma AGT variation between 
individuals (Jeunemaitre et al., 1992). 
 
AGT and Blood pressure 
Several investigators have shown that the AGT M235T variant is associated with EHT in 
various ethnic groups such as French Caucasians and Japanese (Jeunemaitre et al., 1992; 
Hata et al., 1994; Tiret et al., 1998). The details of the numbers of subjects studied and 
their population groups are given in the following sentences. Jeunemaitre et al., (1992) 
recruited Caucasian hypertensive sibling pairs from America (144 males and 165 
females) and 140 controls and from France hypertensive cases (99 males and 91 females) 
and 98 healthy normotensives for case-control association analysis. The case-control 
study by Hata and colleagues (1994) enrolled 105 hypertensives (SBP > 160 and DBP > 
95mmHg) and 81 normotensives (SBP < 140 and DBP < 90mmHg) from Japan, while 
Tiret et al., (1998) included French hypertensive cases (453 men and 326 women) (DBP 
≥ 100mmHg) and normotensive controls (362 men and 170 women).  
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However, subsequent studies performed in different cohorts of subjects generated 
discrepant findings, as no association was found between AGT M235T and EHT in 
Caucasians (Caulfield et al., 1994), Japanese (Kato et al., 1999 and 2000) and Chinese 
subjects (Cheung et al., 1998) (as discussed in detail below). However, Caulfield and 
colleagues (1994) found significant linkage between AGT and EHT in the 63 European 
Caucasian families using dinucleotide-repeat markers flanking AGT, while no association 
in the reported population was found between the AGT M235T and T174M 
polymorphisms and EHT. Hypertension was diagnosed when DBP was >95mmHg, while 
individuals with secondary hypertension due to renal disease, (renovascular hypertension) 
were excluded from the study (Caulfield et al., 1994). The association studies undertaken 
in Japanese individuals by Kato et al., (1999) included 1232 individuals stratified into 
two groups consisting of 254 cases (hypertensives SBP > 160 and DBP > 95mmHg) and 
224 normotensive subjects and 463 hypertensive cases and 291 normotensive individuals, 
respectively. The ensuing case-control study by Kato and colleagues (2000) enrolled 
1476 Japanese individuals, 843 hypertensive subjects and 633 normotensive subjects 
(SBP < 160 and DBP < 95mmHg).  
 
The case-control study by Cheung et al., (1998) consisted of 204 subjects stratified into 
two groups, cases (101 newly diagnosed hypertensives SBP> 160 and DBP > 90mmHg) 
and controls (103 healthy subjects without secondary hypertension, heart disease, 
vascular disease and diabetes). No association between AGT M235T and EHT was found 
in these studies. 
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Figure 1.7: Genomic organisation of the human angiotensinogen gene (AGT) showing variants 
investigated in association studies. The locations of various polymorphisms being investigated for 
possible association with LVH (indicated by vertical black arrows). The markers highlighted in 
red indicate variants investigated in previous association studies and the blue highlighted markers 
indicate variants that have not yet been investigated (Table 1.2 section 1.3.2).  
 
Examining the influence of the AGT 235T allele in 57 hypertensives (SBP ≥ 140 and 
DBP ≥ 90mmHg) and 130 normotensive unrelated subjects of African ancestry failed to 
confirm any association between AGT M235T variant and hypertension, because the 
allele was non-informative within the ethnic group (Rotimi et al., 1994). Inconsistent 
results were found for the role of AGT in BP (as referred to below) (Hingorani et al., 
1996; Kiema et al., 1996; Fardella et al., 1998). Moreover, Hingorani and colleagues 
(1996) observed a lack of association between AGT M235T and BP level in subjects from 
East Anglia United Kingdom. A total of 223 hypertensives and 187 normotensives were 
genotyped for the AGT M235T variant and statistically analysed with concomitant 
adjustment for age, sex, BMI and alcohol consumption (Hingorani et al., 1996). In their 
study, hypertensive subjects were stratified according to SBP ≥ 160 and DBP ≥ 90mmHg, 
while controls were healthy individuals matched to hypertensive patients for age, sex and 
BMI and with no history of CVD or any other disease (Hingorani et al., 1996).  
 
The case-control association study by Kiema and colleagues (1996) carried out with 508 
hypertensives and 523 controls from Finland that were matched for age and sex 
demonstrated no statistically significant association between ACE1 I/D and AGT M235T 
polymorphisms and EHT. This was a population-based sample of middle-aged randomly 
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selected individuals from an ethnically homogeneous population with hypertensive 
subjects being defined as DBP > 105mmHg (Kiema et al., 1996). Similarly, another study 
examining the genotypes of 64 hypertensives and 62 normotensives matched for age and 
sex demonstrated no association between the AGT T235-allele and EHT in Chilean 
Hispanic subjects (Fardella et al., 1998). Additionally, no statistical significance was 
found between AGT M235T variant and plasma renin activity and serum aldosterone 
levels in hypertensives (SBP > 140 and DBP > 90mmHg) and normotensives (SBP < 140 
and DBP < 85mmHg) subjects (Fardella et al., 1998). In contrast, another study 
demonstrated a positive correlation between M235T and severity of human hypertension 
in 50 untreated subjects (33 men and 17 women) consisting of 19 Caucasians, 24 
Hispanics and 7 Asians  (Gharavi et al., 1997), whereas yet another study failed to show 
an association in 343 Caucasian German subjects (Beige et al., 1997).  
 
A series of 477 probands of French Caucasian hypertensive families and 364 control 
individuals and 92 Japanese hypertensive individuals (DBP ≥ 95mmHg) and 122 controls 
were genotyped for AGT M235T (Jeunemaitre et al., 1997). This study showed a positive 
association between the AGT M235T polymorphism, specifically the T235-allele and 
hypertension in both populations investigated. However, other studies failed to 
demonstrate an association between AGT variants and EHT in 350 hypertensive sibships 
consisting of 630 European affected sibling pairs (Brand et al., 1998) and 111 Australian 
Anglo-Celtic Caucasian hypertensive subjects (SBP > 140 and DBP > 90mmHg) (Wang 
et al., 1999). Furthermore, in a case-control study, no association was found between 
AGT M235T and T174M variants and EHT in 75 patients with EHT (SBP ≥ 160 and 
DBP ≥ 100mmHg) and 75 healthy Spanish Caucasian controls (SBP < 130 and DBP < 
85mmHg), despite adjustments for confounding variables like age, gender, BMI and 
alcohol consumption (Fernandez-Llama et al., 1998).  
 
In a population-based study of 9100 Danish men and women matched for age, results 
showed that the AGT M235T polymorphism, particularly the T235-allele, was associated 
with elevated SBP in women but not in men (Sethi et al., 2001). This association was 
strengthened for subjects that were homozygous for the T235-allele and the T174-allele. 
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Moreover, the plasma levels for the double homozygous T235 and T174 correlated with a 
10% elevated plasma AGT level in both genders. An association with EHT was evident 
in 109 hypertensive subjects (SBP > 140 and DBP > 90mmHg) and 86 normotensive 
individuals (SBP < 140 and DBP < 90mmHg) of Turkish descent (Agachan et al., 2003). 
In addition, Agachan and colleagues (2003) showed that the frequency of the AGT 
M235T variant (the TT genotype) and the T174M variant (the 174M-allele) were higher 
in hypertensive than control subjects. A study that recruited 188 Malaysian subjects, 101 
hypertensives (SBP ≥ 140 and DBP ≥ 90mmHg) and 87 normotensives (SBP ≤ 140 and 
DBP ≤ 90mmHg), and recorded BP and BMI measurements found that the TT genotype 
of the AGT M235T polymorphism was significantly associated with EHT (Say et al., 
2005).  
  
The influence of various promoter region variants [-20 adenine (A)/cytosine(C) and -6 
guanine (G)/A] on AGT basal transcription rates might be used as an indicator of severity 
of hypertension. Previously a correlation was observed between an increased AGT 
concentration and variants -20A/C and -6G/A (Inoue et al., 1997; Ishigami et al., 1997; 
Zhao et al., 1999); however a non-significant association was observed between the -6 
G/A variant and BP in 518 normotensive Oji-Cru Canadians (Hegele et al., 1998). 
Caulfield et al., (1995) established linkage and association between the AGT locus and 
hypertension in 63 affected sibling pairs of African-Caribbean descent using 
microsatellite dinucleotide (GT) repeats located in the 3’ flanking region of AGT. The 
study included individuals with hypertension defined as DBP > 95mmHg and excluded 
individuals with clinical evidence of secondary hypertension and diabetes mellitus.  
 
Genotyping 556 hypertensives and 547 controls of African ancestry (Nguni, Sotho and 
Venda Chiefdoms) demonstrated that the AGT -20A/C, variant particularly the -20A-allele 
markedly modified the relationship between BMI and SBP in hypertensive subjects, 
while the -20C-allele had a protective effect (Tiago et al., 2002). A study by Tsai et al., 
(2002) recruited 408 hypertensives (229 men and 179 women) and 286 normotensive 
Taiwanese subjects (151 men and 135 women) and excluded subjects if they had 
secondary hypertension, caused by primary aldosteronism, renalvascular hypertension, 
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Cushing syndrome and heart disease. Performing haplotype analysis of the AGT locus 
revealed that the haplotype GGAGCC (which incorporates the -217G, -152G, -20A, -6G, 
from 522C (T174M) and from 704C (M235T) alleles) is significantly associated with 
hypertension in the homogeneous Taiwanese population (Tsai et al., 2003). Additionally, 
Tsai and colleagues (2003) observed a higher frequency of the haplotype in hypertensive 
individuals with the ACE1 II genotype, suggesting a synergistic interaction between the 
two genes. Zhu et al., (2005) examined haplotypes produced from rare variants in AGT to 
determine its relationship with BP in 29 Nigerian men with high plasma AGT and 28 
with low levels of plasma AGT. From the 24 rare haplotypes produced, 19 haplotypes 
carried haplotype GCT (consisting of -217G/A, 172C/T and 2186G/T), providing 
evidence that rare sequence variants might have an influence on variation of BP 
phenotype. Table 1.3 contains a detailed summary of various case-control association 
studies discussed in previously written sections.     
 
In summary, various case-control association studies that have been undertaken have 
yielded discrepant findings as some showed positive association and others show no 
association with hypertension, however, a large number of these studies reveal no 
relationship between AGT and hypertension.   
 
 
AGT and LVH per se 
A study by Jeng et al., (1999) genotyped 91 males and 84 females with hypertension 
(DBP > 95mmHg) for the M235T variant in AGT, while controlling for confounding 
factors of hypertrophy such as age, gender and BMI and found an association of the TT-
genotype with LVMI. Hence, they suggested that variants within AGT might be potential 
independent mediators of LVM. 
 
Using a study cohort consisting of 80 elite athletes from Finland (50 men and 30 women), 
Karjalainen et al., (1999) demonstrated that the AGT M235T polymorphism significantly 
associates with LVM independently of BP in both male and female endurance athletes 
with adaptive cardiac hypertrophy. Genotypes of AGT M235T, ACE1 I/D and AGTR1 
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A/C1166 were determined in 83 German male Caucasian endurance athletes to assess if 
these variants are associated with LVM (Diet et al., 2001). Separate analysis of each 
polymorphism revealed no association with LVM, while combined analysis confirmed an 
association in ACE1 DD and AGT TT genotypes with greater LVM, compared to other 
genotype combinations. None of the athletes participating in the study had any history of 
heart disease, hypertension, smoking or kidney disease. Analysis was done adjusting for 
the influence of covariates such as age, type of sport, number of years active in 
competitive sport, height, weight, body surface area, SBP and DBP (Diet et al., 2001). 
 
Genetic variation in AGT was also modestly associated with LVH in normotensive 
compared to hypertensive subjects (Tang et al., 2002). This association was independent 
of the effects of covariates of hypertrophy, such as weight, height, age, sex, SBP, DBP, 
presence of diabetes and anti-hypertensive medication in 605 participants (302 men and 
303). 
 
Kurland et al., (2002) found that the AGT T174M variant (heterozygote TM genotype), 
the T235-allele of M235T and the AGTR1 A/C1166 variant (heterozygote AC genotype) 
correlated with a change in LVH during antihypertensive treatment with the AGTR1 
receptor antagonist Irbesartan. In the 84 random Swedish Caucasian subjects analysed, 
individuals received either Irbesartan or the β-1 adrenergic receptor antagonist atenolol. 
While only AGT and AGTR1 variants showed association, neither of the ACE1 I/D nor 
CYP11B2 -344C/T variants were associated with reduction in LVMI after treatment with 
either drug (Kurland et al., 2002).  
 
AGT and HCM 
In HCM, the role of the AGT M235T polymorphism is controversial. Numerous 
investigators have reported both positive and negative findings regarding the relationship 
between the M235T variant and LVMI. In one Japanese study, a relationship was found 
between M235T variant and cardiac hypertrophy (Ishanov et al., 1997). A higher 
occurrence of the T235-allele was observed in 96 sporadic HCM cases compared to 105 
unaffected control individuals (Ishanov et al., 1997). However, a meta-analysis in 1999 
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yielded no significant association between AGT M235T polymorphism and HCM or 
DCM and produced a low odds ratio (Staessen et al., 1999). The CC genotype of AGT 
M235T polymorphism showed a trend of association with LVH in a single family of 
HCM patients (Ortlepp et al., 2002). 
 
Functionality of AGT variants 
In the following paragraph the role of the AGT M235T polymorphism and other promoter 
region variants in hypertension and CVD development will be discussed.  
 
The localised expression of AGT occurs within the myocardium and makes it a good 
candidate gene to assess its influence on cardiac growth (Dzau et al., 1987; Baker et al., 
1992; de Mello and Danser 2000). Several mechanisms of action have been proposed to 
account for the significant correlation between the AGT M235T polymorphism and 
hypertension. Firstly, Bohlender et al., (1996) showed a significant correlation between 
this polymorphism and an increased ANGI generation, while the plasma renin 
concentration did not change. Secondly, in gene titration experiments done in animal 
models, mice with four copies of AGT showed a linear increase in the enzyme 
concentration compared to zero copy mice (Bohlender et al., 1996; Inoue et al., 1997; 
Smithies et al., 1997).  
 
It has been demonstrated by in vitro experiments that the promoter region variant of AGT, 
the -6A/G substitution, affects basal transcription rates of AGT (Inoue et al., 1997). 
Additionally, investigators have identified polymorphisms in this region that are in 
complete LD with the AGT M235T variant in exon 2 (Jeunemaitre et al., 1997; Zhao et 
al., 1999). A previous linkage study indicated that the AGT T174M polymorphism is in 
complete LD with the AGT M235T sequence variant (Jeunemaitre et al., 1992). 
Jeunemaitre et al., (1992) also found that the AGT 174M-allele is present in individuals 
carrying the 235T-allele. Moreover, it was shown by Jeunemaitre et al., (1992) that the 
T174M polymorphism is associated with hypertension in French Caucasians.  
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The variants -20A/C, -18C/T and -6G/A are located in the promoter region of the AGT 
gene between the TATA box and the transcription initiation site. The AGT promoter 
variants -20A/C and -6G/A  have been found to have a significant association with the 
plasma AGT concentration and EHT (Ishigami et al., 1997; Jeunemaitre et al., 1997). A 
previous report describing transfection analysis indicated that human hepatoma cells with 
-20C-allele mutation transcribe a reporter gene at a higher level than the -20 A-allele of 
AGT (Zhao et al., 1999). In humans, the transcriptional activity of the -20A/C 
polymorphism is considered to alter the plasma AGT concentrations of the AGT mRNA 
(Ishigami et al., 1999). 
 
Additionally, the -20A/C polymorphism is in LD with the AGT M235T variant (Sato et 
al., 1997). The -20 C-allele in Japanese population substructures was associated with 
hypertension (Ishigami et al., 1997), although this finding was not confirmed by other 
investigators (Jeunemaitre et al., 1992, 1997; Sato et al., 1997). Numerous genetic studies 
have provided evidence that genetic polymorphisms in general can act independently, or 
in concert, to elicit a pathological effect in various CVDs (Tiret et al., 1992; Pfeufer et al., 
1996; Marian et al., 2002).  
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Table 1.3 Summary of association studies of AGT polymorphisms in hypertension. 
AGT  
Polymorphisms Reference Cohorts Method Findings 
M235T 1 ■ 309 American & 109 French Caucasian hypertensive sibling pairs  (SBP>160 and DBP>95mmHg) Case-control positive association with EHT 
  and 140 American & 98 French normotensive controls (SBP<140 and DBP<90mmHg) association  
 2 ■ 105 Japanese hypertensives (SBP>160 and DBP>95mmHg) and  Case-control positive association with EHT 
  81 normotensives (SBP<140 and DBP<90mmHg) association  
 3 ■ 779 French hypertensives (DBP≥100mmHg) and normotensive  Case-control positive association with EHT 
  controls association  
 4 ■ 63 European Caucasian families (parents and offspring) and APM and  Linkage of AGT with EHT 
  63 index patients and 64 European population-based controls Case-control negative association with EHT 
 5 ■ Two Japanese groups: 1) 254 hypertensives (SBP>160 and DBP>95mmHg) Case-control negative association with EHT 
  and 224 normotensive 2) 463 cases and 291 controls  association  
 6 ■ 843 Japanese hypertensives and ethnically matched 633 normotensive  Case-control negative association with EHT 
  controls (SBP<160 and DBP<95mmHg) association  
 7 ■ 101 newly diagnosed Chinese hypertensives (SBP>160 and DBP>90mmHg) Case-control negative association with EHT 
  and 103 healthy subjects without heart disease and diabetes  association  
 8 ■ 57 unrelated African hypertensives (SBP≥140 and DBP≥90mmHg) and  Case-control negative association with HT 
  130 unrelated normotensives of African descent association  
 9 ■ 223 East Anglia United Kingdom hypertensives (SBP≥140 and DBP≥90mmHg)   Case-control no association with BP level 
  and 187 normotensives matched for age,sex and BMI association  
 10 ■ 508 hypertensives (DBP>105mmHg) from Oula (homogeneous population) and   Case-control negative association with EHT 
  523 controls matched for age and sex association  
 11 ■ 64 Chilean Hispanic hypertensives (SBP>140 and DBP>90mmHg) and Case-control negative association with EHT 
  62 normotensives (SBP<140 and DBP<85mmHg) matched for ethnicity, age and sex association  
 12 ■ 477 hypertensive probands and 364 controls (French Caucasian) and  Case-control positive association with HT 
  92 Japanese hypertensives (DBP≥95mmHg) and 122 controls association  
 13 ■ 630 European hypertensive sibling pairs and 111 Australian AngloCeltic Caucasian Affected Sib-pair negative association with EHT 
  hypertensives (SBP>140 and DBP>90mmHg)  analysis  
 14 ■ 75 Spanish Caucasian EHT patients (SBP≥140 and DBP≥90mmHg) and   Case-control negative association with EHT 
  75 healthy controls (SBP<130 and DBP<85mmHg)  association  
 15 ■ 9100 Danish men and women matched for age Case-control 
positive association with BP 
level 
   association in women 
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AGT  
Polymorphisms Reference Cohorts Method Findings 
M235T 16 ■ 109 hypertensives (SBP>140 and DBP>90mmHg) and   Case-control positive association with EHT 
  86 normotensives (SBP<140 and DBP<90mmHg) of Turkish descent association  
 17 ■ 101 Malaysian hypertensives (SBP≥140 and DBP≥90mmHg) and Case-control positive association with EHT 
  87 normotensive controls (SBP≤140 and DBP≤90mmHg)  association  
-6 G/A 18 ■ 393 normotensive Oji-Cru Canadians and 125 hypertensives  (SBP>140 and DBP>90mmHg)  Case-control non-significant association with SBP 
   association  
-20 A/C 19 ■ 556 hypertensives and 547 controls of African ancestry Case-control relationship with SBP in HT 
   association  
-6 G/A and M235T 20 ■ 408 Taiwanese hypertensives and 286 normotensives Case-control haplotype positively associated with HT 
 
   association  
 
Abbreviations used: APM - affected pedigree member; DBP - diastolic BP; EHT - essential hypertension; Hg - mercury; HT - hypertension; mm - millimeters; 
SBP - systolic BP. References: 1) Jeunemaitre et al., 1992; 2) Hata et al., 1994; 3) Tiret et al., 1998; 4) Caulfield et al., 1994; 5) Kato et al., 1999; 6) Kato et al., 
2000; 7) Cheung et al., 1998; 8) Rotimi et al., 1994; 9) Hingorami et al., 1996; 10) Kiema et al., 1996; 11) Fardella et al., 1998; 12) Jeunemaitre et al., 1997; 13) 
Brand et al., 1998; 14) Fernandez-Llama et al., 1998; 15) Sethi et al., 2001; 16) Agachan et al., 2003; 17) Say et al., 2005; 18) Hegele et al 1998; 19) Tiago et al., 
2002; 20) Tsai et al., 2002).    
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1.4.4.3. CYP11B2 
The human CYP11B2 located on chromosome 8q22 comprises nine exons, eight introns 
and a promoter region (figure 1.8). Generally, one common variant that has been 
investigated for association is -344C/T. The genetic polymorphism -344C/T resides at a 
locus where a putative binding site occurs for the steroidogenic transcription factor, SF1 
(White and Slutsker 1995). It has also been found that the -344 C-allele is associated with 
a four-fold increase in SF-1 binding (White and Slutsker, 1995). Additionally, the -344 
C/T variant is associated with plasma aldosterone levels and urinary metabolic excretion 
rates and is therefore considered a potential mediator of EHT through regulatory effects 
on body fluid balance (Pojoga et al., 1998; Davies et al., 1999; Paillard et al., 1999; 
Russo et al., 2002).  
 
CYP11B2 and Blood pressure 
Two genetic association studies have observed an association between EHT, in 380 
hypertensive and 293 normotensive Caucasian men between the ages of 20-30 years old 
(Brand et al., 1998) and 73 EHT subjects (29 men and 44 women) and 134 normotensive 
controls of Japanese ethnicity, (Komiya et al., 2000), and the CYP11B2 -344C/T 
polymorphism in individuals with low renin levels. The Caucasian subject cohort 
consisted of healthy young men, with exclusion of individuals with hypertension, 
diabetes mellitus, hyperlipidaemia and hepatic or renal impairment, while the Japanese 
patients were stratified as EHT subjects if SBP was > 160mmHg and DBP was 
>95mmHg, while the control individuals included those with SBP of <140mmHg and 
DBP <90mmHg.  
 
Staessen et al., (2001) found that three RAAS genes (ACE, α-ADD and CYP11B2) 
demonstrate epistatic interactions and contribute to the prevalence and incidence of 
hypertension in unrelated Flemish Caucasians. Their case-control association study 
included 678 normotensive Caucasian subjects that showed association between the ACE 
I/D, α-ADD Gly460Trp and CYP11B2 -344C/T polymorphisms and hypertension. Other 
studies have undertaken single-gene analyses to demonstrate association between 
hypertension and ACE, α-ADD and CYP11B2 but have produced contradictory results 
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(Wang et al., 2000). The Staessen group notes a limitation of their study may be 
differences in genetic background between case and control individuals (Staessen et al., 
2001).  
 
Similarly, the result of a later case-control association study performed in a total of 1476 
Japanese subjects’ generated discrepant findings, where no association was observed 
between EHT and the CYP11B2 -344C/T polymorphism in a large cohort of non-selected 
renin status candidates (Kato et al., 2002). The patient and control groups in the Kato et 
al., (2002) study were stratified as hypertensive individuals if SBP was > 160mmHg and 
DBP was > 95mmHg and as normotensive individuals if SBP was < 160 and DBP was < 
95mmHg).  
 
Tsukada et al., (2002) demonstrated in a case-control study in 250 EHT subjects (154 
men and 96 women) and 221 control subjects (144 men and 77 women) that the 
CYP11B2 -344C/T polymorphism is associated with genetic predisposition to developing 
EHT in unrelated Japanese subjects. 
 
 
 
 
 
 
 
 
 
Figure 1.8: Genomic organisation of the human aldosterone synthase gene (CYP11B2) showing 
variants investigated in association studies. The locations of various markers being investigated 
for possible association with LVH (are indicated by vertical black arrows). The markers 
highlighted in red indicate three variants investigated in previous association studies (Table 1.2 
section 1.3.2).  
  
In the Tsukada et al., (2002) study, the patient and control groups were stratified using 
the same diagnostic criteria for hypertensive and normotensive subjects as implemented 
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by Kato et al., 2002. A case-control study using 146 hypertensive and 291 Caucasians 
controls of Australian Anglo-Celtic descent demonstrated that the CYP11B2 -344C/T and 
6547A/G polymorphisms showed association with EHT confined particularly to unrelated 
females, results that were reinforced by haplotype analysis (Kumar et al., 2003). Kumar 
et al., (2003) studied multiple markers spread across the gene, thereby increasing the 
statistical power to detect a possible modifying effect of CYP11B2.  
 
Tiago et al., (2003) illustrated in 231 newly diagnosed hypertensive patients (SBP ≥ 140 
and DBP ≥ 90mmHg) that the -344C/T variant of CYP11B2 is associated with the 
severity of systolic BP in hypertensive individuals of African ethnicity. Their study 
included only hypertensive patients of African ethnicity derived from the same gene pool 
(Nguni, Sotho and Venda chiefdoms) of South Africa to control for population 
stratification. Another study, in a total of 503 hypertensive subjects (262 males and 241 
females) and age-gender and area matched control subjects, the alleles of CYP11B2 -
344C/T, Arg173Lys and IC polymorphisms constituted a specific haplotype designated 
number 4 (-344T, 173Lys and IC-conversion alleles), which was shown to be associated 
with female hypertension (Gu et al., 2004). This association remained after adjustment 
for covariates such as BMI, serum concentration of glucose, triglyceride (TG) and high-
density lipoprotein (HDL) cholesterol, while haplotype number 3 consisting of (-344T, 
Arg173-WT and IC alleles) showed a protective effect in both Northern Han Chinese 
males and females (Gu et al., 2004).  
 
CYP11B2 and heart size 
The -344C/T polymorphism of CYP11B2 has been found to be associated with LV cavity 
size and function in a study of 84 healthy young Finnish Caucasian adults who had no 
history of heart disease (Kupari et al., 1998). Similarly, examining this promoter region 
polymorphism in 120 male Caucasian hypertensive subjects, Delles et al., (2001) found 
an association between the -344CC genotype and LV end-diastolic diameter. 
Additionally, the CYP11B2 -344C/T polymorphism, particularly the TC and CC 
genotypes, was found to be significantly associated with LV volume in 201 Japanese 
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DCM patients and 183 age-and sex-matched control subjects enrolled in a study by Takai 
et al., (2002).  
 
The Mayosi et al., (2003) study which employed 995 Caucasians of 229 British families 
demonstrated that a strong genetic component at the CYP11B2 locus determines variation 
in cardiac structure. They analysed six polymorphisms spanning CYP11B2 and found that 
only the 5937G/A polymorphism was associated with cardiac wall thickness and that both 
the IC and 5937G/A polymorphisms were associated with LV cavity size. Their study 
included familial data, thereby increasing genotyping accuracy and reducing the effect of 
population stratification, while concomitantly adjusting for the influence of covariates of 
hypertrophy, namely, age, sex, SBP, height, weight and body size (Mayosi et al., 2003).  
 
In a population-based sample of 562 hypertensive subjects (SBP ≥ 160 mmHg and DBP 
≥ 95 mmHg) of the Monitoring of trends and determinants in CVD in Augsburg 
(MONICA) study, no significant association of the CYP11B2 -344C/T polymorphism and 
LV size and function was detected, even after multivariate analysis to adjust for age, sex, 
BMI, SBP and antihypertensive drug treatment (Schunkert et al., 1999a). Additionally, 
the CYP11B2 -344C/T polymorphism’s allele status was found not to be a strong risk 
predictor for MI and did not influence LV remodeling after MI in 609 German patients 
from the MONICA survey (Hengstenberg et al., 2000).  
 
CYP11B2 and HCM 
The CC genotype of the CYP11B2 -344C/T polymorphism showed a trend of association 
with LVH in a study of a single family of HCM patients (Ortlepp et al., 2002). The study 
by Ortlepp et al., (2002) only looked at a single family harboring the MYBPC3 mutation 
in 48 adults (26 were clinically affected and 22 were unaffected) while 100 unrelated 
healthy patients from the same area as the family served as controls.  
 
Mechanism of CYP11B2 in LVH 
Aldosterone is a major regulator of intravascular volumes and BP and is considered to 
influence cardiac structure and function (Isaji et al., 2005). Aldosterone synthase 
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synthesis occurs within the cardiac tissue that contains the molecular machinery needed 
for CYP11B2 expression (Lombes et al., 1995; Silvestre et al., 1998). The localisation of 
expression makes CYP11B2 an important determinant of LVH through pleiotropic effects 
on LVM. The cardiac growth effects observed could be mediated through both direct 
cellular and/or haemodynamic changes on the heart (Bonvalet et al., 1990; Lombes et al., 
1995).  
 
1.4.4.4. AGTR1   
Most of the effects mediated by ANGII are through the human angiotensin II type-1 
receptor (AGTR1), which belongs to a family of G-protein coupled receptors. The gene 
that encodes the AGTR1 receptor is mapped to chromosome 3q21-15 (Curnow et al., 
1992). The AGTR1 spans 47kb and contains five exons and four introns (figure 1.9). 
AGTR1 is highly polymorphic with at least 50 different SNPs that have been described to 
date (Baudin et al., 2005). The AGTR1 receptor is expressed differently in various CVD, 
it is upregulated in cardiac hypertrophy (Wollert et al., 1997) and downregulated in the 
failing human ventricular myocardium (Asano et al., 1997; Haywood et al., 1997).  
 
AGTR1 and Blood pressure 
The AGTR1 A/C1166 polymorphism in the 3’UTR identified by Bonnardeaux et al., 
(1994) was shown to be associated with hypertension in a case-control association study 
involving 206 Caucasian hypertensive and 298 normotensive  subjects (Bonnardeaux et 
al., 1994). Additionally, case-control studies in Caucasian hypertensive patients indicated 
a significant increase in the C-allele frequency compared to the normotensive group (AA 
or AC) (Bonnardeaux et al., 1994; Wang et al., 1997).  
 
Furthermore, in a study that included 321 Japanese hypertensive subjects and 215 age and 
sex matched normotensive controls, an association was observed between the AGTR1 
1166C-allele and LVMI in normotensive subjects without HCM, independent of age, sex 
and BP (Takami et al., 1998).  
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A case-control study of six promoter region variants of AGTR1 (-1154A/T, -729T/G, -
535C/T, -227A/C, -226G/C and -166A/G) in 149 Japanese hypertensive subjects 
demonstrated that only the AGTR1  -535C/T polymorphism, particularly the -535 T-allele, 
associated with EHT (SBP ≥ 140 and DBP ≥ 90mmHg) (Takahashi et al., 2000). They 
also observed that a synergistic interaction between the AGTR1 -535C/T (T-allele) and 
the ACE1 I/D (the D-allele) polymorphisms determines risk for developing hypertension 
(see section 1.4.5.1).  
 
However, Ono et al., (2003) reported a lack of association between the AGTR1 A/C1166 
polymorphism and hypertension in a large cohort of 1492 Japanese hypertensive subjects. 
Inter-ethnic differences have been suggested to account for the differences in results 
observed in studies (Jiang et al., 2001; Ono et al., 2003). Furthermore, Zhu et al., (2003) 
observed an ethnic-related association between two SNPs in AGTR1 and hypertension in 
patients of African descent. Moreover, six promoter region variants of AGTR1 were 
investigated, although only the -810A/T polymorphism demonstrated a relationship with 
coronary heart disease (CHD) influenced by EHT (Jin et al., 2003). 
 
On the other hand, analysis of the relationship between four RAAS gene polymorphisms 
(ACE1 I/D, AGTR1 A/C1166, 573C/T and AGT -6A/G) and the response to BP in 206 
Caucasian hypertensive patients indicated no association between any of the four RAAS 
gene polymorphisms and reduction of BP following treatment with an angiotensin II 
receptor blocker, telmisartan (Redon et al., 2005).   
 
AGTR1 in cardiovascular structure and function 
Some studies demonstrated no association between the AGTR1 CC genotype and LVH 
(Castellano et al., 1996; Hamon et al., 1997). Castellano et al., (1996) examined 212 
randomly selected individuals from Northern Italy and assessed the relationship between 
the AGTR1 A/C1166 genotype and phenotypes of LVM while adjusting for the influence 
of confounding variables such as age, sex, height, weight, BP, smoking habits and 
biochemical parameters. No association was found even after adjusting for these 
covariates of hypertrophy. The lack of association can possibly be ascribed to a non-ideal 
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study design and insufficient sample size (Castellano et al., 1996).  Similarly, Hamon et 
al., (1997) recruited 141 Caucasian patients with normal coronary arteries for their study, 
but did not find an association between the AGTR1 A/C1166 genotype and phenotypes of 
the LV.   
 
AGTR1 and HCM 
In a study done by Osterop et al., (1998), the AGTR1 A/C1166 polymorphism, 
particularly the C-allele, was associated with a greater LVM in 104 genetically unrelated 
subjects with HCM. The Osterop et al., (1998) study determined LVMI and IVS 
thickness by echocardiographic measurement in a group of severely affected HCM 
subjects (IVS ≥ 15mm) and additionally, quantified the extent of hypertrophy by a point 
score method (Wigle score).  
 
In contrast, Ishanov et al., (1998) found that the AGTR1 A/C1166 polymorphism does not 
contribute to cardiac hypertrophy development in 53 hypertensive patients with LVH and 
96 HCM patients. However, subjects with a family history of HCM who did not manifest 
the disease had a four-fold increase in AGTR1 C and ACE1 D-allele carrier status 
compared to subjects without a family history of HCM.  
 
In a subsequent study, the CC genotype of the AGTR1 A/C1166 polymorphism was 
shown to have an association with LVH in a single family of HCM patients (Ortlepp et 
al., 2002). The study included family members with no HCM-causitive mutations to serve 
as “built-in” controls, in order to control for the effect of population stratification 
(Ortlepp et al., 2002).  
 
Functionality of the A/C1166 polymorphism  
Various mechanisms have been proposed to explain the AGTR1 A/C1166 
polymorphism’s role in CVD. The first evidence for a mechanistic role comes from 
several studies that demonstrate an epistatic interaction between the AGTR1 A/C1166 
polymorphism and ACE I/D polymorphism (Tiret et al., 1994; Alvarez et al., 1998). The 
second mechanism is an increased vasoreactivity of ANGII in the C-allele carriers of the 
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AGTR1 A/C1166 polymorphism (van Geel et al., 2000). The evidence for this is a higher 
BP level in C-allele carriers compared to non C-allele carriers.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Genomic organisation of the human angiotensin II type I receptor gene (AGTR1) 
showing variants investigated in association studies. The locations of various polymorphisms 
being investigated for possible association with LVH (are indicated by vertical black arrows). The 
markers highlighted in red indicate variants investigated in previous association studies and the 
blue highlighted markers indicate variants that have not yet been investigated (Table 1.2 section 
1.3.2). Not indicated are the markers used in previous hypertension association studies, these 
include promoter region variants of AGTR1 (-1154 A/T, -729 T/G, -535 C/T, -227 A/C, -226 G/C 
and -166 A/G) 
 
 
1.4.4.5. CMA  
The human heart chymase gene (CMA) encodes an ANGII-forming serine proteinase 
expressed in the human LV and blood vessels (Urata et al., 1990). The genomic 
organisation of CMA consists of five exons and four introns that span approximately 3kb 
of chromosome 14q11.2 (figure 1.10) (Urata 1991). CMA has a high specificity for 
ANGI, which is cleaved to yield ANGII and Histidine-Leucine (His-Leu) (Urata et al., 
1990). In CMA, only two polymorphisms (1625G/A and -1903G/A) have been 
investigated for association with HCM to date (Pfeufer et al., 1996; He et al., 2005). 
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Figure 1.10: Genomic organisation of the human cardiac chymase (CMA) gene showing variants 
investigated in association studies. The locations of various polymorphisms being investigated for 
possible association with LVH (indicated by vertical black arrows). The markers highlighted in 
red indicate variants investigated in previous association studies and the blue highlighted marker 
indicates a variant that has not yet been investigated (Table 1.2 section 1.3.2).   
 
CMA in LVH 
A recent drug trial demonstrated that treatment of 157 unrelated Chinese hypertensive 
patients (85 males and 72 females) that were matched for age with the antihypertensive 
drug benazepril resulted in a reduction of LVH in ACE1 DD-genotyped patients 
compared to other ACE1 genotypes (II and ID) (He et al., 2005). 
 
However, no association was found between the CMA -1903G/A variant in the 5’ region 
and regression of LVH when treated with the same drug (He et al., 2005). Additionally, 
no evidence was found to support a possible association between ACE1 and CMA in 
regression of LVH (He et al., 2005).  
 
CMA and HCM 
A previous family-based association study failed to illustrate an association between 
CMA -1903G/A variant and LVH in HCM patients (Ortlepp et al., 2002). However, other 
case-control association studies were successful in demonstrating a possible interaction 
between the CMA AA and AG genotypes of 1625G/A polymorphism and ACE1 DD 
genotype in 50 unrelated Caucasian HCM patients and 50 age and gender matched 
controls (Pfeufer et al., 1996) and in 154 patients with type 2 diabetes (Gumprecht et al., 
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2002). He et al., (2005) suggested that their study differed from the Pfeufer et al., (1996) 
and Gumprecht et al., (2002) studies because of the different population groups used, 
genetic heterogeneity, different diagnosis criteria and the level of hypertension and LVH.  
 
1.4.4.6. ACE2  
Recently, a previously unrecognised enzyme, ACE2, has been identified that is involved 
in the reverse reaction of ANGII formation. ACE2 functions as a counter-regulatory 
system to ACE1 by degrading ANGII to ANG 1-7 (Lemos et al., 2002; Ren et al., 2002). 
ACE2 is considered to be involved in regulating cardiac structure and function (Lieb et 
al., 2006). The ACE2 enzyme is a homologue of ACE1 and is highly expressed in the 
heart, kidneys and testes (Donoghue et al., 2000; Tipnis et al., 2000). The ACE2 enzyme 
is encoded by the ACE2 gene mapped to the X-chromosome. The human form of ACE2 
comprises 18 exons and 17 introns (figure 1.11) and encodes 805 amino-acid residues 
(Danilczyk et al., 2003). To date, no studies of ACE2 involvement in HCM have been 
published. 
 
 
Figure 1.11: Genomic organisation of the human angiotensin-converting enzyme 2 (ACE2) gene 
showing variants investigated in association studies. The locations of various markers (SNPs) 
being investigated for possible association with LVH (indicated by vertical black arrows). The 
markers highlighted in red indicate variants investigated in previous association studies and the 
blue highlighted marker indicates a variant that has not yet been investigated (Table 1.2 section 
1.3.2).   
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ACE2 and blood pressure 
It is suggested that ACE2 is a good candidate for studying hypertension in rats because 
both ace2 and hypertension has been genetically mapped to QTL on the X-chromosome 
in three different rat models (Crackower et al., 2002). Additionally, it was demonstrated 
that ACE2 disruption resulted in reduced cardiac contractility and increased ANGII 
circulating levels in rats (Crackower et al., 2002). However, investigations of human 
ACE2’s role in hypertension showed no association between any of the four intronic 
SNP’s spread across the gene (1075A/G, 8790G/A, 28330C/G and 36787G/C) with EHT 
in an Australian Caucasian population (Benjafield et al., 2004). 
 
ACE2 and LVH 
A MONICA echocardiographic sub-study of 1294 German subjects stratified according 
to gender and age found that polymorphisms of ACE2 might be associated with LVH. 
Lieb and colleagues (2006) found a positive correlation between the minor alleles of four 
variants (T-allele of rs4646156, G-allele of 28330C/G, G-allele of rs4240157 and the C-
allele of rs233575) in men, resulting in a shared common haplotype TGGC for LVM, 
septal wall thickness (SWT) and LVH. However, women showed no association between 
any of these minor alleles or any haplotype consisting of these four SNP’s investigated 
and LVH (Lieb et al., 2006). The Lieb et al., (2006) study found gender-specific 
associations in the general population. The study also adjusted for covariates of 
hypertrophy, namely, age, body mass index (BMI), systolic BP and antihypertensive 
medication. Additionally, pair-wise analysis suggested that the four ACE2 SNP’s are in 
LD (Lieb et al., 2006).  
 
Interestingly, a correlation has been observed between ACE2 mRNA upregulation in 
DCM and ischaemic cardiomyopathy (ICM) patients and in both human and rat hearts 
after MI (Goulter et al., 2004; Burrell et al., 2005).  
 
Summary of the Role of RAAS gene variants in LVH and HCM in general 
In summary, some genetic studies provide evidence for the role of genetic variants within 
the RAAS to be associated with electrocardiographic or echocardiographic determined 
LVH (Iwai et al., 1994; Schunkert et al., 1994; Delles et al., 2001; Schmieder et al., 
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2001). However, contradictory results exist on the role of RAAS gene variants in HCM 
(Marian et al., 1993; Lechin et al., 1995; Yoneya et al., 1995; Brugada et al., 1997; 
Ishanov et al., 1997; Tesson et al., 1997; Osterop et al., 1998; Ortlepp et al., 2002), and 
thus the present study will attempt to elucidate whether there is a role for RAAS gene 
variants as modifiers of the hypertrophic phenotype in South African families in which 
HCM-causing founder-mutations segregate (Moolman-Smook et al., 1999).  
 
1.5. Bioinformatics 
For the current study, literature on case-control studies performed in various ethnic 
groups (sections 1.4.5.1 to 1.4.5.6) that demonstrated or failed to show association of 
RAAS gene variants with LVH and hypertension (mentioned in section 1.3.2 table 1.2 ) 
were electronically accessed from the Pubmed (http://www.ncbi.nlm.nih.gov/PubMed) 
database. Furthermore, the Pubmed database is linked to databases containing all 
experimentally-derived and computer-predicted biological information on the genes and 
clinical conditions being investigated. A brief introduction to the “database mining” 
approach used in the present study is provided below.  
 
The sequencing of the human genome has generated genomic data for use in developing 
new technologies within biological fields (International Human Genome Sequencing 
Consortium, 2001; Venter et al., 2001; Baxevanis et al., 2003). This has facilitated the 
combination of both laboratory techniques and computer programs to form one discipline 
termed bioinformatics (Baxevanis et al., 2003). This newly developed resource is 
computationally integrated within various databases to a specific biological segment 
either DNA, RNA or protein format accessible to users. A total of 968 databases are 
listed within the January 2007 Nucleic Acid Research (NAR) issue (Galperin et al., 2007) 
and are accessible via the NAR website at http://www.nar.oupjournals.org. 
 
For the present study, three primary human genome sequence databases, The National 
Centre for Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov), 
Ensembl (http://www.ensembl.org) and the University of California Santa Cruz (UCSC) 
database (http://www.genome.ucsc.edu) were used to access published information on the 
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genes involved in hypertension and HCM. Compiled within these three databases are 
detailed annotations of the human genome, as well as additional features such as 
repetitive DNA, CpG islands, expressed-sequence tags (ESTs) and, most importantly for 
this research, SNPs. The databases include programs that enable certain computational 
manipulations like data input, retrieval, sequence comparisons and functional prediction.  
 
During 2002, a global initiative (called the International HapMap project) was undertaken 
to develop a new bioinformatic tool to aid in assessing biological information in a more 
user friendly way, thereby reducing costs of genotype-phenotype association studies on 
various disease. The following section will briefly discuss the HapMap project and its 
goals and applications.  
 
In 2002, the International HapMap project was established to determine common patterns 
of DNA sequence variation in the human genome and to make this information freely 
available in the public domain (The International HapMap Consortium, 2003). This 
international consortium developed haplotype maps of the common DNA patterns across 
the genome by characterising sequence variants, their frequency and correlations between 
them, in DNA samples from population groups from African, Asian and European 
descent. In 2005 the HapMap project deposited data on new “tag” SNPs, allele and 
genotype frequencies released into the public domain onto the internet at the HapMap 
data coordination Center (DCC) (http://www.hapmap.org). The availability of this tagged 
data could provide a new tool for investigating genetic factors that contribute to disease 
susceptibility, protection against illnesses and to individual drug response (The 
International HapMap Consortium, 2003).  
 
1.6. The present study: Aim and design 
The objectives of this study were to elucidate the possible role of hypertrophy modifier 
genes by, firstly, selecting genes involved in the RAAS, secondly, looking for variations 
in these genes, thirdly, prioritising variations for investigation and, fourthly, investigating 
a role for the selected candidate modifier genes in the clinical phenotype by family-based 
association studies.  
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The present study focused on previously postulated hypertrophy-modifier candidate 
genes, such as those involved in the peptide hormone pathways, specifically the RAAS. 
The rationale was that variation in, or modulation of, components of these pathways have 
been shown to have some effect on the extent of hypertrophy that develops in the 
presence of an HCM-causing mutation, as shown in animal models and HCM patients 
(Semsarian et al., 2001; Marian et al., 2002). However, previous association studies were 
inconsistent in design, covariates adjusted for, parameters tested, and in results generated, 
as discussed earlier, and thus the interpretation of the results remained inconclusive and 
warranted further investigation. 
 
Using a candidate gene approach and prioritising SNPs that have been used in previous 
studies allows a more robust opportunity to test their role in the development of 
hypertrophy and hypertension. Moreover, as previous case-control studies were less than 
optimally designed for detecting genetic modifiers of hypertrophy, their analysis often 
consisted of investigating only single SNPs within genes in population groups that were 
frequently not matched for genetic background or causal mutation (reviewed by Marian 
et al., 2002 and sections 1.4.5.1 to 1.4.5.6).  
 
The current association study improves on previous studies by investigating a range of 
SNPs across each gene using a large group of 353 subjects that are of Caucasian and 
Mixed-Ancestry descent, in which the causal-mutation status was known. Specifically, 
this study focused on 22 South African HCM families, 12 of which harbour the 
Ala797Thr founder mutation in MYH7, three harbour the Arg403Trp founder mutation, 
also within MYH7, and seven harbour the Arg92Trp founder mutation in TNNT2. 
 
Study design: 
The Pubmed (http://www.ncbi.nlm.nih.gov/PubMed) publication database was searched 
for genes involved in the RAAS. The NCBI database was used to retrieve genomic 
nucleotide sequences for six selected RAAS genes (ACE1, AGT, AGTR1, CYP11B2, 
CMA and ACE2), which included annotations of previously reported SNPs’ positions. At 
least three intragenic SNPs spread throughout each gene were chosen to be investigated 
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except in CMA where only two SNPs were chosen. SNPs that had been previously 
investigated in other studies and had a high heterozygosity value (>40%) were given 
selection priority. Primers were designed to flank regions containing selected SNPs and 
were used for PCR amplification of 353 individuals of the 22 South African HCM 
families described above. The PCR products were genotyped using Snapshot primer 
extension analysis and allele specific restriction enzyme analysis (ASREA). Sequence 
variants identified by SNaPshot were validated by automated sequence analysis in a 
representative sample, ~10% of the SA HCM cohort. Thereafter, association was 
investigated between identified genotypes and the disease phenotype by performing 
quantitative transmission disequilibrium test (QTDT) analysis (refer to figure 1.12 for a 
study design summary). However, the X-linked gene ACE2 was statistically analysed 
with mixed-effects models using the program R (R Development Core Team., 2007), as 
at the time of writing, no X-linked family-based association analysis program existed that 
was capable of handling multi-generation families of various sizes, and also allowed for 
covariate adjustment. 
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Bioinformatics tools and published material 
(for association status of previously postulated candidate modifier genes) 
 
 
Six genes involved in the RAAS selected 
 
 
 
Panel of 22 HCM families (carriers 195 and non-carriers 158) 
(Carriers harboured one of the 3 distinct HCM-causative mutations in MYH7 or TNNT2) 
 
 
 
 
 
 
Primers designed for prioritised SNPs 
 
 
 
Genotyping via 
PCR-based methods 
 
 
 
 
Snapshot primer extension analysis  Automated Sequencing  ASREA 
          
        
  
 
 
 
 
 
QTDT analysis 
 
Figure 1.12: Summary of the design of the present study, explained in detail in the text. 
Abbreviations: SNP- single nucleotide polymorphism, PCR- polymerase chain reaction, ASREA- 
allele specific restriction enzyme analysis, QTDT- quantitative trait disequilibrium test. 
 
 
 
Mixed-effects models 
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CHAPTER 2 
2. Materials and Methods: 
2.1. Study subjects 
The University of Stellenbosch (US) Ethics Committee reviewed and granted approval 
for the present study (N04/03/062). Subjects entered into the study gave written informed 
consent and blood samples were collected from each subject for molecular genetic 
testing. During routine mutation screening for HCM-causing mutations, a panel of HCM 
probands was screened for disease-causing mutations in 11 sarcomeric genes that account 
for 95% of all HCM. In the process, 22 probands carrying one of three mutations that 
occur as founder mutations in South Africa, viz. R92W in TNNT2, R403W in MYH7 and 
A797T in MYH7 (previously described within a South African population by Moolman-
Smook et al., 1999), were identified. Pedigree tracing was performed for these 
individuals and family members asked to participate in this modifier gene study. These 
families were of South African Caucasian and of Mixed Ancestry descent (table 2.1). 
Thus, a panel of 353 individuals that included genetically and clinically affected and 
unaffected family members was identified and these individuals were screened for the 
presence of all three founder mutations. 
 
The subjects used in the present study are individuals 18 years and older and were 
comprehensively clinically characterised by 2D-echo performed by a single cardiologist 
(Dr Miriam Revera from Pavia University, Italy) who was unaware of the mutation status 
of each subject. Analysis included echocardiographic recordings in M-mode, 2D and 
Doppler blood-flow imaging using a 2,5Hz transducer in standard parasternal long-axis 
and short-axis, apical four-and two-chamber views using a GE Healthcare Vivid7 
cardiovascular ultrasound system. To determine the maximal wall thickness (MWT), the 
heart muscle was divided into three levels, namely, mitral valve, papillary muscle and 
supra-apex level (figure 2.1). 2D-echo measurements were done in 6 segments of the 
mitral valve and papillary muscle levels, and in four segments of the smaller supra-apex 
level, thus in total 16 segments (figure 2.2).  The six segments measured in the mitral 
valve and papillary muscle levels consisted of the anterior interventricular septum (aIVS), 
posterior interventricular septum (pIVS), anterior wall (AW), lateral wall (LW), inferior 
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wall (IW) and posterior wall (PW). Evaluation of the supra-apex level consisted of 
segments IVS, AW, LW and PW as per four chamber view. All these variables were 
measured according to the recommendation of the American Society of 
Echocardiography (http://www.asecho.org/guidelines.php) while the atrium volumes 
were measured using the biplane area-length method (Schiller et al., 1989). Covariates of 
cardiac structure were noted for each participant; these included systolic BP (SBP), 
diastolic BP (DBP), age, sex, body surface area (BSA) and heart rate (HR).  
 
Table 2.1: South African HCM-affected families of Caucasian and Mixed Ancestry 
descent that were analysed in the present study. 
 
  Pedigree Ethnic group n Gene Mutation Location
1 131 Caucasian 25 MYH7 A797T exon 21 
2 101 Caucasian 22 MYH7 A797T exon 21 
3 104 Mixed Ancestry 14 MYH7 A797T exon 21 
4 124 Caucasian 4 MYH7 A797T exon 21 
5 123 Mixed Ancestry 16 MYH7 A797T exon 21 
6 138 Caucasian 32 MYH7 A797T exon 21 
7 145 Mixed Ancestry 4 MYH7 A797T exon 21 
8 147 Mixed Ancestry 10 MYH7 A797T exon 21 
9 158 Caucasian 5 MYH7 A797T exon 21 
10 159 Mixed Ancestry 11 MYH7 A797T exon 21 
11 163 Caucasian 9 MYH7 A797T exon 21 
12 172 Caucasian 8 MYH7 A797T exon 21 
13 106 Mixed Ancestry 69 MYH7 R403W exon 13 
14 134 Mixed Ancestry 9 MYH7 R403W exon 13 
15 157 Mixed Ancestry 4 MYH7 R403W exon 13 
16 100 Mixed Ancestry 43 TNNT2 R92W exon 9 
17 103 Mixed Ancestry 5 TNNT2 R92W exon 9 
18 109 Mixed Ancestry 8 TNNT2 R92W exon 9 
19 139 Mixed Ancestry 41 TNNT2 R92W exon 9 
20 137 Mixed Ancestry 7 TNNT2 R92W exon 9 
21 149 Mixed Ancestry 10 TNNT2 R92W exon 9 
22 173 Mixed Ancestry 2 TNNT2 R92W exon 9 
n = number of individuals screened for SNPs in the present study includes mutation and non-mutation 
carriers, MYH7 -myosin heavy chain gene 7; TNNT2- troponin T gene 2.  
 
Additional hypertrophy parameters, viz. LVM, the Wigle score (Wigle et al., 1985), 
Spirito-Maron score (Spirito and Maron et al., 1990) and two dimensional left ventricular 
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hypertrophy score (2-DLVH) (Forissier et al., 2005), were calculated to better describe 
the extent of hypertrophy. The Wigle score is a semi-quantitative point score method 
proposed by Wigle et al., (1985) which uses a 10 point scale (refer to section 1.2). The 
Spirito-Maron score is the sum of greatest wall thickness observed at the mitral valve 
level in any one of the segments and the greatest wall thickness in any one of the 
segments at the papillary level, as per definition (Spirito and Maron et al., 1990) (refer to 
section 1.2), while the 2-DLVH-score is the sum of measurements of MWT in each of the 
segments at both the mitral valve and papillary level as per definition (Forissier et al., 
2005) (refer to section 1.2). Additionally, a new cumulative wall thickness score (CWT) 
was determined by adding the wall thickness in all three levels of the heart, thus in the 16 
segments in total.  
 
The clinical information for each subject was archived in a Microsoft excel file (in M-
link format), independently from the primary pathogenic mutations and RAAS genotype 
status. 
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Fig 2.1: Graphical representative example of the heart being divided into 3 levels.  A) Long-
axis view of left ventricle, taken at level of mitral valve, papillary muscles as well as just above 
apex (levels indicated by dotted lines). B) An example of a 2D echo ultrasound of the left 
ventricle. Abbreviations: AV- aortic valve, LA-left atrium, LV-left ventricle, LVOT-left 
ventricular outflow tract, MV- mitral valve, RVOT-right ventricular outflow tract. Taken from 
(http://www.med.yale.edu/.../aortic_regurgitation.html) with minor modifications by JC 
Moolman-Smook. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
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Fig 2.2: Diagrammatic representation of the cardiac wall thickness measurements.   
Short-axis view of left ventricle indicating the six segments into which the cardiac walls of the 
mitral valve and papillary muscles were divided. Not indicated is the apex wall, which was 
divided into four segments. 
 
2.2. Blood collection 
Blood from each individual was collected in 2x 5ml ethylene-diamine-tetra-acetic acid 
(EDTA) tubes (Vacutainer, RSA) for DNA extraction and in 1x 10ml heparin tube 
(Vacutainer, RSA) to establish a permanent lymphoblastoid cell lines using the method 
described by Neitzel (1986). Blood that was drawn from patients at other centres in South 
Africa was couriered to the research laboratory within 24 hours of sampling. 
 
2.3. DNA extraction 
2.3.1 Extracting nuclei from whole blood 
DNA was extracted from nucleated blood cells using the method previously described by 
Corfield et al., (1993) with minor modifications. The DNA extractions were performed 
by Mrs Ina le Roux. A list of the solutions used for DNA extractions is provided in 
Appendix I.  
 
 
Right ventricle 
 
Lateral wall 
Posterior wall
Anterior wall
Inferior wall 
Posterior septum 
Anterior septum 
Left ventricle cavity 
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2.4. Bioinformatic selection of candidate, RAAS gene sequences 
From the literature, six genes known to be involved in the RAAS were selected to be 
investigated (table 2.2). Publication databases (Pubmed/Medline) 
(http://www.pubmed.gov) were searched for information on the reported association 
status of these genes in hypertrophy and hypertension. The National Centre for 
Biotechnology Information (NCBI) database (http://www.ncbi.nlm.nih.gov) was used to 
retrieve genomic nucleotide sequences which included annotations of previously reported 
SNPs’ positions for the chosen genes. The SNPs selected were those that had been 
previously investigated in other studies as well as novel SNPs that have a high 
heterozygosity value (≥0.4), validated by calculated frequency of alleles within African 
American and European Caucasian ethnic groups (URL: dbSNP). Additionally, 
polymorphisms that occur in functionally important regions (promoter or exonic) of the 
gene also received selection priority, as they have the potential to result in protein 
sequence changes or changes that may affect gene expression levels. Further 
bioinformatics applications that involved designing primers for both polymerase chain 
reaction (PCR) and SNaPshot primer extension technique will be discussed in further 
detail later.  
 
2.5. Polymerase chain reaction (PCR) 
The PCR is a technique that enables rapid in vitro amplification of a specific DNA 
fragment which is flanked by unique regions to which oligonucleotide primers are 
designed (Saiki et al., 1985). Primers bind to these regions and lead to exponential 
amplification of the target region (figure 2.3). The PCR technique was used to amplify 
the polymorphic regions of the six chosen RAAS genes.  
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Table 2.2 Candidate genes: ACE1, CYP11B2, AGTR1, AGT, CMA and ACE2 chosen 
for investigation. 
Gene Localisation Size (kb) Protein function References 
(Association)  
ACE1 17q23 44.770 converts ANGI to ANGII,  a potent vasoconstrictor 1 (LVH) 
CYP11B2 8q22 7.284 
catalyses conversion of  
 11-deoxycorticosterone  
to aldosterone 
2 (LVH) 
AGTR1 3q21 45.123 receptor for angiotensin II 3 (LVH) 
AGT 1q42 11.582 
cleaved by renin to yield  
angiotensin I, leads to 
angiotensin II formation 
4 (LVH) 
CMA 14q11 2.759 breaks ANG I down to  ANG II 5 (LVH) 
ACE2 Xp22 39.981 hydrolyses ANG II →  ANG (1-7) 6 (LVH) 
Abbreviations used: ACE1-angiotensin-1 converting enzyme; ACE2-angiotensin converting enzyme 2; 
AGT-angiotensinogen; AGTR1-angiotensin 2 type-1 receptor; ANGI-angiotensin 1, ANGII-angiotensin 2, 
CMA-cardiac chymase; CYP11B2-aldosterone synthase; HCM-hypertrophic cardiomyopathy; kb-kilo-
bases; LVH-left ventricular hypertrophy. References for positive and negative association of genes listed 
with LVH: 1) Lechin et al., 1995 and Tesson et al., 1997; 2) Patel et al., 2000; 3) Osterop et al., 1998; 4) 
Brugada et al., 1997 and Yamada et al., 1997; 5) Pfeufer et al., 1996; 6) Lieb et al., 2006.  
 
2.5.1. Oligonucleotide primers 
Oligonucleotide primers were designed from published gene sequences with the aid of 
the primer design program DNAMAN version 4.1 (Lynnon Biosoft, USA) (table 2.3). 
The fragments to be amplified contained more than one SNP, thus primers were selected 
from DNA sequence 120 base pairs (bp) 5’ or 3’ to the relevant outermost SNPs. These 
sequences were copied and pasted into DNAMAN for subsequent primer designing. 
Primers were designed to have melting temperatures between 50 oC and 65 oC and the 
guanine-cytosine (GC) content of each primer ranged from 40 to 60%. Primers were 
discarded if possible potential hairpin formations with greater than three intrastrand 
bonds were detected, meaning a primer would be able to fold upon itself to form a hairpin 
structure. For each primer the length was ≥ 18bp (table 2.3). In addition, primer sets that 
contained a GC sequence (clamp) at their 3’ ends were always chosen, because of their 
ability to form three hydrogen bonds, (compared to two by nucleotides AT) with their 
complimentary base pair. The PCR-amplification primers were custom synthesised at 
Inqaba Biotec (Pretoria, RSA) or the DNA laboratory, University of Cape Town. 
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Thereafter, PCR reactions were performed to amplify relevant fragments for each gene as 
template for SNaPshot analysis (see section 2.7.2.1) or allele-specific restriction enzyme 
analysis (ASREA) (see section 2.7.3). 
 
2.5.2. SNaPshot interrogation primer design 
The oligonucleotide primers designed for SNaPshot primer extension reactions differed 
between 4-6 nucleotides in length. This was a necessity in order to avoid overlap between 
the final SNaPshot products, if two or more primers were to be combined in a single 
SNaPshot reaction termed multiplexing. The primers for the present study were designed 
only in the forward direction and were designed to bind upstream of the SNP and 
terminate directly 5’ of the SNP site (Makridakis and Reichardt, 2001) (figure 2.4). (table 
2.4). SNaPshot interrogation primers were custom synthesised at the DNA Laboratory, 
Department of Biochemistry, University of Cape Town (UCT), RSA. All primers 
underwent High Pressure Liquid Chromatography (HPLC) purification (Makridakis and 
Reichardt, 2001), even though the primers were shorter than 30 nucleotides, in order to 
prevent failure sequences from possibly extending at incorrect positions. 
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Fig 2.3: Amplification of specific nucleotide sequences using PCR.  The double stranded DNA is 
separated into two strands. The two oligonucleotide primers that are complimentary to each anneal to each 
separated strand, a DNA polymerase finds each of the primer’s binding site and starts the synthesis of the 
new double stranded DNA molecules. This cycle is repeated for 30 cycles and produces PCR product that 
doubles in each cycle. 
Reproduced and adapted from Molecular Biology of the Cell, 3rd edition. 
 
 
2.5.3. PCR-amplification conditions 
To prepare the amplification reaction mixture, 75μM of each dATP, dCTP, dGTP and 
dTTP (Promega Corp, Madison Wisconsin USA), 5 microlitres (μl) of a 10X Taq DNA 
polymerase buffer (Bioline UK Ltd, London, UK), 150ng of each oligonucleotide primer 
(table 2.3), 0.5 unit (U) Taq DNA polymerase (Bioline UK Ltd, London, UK), 1.5mM 
MgCl2, and water to a final volume of 50μl were added to individual, labelled 0.5ml 
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Eppendorf centrifuge tubes. Finally, 200 nanograms (ng) of genomic DNA as template 
was aliquoted into each tube. For fragments 1 and 3 of CMA, fragment 3 of AGT and 
fragment 2 of ACE1, 5% formamide (Sigma, RSA) was added to reduce non-specific 
amplification. For fragments 1 and 2 of AGT, fragment 1 of ACE1, fragments 1, 2, 3 and 
4 of CYP11B2 and fragments 1, 2, 3, and 4 of ACE2 no additives were used, while for 
fragment 3 of ACE1 and 5% dimethylsulfoxide (DMSO) (Sigma, RSA) was added to the 
reaction mixtures to reduce non-specific amplification.  
 
Amplification was performed in a Perkin-Elmer thermal cycler (Applied Biosystems Inc, 
Foster City CA, USA). The cycling parameters and the PCR conditions for each set of 
oligonucleotide primers are shown in table 2.5. After cycling had been completed, 
amplification products were analysed on either a 1% or a 2% agarose gel (Hispanger, 
Spain), depending on the sizes of fragments generated.  
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Table 2.3: Primer sequences used to amplify polymorphic sites in candidate genes. 
Outer primers 
gene/ 
protein FRAGMENTS 
forward  
primer 
 5'-3' 
length 
bp 
reverse  
primer 
 5'-3' 
length
 bp 
PCR 
product 
size, bp 
ACE1 
1 ctcaccaacatcctggcttcc 21 gcctgcttcttcatgcatcg 20 1274 
2 gactctgtaagccactgctgg 21 ccaacaccacattacctgcc 20 450/737 
3 cagccttgggtcttaacc 18 tggcagtgttagaatggc 18 1198 
CYP11B2 
1 tcgagattcctcacatgg 18 cttatcgtgagatgagaggg 20 177 
2 gaacccagatgtgctgtcg 19 catagagttggccttgatggc 21 907 
3 cgtttcccttgctgatgacg 20 agattctgtctgccaccaccc 21 244 
4 tggtgagctcagacttggtgc 21 gagttccatttgtgcaggagc 21 1011 
5 atgtgtgcctgcgaatgg 18 agtcttctcctggcctgtgg 20 156 
AGTR1 
1 tcctagacacgggacatcg 19 tggagggaaccttatggg 18 992 
2 aatacagtgcagacctgg 18 attgctgaggaagattgc 18 1120 
3 ttgtagccaaagtcacctgc 20 aatgtgcagtaccaggtgc 19 1141 
AGT 
1 catctgtccttctggccagc 20 ccgggctgaatgctaaagg 19 1030 
2 ttccatggagctttgaatcc 20 ttgccttaccttggaagtgg 20 1328 
3 caccttcaatgcagccaacc 20 tccttgcagcaccagttgg 19 332 
CMA 1 ggaaatgtgagcagatagtgcagtc 25 aatccggagctggagaactcttgtc 25 185 
2 tccttcaggtcctcattgcc 20 agtctctgaagtggctgcagg 21 333 
ACE2 
1 tcttcctggctccttctcagc 21 accacaatggcagagaaaggg 21 1044 
2 gtttgtaacccagataatcc 20 gttgaaacacacatatctgc 20 130 
3 ttgtgttaagatcttgtccc 20 aataaactgagctccagc 18 188 
4 tacagggaggaggatgtgcg 20 tgatggcaatacctgtccacg 21 680 
Abbreviations used: ACE1-angiotensin-1 converting enzyme; ACE2-angiotensin converting enzyme 2; AGT-angiotensinogen; AGTR1- angiotensin2 
type-1 receptor; bp-base pairs; CMA-cardiac chymase; CYP11B2-aldosterone synthase. For ACE1 fragment 2 the two fragment sizes correspond to 
deletion allele (450bp) if present or insertion allele (737bp) if present. 
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Table 2.4: SNaPshot primer sequences used in primer extension analysis to detect ACE1, AGT and CMA gene variants. 
 
Abbreviations used: ACE1-angiotensin-1 converting enzyme; AGT-angiotensinogen; bp-base pairs; CMA-cardiac chymase. 
 
 
 
 
 
 
 
 
 
 
 
 
SNaPshot primers 
gene 
 
region/ 
site SNP Sequence (5'- 3') 
primer 
sets 
length  
bp location 
ACE1 rs4298 c/t tgggagggctggcacaa 1 17 exon rs4303 g/t acctccatgccttcgtccgccgc 23 exon 
AGT 
rs5051 c/t agaacaacggcagcttcttcccc 1 23 promoter 
rs4762 c/t ccagctgctgctgtcca 2 17 promoter rs699 c/t gacaggatggaagactggctgctccctga 29 promoter 
rs11122575 t/c tcttctatgtccctcacatagtattgcaaatgaca 3 35 intronic rs1926723 a/g tcttctatgtccctcacatagtattgcaaatgaca 23 intronic 
CMA rs1800875 a/g cctcagccaggcaggtg 1 17 promoter rs1885108 g/a actgtccagagcccatttcgaggactgac 2 29 intronic 
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Table 2.5: PCR cycling conditions used in amplification of polymorphic sites in ACE1, CYP11B2, AGTR1, AGT, CMA and 
ACE2 candidate genes. 
gene/ 
protein 
region or 
site Fragments 
TD  
oC 
Time  
sec 
TA  
oC 
Time  
sec 
TE  
oC 
Time  
min 
ACE1 ~ 
rs4298/ rs4303 1 94 30 63 oC 40 72 1 
rs4342/ rs4343 2 94 30 57oC 40 72 1 
rs4364/ rs4365 3 94 30 62oC 40 72 1 
CYP11B2 * 
rs1799998 1 94 30 49oC 30 72 1 
rs4539 2 94 30 58oC 30 72 1 
rs5314/ rs3097 4 94 30 60oC 30 72 1 
AGTR1 
rs2640539 1 94 30 54oC 30 72 1 
rs3772627 2 94 30 58oC 30 72 1 
rs5182/ rs5186 3 94 30 61oC 30 72 1 
AGT 
rs5051 1 94 30 55oC 30 72 1 
rs699/ rs4762 2 94 30 53oC 30 72 1 
rs11122575/ rs1926723 3 94 30 55oC 30 72 1 
CMA 
rs1800875 1 94 30 57oC 40 72 1 
rs1885108 2 94 30 57oC 40 72 1 
ACE2 
rs1978124 1 94 30 60oC 30 72 1 
rs2285666 2 94 30 43oC 30 72 1 
rs879922 3 94 30 48oC 30 72 1 
rs4646179 4 94 30 59oC 30 72 1 
Abbreviations used: ACE1-angiotensin-1 converting enzyme; ACE2-angiotensin converting enzyme 2; AGT-angiotensinogen; AGTR1- angiotensin 2 
type-1 receptor; CMA-cardiac chymase; CYP11B2-aldosterone synthase; oC-degrees Celcius; min-minute; sec-seconds; TA-annealing  temperature; TD-
denaturing temperature; TE-extension temperature. * CYP11B2 fragments 3 and 5 were amplified but the SNPs within these fragments were not 
considered for the present study and thus omitted. ~ ACE1 fragments 2 and 3 contained the SNPs rs4342, rs4343 and rs4364 which were omitted from 
the association results because their genotypes did not have a 100% correspondence with the sequencing results.   
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2.6. Gel electrophoresis 
2.6.1. Agarose gel electrophoresis 
Verification of PCR-amplification was performed by electrophoresis, allowing 
visualisation of DNA bands on an agarose gel. The agarose gel was prepared by mixing 
1g or 2g of agarose powder (Whitehead Scientific, RSA) with 100ml of 1 X TBE or 1 X 
di-sodium tetraborate-decahydrate (SB) for a 1% or 2% agarose gel (Appendix I). The 
mixture was then heated in the microwave oven until the agarose was completely 
dissolved and thereafter left to cool for 2 minutes. Five microlitres of (10mg/ml) ethidium 
bromide (Whitehead Scientific, RSA) was added to the agarose solution, which was then 
poured into a casting tray containing a well-forming sample comb and allowed to solidify 
at room temperature. 
 
After solidification of the gel, the comb was removed and the gel was placed horizontally 
into the electrophoresis chamber and covered with buffer (1XTBE or 1XSB) (Appendix 
I). Electrophoresis was performed as follows: 8μl of each amplification product was 
mixed with 1μl of bromophenol blue loading dye (Appendix I) and then pipetted into the 
sample wells. One of two molecular size markers were used to co-electrophorese with 
PCR products, these included bacteriophage λ DNA (Promega, USA), which had been 
digested with Pst I restriction enzyme (λ Pst) (Promega,USA) and 100bp DNA ladder 
(Appendix I). Electrophoresis of samples occurred at 200-300V for 15-20 minutes in 1X 
SB buffer solution or at 100-150V in 1X TBE for 30-45 minutes. Electrophoretically 
seperated PCR samples were then visualised under ultra violet (UV) light using the 
Syngene gel documentation G-box HR (Frederick, MD, USA). A permanent 
photographic record of the gel analysis was obtained again using the Syngene gel 
documentation G-box HR (Frederick, MD, USA).  
 
2.6.2. 12% non-denaturing polyacrylamide gel electrophoresis (PAGE) 
For detection of polymorphic restriction enzyme recognition sites, non-denaturing 
polyacrylamide gels were used to differentiate between 100bp and smaller fragments. 
This method involves size separation of restriction enzyme digests using a 12% 
polyacrylamide solution (Appendix I). The polymorphisms detected using 12% 
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polyacrylamide gels included, CYP11B2 rs1799998, rs4539 and rs3097, AGTR1 
rs2640539, rs3772627 and rs5182, ACE2 rs1978124, rs2285666, rs879922 and 
rs4646179, and ACE1 rs4365 (table 2.7).  
 
2.6.2.1. Casting the gel 
For a large number of samples, two 400mm x 800mm wide plates, termed the notched 
(front) and un-notched (back) plates, were washed with Cal-liquid hand soap (Cal-Chem, 
RSA), rinsed and dried using paper towels. The plates were treated with 70% ethanol 
sprayed onto the surfaces and wiped clean using paper towels. GelbondTM PAG polyester 
film (FMC, Bioproducts, Rocklands, Maine, USA) was attached to the back plates 
surface by its hydrophobic side, after spraying 70% ethanol between the plate and the 
gelbond. The exposed hydrophilic side enhances covalent bonding between the gel 
solution and the gelbond film to create a solid support for subsequent staining of the gel. 
One millimetre spacers were sprayed with 70% ethanol and placed onto the back plate 
with the front plate being placed on top of the spacers to create a space for the later 
insertion of a comb. The plates were clamped firmly together and were sealed at the 
bottom and the sides using gel-sealing tape (Sigma, Germany). Finally, the gel solution 
was poured between the two assembled plates and a well-forming comb was inserted 
between the plates. Thereafter the gel was allowed to polymerise for 30 minutes before 
use. 
 
2.6.2.2. Electrophoresis 
After the gel had polymerised, the gel-sealing tape was removed from the bottom of the 
plates, and the “well-forming” comb was also removed. The gel was vertically mounted 
and clamped onto the gel electrophoresis apparatus (Scigen vertical mini apparatus, 
Whitehead Scientific, R.S.A); if wider plates were used, the larger gel electrophoresis 
apparatus (Omeg scientific, RSA) was used. The buffer chambers of the apparatus were 
filled with 1xTBE electrophoresis buffer (Appendix I) and the wells were washed with 
buffer to remove any acrylamide residue. The digested PCR products (20μl) were mixed 
with bromophenol blue loading dye (10μl) to give the sample density and aid in 
visualisation. Thereafter, the total (30μl) of the digested samples, an undigested sample 
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and a 100bp generuler (Inqaba Biotec, RSA) were loaded into separate wells and 
electrophoretically separated for 2-3 hours at 150 volts (room temperature).  
 
2.6.2.3. Silver staining 
Following completion of electrophoresis of samples, the gel apparatus was dismantled 
and the gel removed. The gel supported by the GelbondTM (or the gel itself for smaller 
gels) was placed into a suitable size tray covered with solution B (0.1% AgNO3) 
(Appendix I) and agitated on a Labcon shaker (Labdesign, Maraisburg) for 10 minutes. 
Solution B was then decanted and the gel rinsed with water. Subsequently, solution C 
(Appendix I) was added to the tray containing the gel and then agitated until stained 
bands were visible. The gel was viewed on a white light illuminator box (Lauda 
Thermostat, Germany) and photographed using the Syngene gel documentation G-box 
HR (Frederick, MD, USA). The gel was sealed in a plastic bag for future reference. 
 
2.7. Genotype analysis 
2.7.1. Genotyping ACE1 I/D polymorphism 
PCR-amplification was used to genotype individuals for the insertion/deletion (I/D) 
polymorphism located within ACE1. The primers amplified either 737-bp genomic DNA 
segment if the insertion (I) allele was present or a 450-bp segment if the deletion allele 
(D) was present. Both fragments were amplified in heterozygotes (ID). Visualisation of 
the PCR products was done by electrophoretic separation on a 2% agarose gel stained 
with ethidium bromide. The results generated on those samples previously included in the 
study by the Tesson et al., (1997) were compared to present study results. 
 
2.7.2 Genotyping of SNPs 
Some of the SNPs localised within ACE1, AGT and CMA were genotyped performing 
SNaPshot primer extension analysis (table 2.6), while other SNPs localised within 
CYP11B2, AGTR1, ACE2 and ACE1 were genotyped performing allele specific 
restriction enzyme analysis (ASREA) (table 2.7).  
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Table 2.6: Thermal cycling conditions for SNaPshot multiplex primer extension analysis. 
gene 
 
region or 
site Fragments
TD  
oC 
Time 
sec 
TA  
oC 
Time 
sec 
TE  
oC 
Time 
min 
ACE1 rs4298/rs4303 1 94 30 63 oC 40 72 1 
AGT 
rs5051 1 94 30 55oC 30 72 1 
rs699/rs4762 2 94 30 53oC 30 72 1 
rs11122575/rs1926723 3 94 30 55oC 30 72 1 
CMA rs1800875 1 94 30 57
oC 40 72 1 
rs1885108 2 94 30 57oC 40 72 1 
In a single reaction primerset 1, which included both primers designed for ACE1 variant regions rs4298, rs4303, analysis was done in a single reaction. 
For CMA, primer sets 1 and 2 were added in a single reaction, which included both primers designed for variant regions rs1800875 and rs1885108 in a 
multiplex reaction. For AGT, primer set 1, 2 and 3 each were used in single reactions, which included the primers designed for variant regions rs5051 in 
a single reaction, rs699 and rs4762 in a single reaction and rs1122575 and rs1926723 in a single reaction. Abbreviations used: ACE1-angiotensin-1 
converting enzyme; AGT-angiotensinogen; CMA-cardiac chymase; oC-degrees Celcius; min-minute; sec-seconds; TA-annealing temperature; TD-
denaturing temperature; TE-extension temperature. 
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Table 2.7: Details of conditions used for ASREA genotyping of selected gene polymorphisms. 
Gene SNP Alleles Enzyme 10 X buffer 
Digest 
time 
Digest PCR product Fragment sizes, bp 
Type of Gel 
temperature size, bp Major allele Minor allele 
CYP11B2 
rs1799998 T/C HaeIII NEB 2 overnight 37oC 177 177 (T) 157, 20 (C) 12% PAGE 
rs4539 A/G Bsu36I NEB 3 4 hours 37oC 907 907 (A) 823, 84 (G) 1.5% Agaose 
rs3097 G/A NspI NEB 2 overnight 37oC 1011 744, 267 (G) 690, 267, 54 (A) 12% PAGE 
AGTR1 
rs2640539 G/C Mspa1 NEB 4 4 hours 37oC 992 992 (G) 609, 383 (C) 1.5% Agaose 
rs3772627 A/G Bsah1 NEB 4 4 hours 37oC 1120 697, 423 (A) 496, 423, 201 (G) 1.5% Agaose 
rs5182 T/C Mnl1 NEB 2 4 hours 37oC 1141 422, 309, 127, 68 (T) 325, 309, 127, 97, 68 (C) 12% PAGE 
ACE2 
rs1978124 A/G Sau96I NEB 4 overnight 37oC 1044 1044 (A) 962, 82 (G) 1.5% Agaose 
rs2285666 G/A AluI NEB 2 overnight 37oC 130 130 (G) 78, 52 (A) 12% PAGE 
rs879922 C/G BfaI NEB 4 overnight 37oC 188 188 (C) 146, 42 (G) 12% PAGE 
rs4646179 T/C HpyCH4IV NEB 3 4 hours 37oC 680 402, 257, 21 (T) 402, 180, 77, 21 (C) 2.5% Agaose 
ACE1 rs4365 A/G AluI NEB 4 overnight 37oC 1198 332, 316, 261, 129, 120 (A)  332, 316, 175, 129, 120, 86 (G) 12% PAGE 
 
Abbreviations used: ACE1-angiotensin-1 converting enzyme; ACE2-angiotensin converting enzyme 2; AGTR1-angiotensin 2 type-1 receptor; bp-base pairs;  
CYP11B2-aldosterone; oC-degrees Celcius; NEB-New England Biolabs; PAGE-Polyacrylamide gel electrophoresis 
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2.7.2.1. SNaPshot primer extension analysis 
SNP genotyping was performed using SNaPshot primer extension analysis, a technique 
used for rapid SNP detection by extending a single base at the target SNP site 
(Makridakis and Reichardt, 2001) (figure 2.4). This stepwise procedure involves 
amplifying a PCR fragment containing the SNP of interest. Samples amplified by PCR, 
along with the relevant oligonucleotide primers (see section 2.5.2) were prepared, in 
separate Eppendorf tubes, for genotyping analysis via the SNaPshot primer extension 
technique, according to the manufacturer’s instructions (Applied Biosystems, USA). All 
SNaPshot primer extension analyses were performed at the US Faculty of Health 
Sciences Department of Medical Biochemistry. 
 
Purification of the PCR DNA template involved removal of unincorporated dinucleotide-
triphosphates (dNTPs) and excess amplification primers by treating the PCR products 
with both shrimp alkaline phosphatase (SAP) (USB Corporation, USA) and exonuclease 
1 (Exo1) (New England Biolabs, USA) enzymes. For multiplex reactions, PCR products 
were combined before enzyme treatment. To achieve cleanup, PCR products were 
incubated at 37oC for 1 hour, followed by incubation at 75 oC for 15 minutes (to 
inactivate enzymes), and stored at -20oC. 
 
The SNaPshot interrogation primer, diluted to a final concentration of 0.5μM, and 
multiplex reaction mix was added to the combined purified PCR products and subjected 
to thermal cycling according to manufacturers’ instructions in a GeneAmp 9700 (Applied 
Biosystems Inc, Foster City, CA, USA). Three cycling conditions were set for the single 
base extension technique and repeated for 27 cycles (see Table 2.6). Following primer 
extension, each reaction was treated with 1U SAP and incubated for one hour at 37oC to 
remove unincorporated fluorescently labelled dideoxy-nucleotide-triphosphates 
(ddNTPs) with subsequent incubation at 72oC for 15 minutes to inactivate SAP. 
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Figure 2.4: A schematic overview of the SNaPshot primer extension technique indicating the different 
components used in analysing the different fluorescently labelled nucleotides. (Taken from 
http://www.appliedbiosystems.com/techsupp.) 
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Samples were denatured in a loading mix containing 1μl product, 0.4μl fluorescently 
labelled LIZ 120 size standards (Applied Biosystems) and 9μl de-ionised formamide. The 
denatured samples were electrophoresed on an ABI Prism® 3100 Avant genetic Analyser 
(Applied Biosystems) and run in filterset E5; on a 50cm capillary with POP6 using 1X 
TBE as running buffer according to custom-made run module conditions (see Appendix 
I). The LIZ 120 size standard was included with each run to determine the size of 
fragments. The data obtained were analysed using Genotyper 3.7 NT software (Applied 
Biosystems). 
 
2.7.3. Allele-specific restriction enzyme analysis (ASREA) of CYP11B2, AGTR1, 
ACE2 and ACE1 polymorphisms 
All of the polymorphisms chosen underwent DNAMAN restriction mapping to predict 
whether the polymorphisms affected specific restriction enzyme recognition sequences 
and to determine expected fragment sizes after ASREA for each amplicon. Only those 
that resulted in a gain or loss of restriction enzyme recognition sequence were appropriate 
for investigation using ASREA.  ASREA was used to genotype SNPs, localised within 
CYP11B2, AGTR1, ACE2 and ACE1. 
 
In CYP11B2, three polymorphisms, rs1799998, rs4538 and rs3097, and in AGTR1 three 
SNPs, rs2640539, rs3772627 and rs5182, resulted in an alteration of a restriction enzyme 
recognition site (table 2.7). In ACE2, four polymorphisms, rs1978124, rs2285666, 
rs879922 and rs4646179, also altered a restriction enzyme recognition sequence (table 
2.7). In ACE1, of the prioritized SNPs, only rs4365 was suitable for ASREA analysis 
(table 2.7). 
 
As a quality control measure for ASREA genotyping Mendelian inheritance was 
confirmed within families using the pedigree statistics (PEDSTATS) (Wiggington and 
Abecasis et al., 2005) program and inconsistencies were resolved by re-examination of 
the raw data, and re-genotyping where necessary.  Additionally, ASREA gels were co-
scored by two independent individuals blinded to affectation status, to confirm 
genotyping accuracy. 
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2.7.4 Restriction enzyme digestion 
PCR-based ASREA was used to screen all mutation and non-mutation carriers in the 
HCM cohort for the previously mentioned SNPs in the CYP11B2, AGTR1 and ACE2 
genes (table 2.7).  
 
PCR-amplification products were digested using the appropriate enzymes (table 2.7) and 
buffers. Briefly, 10µl of the relevant amplified PCR product was aliquoted into a 500µl-
eppendorf microcentrifuge tube. Thereafter, 2µl of the appropriate 10x restriction enzyme 
buffer (New England Biolabs, USA), 2-5U of the restriction enzyme (table 2.7) and water 
to a final volume of 20µl were added to the PCR product. Subsequently, the mixture was 
incubated at 37oC for 2-4 hours or overnight to allow digestion to proceed. Agarose gels 
(1.5 or 2.5%) or non-denaturing polyacrylamide gels (12%) were used for size separation 
of PCR-amplified products digested with restriction enzymes (table 2.7) (see sections 
2.6.1 and 2.6.2).  
 
2.7.5. Sequence analysis 
Sequence analysis was performed to confirm SNaPshot primer extension results for 32 
selected individuals ~(10%) of the HCM cohort for each polymorphism analysed by 
SNaPshot in ACE1, AGT and CMA (table 2.5).  
 
2.7.5.1. Purification of PCR fragment 
Prior to sequencing, 37μl of PCR product was purified using the GFX PCR DNA 
purification kit (Amersham Biosciences, UK). Firstly a GFX column (Amersham 
Biosciences, UK) was placed in a collection tube for each purification. 500μl Capture 
buffer (Amersham Biosciences, UK) was added to the GFX column and the PCR product 
was transferred onto the column. The two solutions were mixed by pipetting and 
centrifuged at 13000 revolutions per minute (rpm) for 30 seconds (sec) in a Beckman 
bench top centrifuge (Benchman Instruments Inc, CA, U.S.A). The flow-through was 
discarded and the GFX column placed back inside the collection tube. A volume of 500μl 
Wash buffer was added to the GFX column and centrifuged at 13000 rpm for 30 sec. 
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The flow-through was discarded and the GFX column placed into a fresh 1.5ml micro-
centrifuge tube. To elute DNA, 50μl of water was applied directly to the top of the glass 
fibre matrix in the GFX column. The sample was incubated at room temperature for one 
minute and was subsequently centrifuged at 13000 rpm for one minute to recover purified 
DNA. 
 
2.7.5.2. Automated sequencing analysis 
The purified PCR products that contained the amplified polymorphic sites were 
sequenced according to established protocols using BIGDye terminator v3.1 cycle 
sequencing kit (Applied Biosystems) at the US Department of Biomedical Sciences 
Tygerberg, South Africa. All samples were analysed using an ABI 3100-Avant genetic 
analyser. 
 
2.8. Statistical analysis 
Genotypic and phenotypic data were captured onto family trees using Cyrillic 2.1 
(Cherwell Scientific, UK). This data was converted into an MLINK format, exported and 
combined with the Excel sheet containing the 2D-echo and covariate data (see section 
2.1), to create a pedigree file for statistical analysis.  
 
Family-based association methods, viz. quantitative transmission disequilibrium test 
(QTDT) and mixed-effects models, were employed to investigate association between 
polymorphisms and hypertrophic phenotypes, viz.  the 16 wall thickness parameters as 
well as the CWT score (Spielman et al., 1993). QTDT was used for all analyses except 
ACE2; the reason for this is that ACE2 is an X-linked gene and these can not be analysed 
by QTDT yet.  In mixed-effects models, the variance is split into components for family 
and not family, whereas the QTDT method further adjusts variance components for 
specific family and genetic relationships. 
 
2.8.1. Distribution of variables (Summary statistics) 
Descriptive statistics were calculated using PEDSTATS (Wiggington and Abecasis et al., 
2005). Graphical outputs were generated to summarise the completeness of genotyping, 
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heterozygosity of markers and their distribution, as well as the distributions and familial 
correlations for quantitative traits.  
 
2.8.2. Hardy-Weinberg equilibrium (HWE) testing and Linkage disequilibrium 
(LD) determination  
The Haploview v3.6 (Barrett et al., 2005) program was used to assess Hardy-Weinberg 
equilibrium (HWE) and LD patterns between alleles within our SA HCM cohort. HWE 
was tested for in unrelated individuals selected from each family by the program.  
 
The Haploview program enables the construction and analysis of haplotypes generated 
for SNPs within a gene, based on haplotype blocks. Haplotype blocks generated by 
Haploview are automatically selected using a common block definition from Gabriel et 
al., (2002). Pairwise LD is analysed in terms of D’ values; 95% confidence bounds on D’ 
are generated and based on these, each pair of SNPs is labeled as being in strong LD, 
uncertain or in strong recombination. If a D’ value indicates strong LD, a block would be 
created.  
 
2.8.3. Quantitative transmission disequilibrium test (QTDT) 
QTDT can be used to perform both linkage and association analysis of quantitative traits 
using families of any size, depending on the model implemented in the program 
(Abecasis et al., 2000). As the families used in this study ranged from 1-4 generations 
and between 2-69 individuals, and included individuals and families who were not of the 
same ethnic origin, the Abecasis test of association was used. This orthogonal model can 
analyse families of any size, allows for missing parental information and automatically 
protects against population stratification. The quantitative traits assessed in this analysis 
are listed in table 2.8. The following covariates were included in the statistical analysis: 
age, sex, HR, systolic BP, diastolic BP, mutation (yes/no) and (BSA). Additionally, 
mutation founder groups (A797T, R403W and R92W) were included to adjust for the 
possible influence of distinct mutations on hypertrophic variability, as well as to adjust 
for ancestral relatedness within each founder group. The specific relationship between 
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family members was incorporated into the models using identity by descent (IBD) 
probabilities estimated with simwalk2 (Sobel et al., 2001). 
 
Table 2.8: Summary of 2D-echo traits measured at three levels and composite scores. 
Overall  Mitral valve level Papillary level Apex level Composite scores
LVM mLVWTmit mLVWTpap mLVWTapx Maron-Spirito score 
mIVS mIVSTmit mIVSpap  IVSapx CWTscore 
mLVWT pIVSmit pIVSpap AWapx Wigle score 
mPWT aIVSmit aIVSpap LWapx  
 AWmit AWpap PWapx  
 LWmit LWpap   
 IWmit IWpap   
  PWmit PWpap     
Abbreviations used for overall, at three levels measures and composite scores see Appendix I. 
 
 
Building up of variance component model 
A variance is a number that indicates the spread of the values of a trait between 
individuals: for example age, if everybody is the same age the variance is zero.  QTDT 
allows the build-up of a variance component model, where the trait variance can be 
decomposed into three components, namely, residual environment variance, polygenic 
variance and additive component of variance.  
 
Procedure of analysis 
We firstly performed a heritability test using a variance-component analysis for 
quantitative traits, which does not require genotypic data. It was suggested by Harshfield 
et al., (1990), that age and gender of the genotype individuals be used as covariates, 
because heart size is known to be influenced by age, gender and body mass of 
individuals. In this study, these covariates as well as HR, systolic BP, diastolic BP, 
mutation (yes/no), mutation founder groups (A797T, R403W and R92W) and (BSA), 
were included in heritability analysis.  
 
Subsequently, upon proof of heritable traits, linkage tests were performed by testing the 
polygenic variance-component, generating p-values for the linkage component.  
However, QTDT does not provide LOD scores.  Instead of only interpreting the linkage 
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p-values, the results generated from QTDT tests were transformed to logarithm of the 
odds (LOD) score values by (x2/(2ln(10)) (Ott et al., 1999) and evidence of significant 
linkage was considered if the LOD score was ≥ 3 and excluded if the LOD score was 
below -2, while scores between 3 and -2 were considered ambiguous (Ott et al., 1999).   
 
The association tests were performed with the QTDT programme, using Abecasis’s 
orthogonal model, allowing for additive environmental and genetic effects. The 
association tests performed assessed association between the 17 markers investigated and 
the 16 quantitative traits and one composite score, the CWT-score, while adjusting for all 
covariates mentioned earlier.  
 
Testing linkage in the presence of association 
To determine if the investigated marker could be the causal susceptibility variant, 
orthogonal association was included in the model while testing major gene locus linkage.  
In such an analysis, a large, i.e. non-significant, p-value would indicate that there is no 
statistically significant linkage in the presence of association and thus that association 
accounts for the entire signal (thus that the marker locus could be the true, functional 
modifier locus). However, a significant p-value indicates that the linkage observed is not 
explained by the association, suggesting that the marker locus is linked by LD to the 
modifier locus.   
 
Estimating exact p-values 
The significant associations found in the analysis, were retested using Monte-Carlo (1000 
times) permutation tests (McIntyre et al., 2000). The empirical p-values derived from 
1000 permutations are reported in the result section for these association tests.   
 
2.8.4. Linear mixed-effects models 
X-linked ACE2 analysis 
The X-linked gene ACE2 was statistically analysed with mixed-effects models using the 
package nlme (Pinheiro, et al., 2007) in the programming environment R (R 
Development Core Team., 2007). The mixed-effects models are simplifications of the 
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QTDT models with the only difference being that the variance is split into family and 
not-family, but cannot adjust for IBD probabilities and variance components.   
 
The mixed effects models were, like the QTDT models, adjusted for age, sex, BSA, SBP, 
DBP, HR, mutation (fixed effects) and for family membership (as a random factor). 
There are three mutation groups; namely, R403W, R92W and A797T, and each of these 
are coded as mutation: yes/no. Analysis was done to assess the association between the 
four X-linked SNPs and the 16 individual traits and CWT-score. 
http://scholar.sun.ac.za
 90
3. RESULTS 
 
INDEX         PAGE 
3.1. Candidate genes selected           91 
3.2. Prioritising SNPs for investigation         91 
3.3. Primer design            94 
3.4. Polymerase chain reaction (PCR)         99 
 3.4.1. Optimising of PCR primer conditions        99 
3.5. Genotyping of individuals         105 
 3.5.1. Genotyping ACE1 I/D polymorphism by PCR-based     105  
           method 
3.5.2. SNaPshot primer extension results       105 
 3.5.3. Allele specific restriction enzyme analysis      110 
3.6. Automated sequence analysis         119 
3.7. Statistical analysis          124 
 3.7.1. Distribution of variables (summary statistics)      124 
3.7.2. Hardy-Weinberg equilibrium (HWE) testing       124  
          and LD determination     
3.7.3. Population stratification tests        128 
3.7.4. Variance component models: heritability test      130 
3.7.5. Variance component models: environment, polygenes and    130  
          additive component  
3.7.6. Linkage analysis         138 
3.7.7. Association tests         138  
 3.7.8. Linkage in the presence of association       139 
 3.7.9. X-linked gene analysis         148 
 
 
 
 
 
 
http://scholar.sun.ac.za
 91
3.1. Candidate genes selected 
Bioinformatic-based literature searches aided in the identification of six candidate 
genes which encode key components of the RAAS and have been previously shown 
to be associated with hypertension and LVH (section 2.4, table 2.2).  
 
3.2 Prioritising SNPs for investigation 
This study aimed to target at least three SNPs spread throughout the candidate genes, 
however, in CMA only a single SNP in the 5’ regulatory region and one in the middle 
of the gene were targeted (figure 3.1A-F). The SNPs selected in each of the six 
chosen genes were prioritised based on the following criteria: those previously 
reported in other relevant studies of RAAS in CVD (section 2.4, table 2.2) and those 
with known heterozygosity values ≥ 40% and known intragenic locations (table 3.1). 
Most of the SNPs within ACE1, AGT and CMA were genotyped by SNaPshot 
analysis, using primers that differed in four to six nucleotides in length, according to 
each variant, and which could therefore be used in a single multiplex reaction. The 
SNPs located within AGTR1, CYP11B2, ACE2 and one SNP within ACE1 were 
chosen for investigation not only because they possessed a high heterozygosity value 
but also because they could be genotyped by a loss or gain of a restriction enzyme site 
(referred to as ASREA in this work). An exception was the ACE1 I/D polymorphism 
which was genotyped by gel-observation of the different sized PCR amplification 
products.  
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A) ACE1 
 
B) AGT 
 
 
 
 
 
 
 
 
 
 
C). AGTR1 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 
-6 G/A
T174M
M235T
rs1926723rs11122575
Exons 
(rs4762)
(rs699)
(rs5051)
 1 2 3
573C/T 
rs3772627rs2640539
Exons 5
(rs5182) 
4 
  
1 2 3 4 5 
I/D
2524 16 17
rs4298 rs4303
Exons
(rs4340)
6 {18 – 23}{7 – 15}
rs4365
http://scholar.sun.ac.za
 93
D). CYP11B2 
 
 
 
 
 
 
 
 
E). CMA 
 
F). ACE2 
Figure 3.1: Schematic diagrams showing exon/intron structure of the candidate genes and 
location of targeted SNPs in A) ACE1, B) AGT, C) AGTR1, D) CYP11B2, E) CMA and F) 
ACE2. Variants indicated in boxes were investigated by SNaPshot, while the other variants 
were investigated by ASREA, except for the I/D polymorphism in ACE1. The markers 
highlighted in red indicate variants investigated in previous association studies and the 
markers highlighted in blue indicate variants that have not yet been investigated (Table 1.2 
section 1.3.2). 
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Table 3.1: SNPs prioritised for investigation. 
Gene/ 
protein 
dbSNP 
rs#cluster  id Heterozygosity Validation
Intragenic location 
Ex Syn/ Ex Nsyn (AA) 
ACE1 
rs4298 0.212 C,F,2 Ex syn (Asn) 
rs4303 0.051 C,F Ex Nsyn (Ser→Ala) 
rs4340 N.D N.D Intron 
rs4365 0.064 C,F Ex syn (Glu) 
CMA 
rs1800875 N.A C,2 -1903 Promoter 
rs1885108 0.491 C,F,2,H Intron 
AGT 
rs5051 0.456 C,F -6 Promoter 
rs4762 0.154 F,H Ex Nsyn (Met→Thr) 
rs699 0.467 F,2 Ex Nsyn (Thr→Met) 
rs11122575 0.271 C,F Intron 
rs1926723  0.256 C,F Intron 
CYP11B2 
rs1799998 0.436 C,F,2,H -344 Promoter 
rs4539 0.286 C,F Ex Nsyn (Arg→Lys) 
rs3097  0.213 F,2,H 3’ untranslated 
AGTR1 
rs2640539 0.189 F,2 Intron 
rs3772627 0.483 C,F Intron 
rs5182 0.491 F Ex syn (Leu) 
ACE2 
rs1978124 0.330 F,2,H Intron 
rs2285666 0.454 C,F,2 Intron 
rs879922 0.405 F,2,H Intron 
rs4646179 0.046 C,F,H Intron 
Abbreviations used: Amino acid (AA), Cluster (C), Exon (Ex), Frequency (F), HapMap (H), 
Non-synonymous (Nsyn), Not available (NA), Not determined (N.D), Synonymous (syn) and 
Two hit (2).Validation status descriptions: Cluster-validated by multiple independent 
submissions to the refSNP cluster, Frequency- validated by frequency or genotype data: 
minor alleles observed in at least two chromosomes, HapMap- genotyped by HapMap project, 
Two hit- All alleles have been observed in at least two chromosomes a piece.   
 
 
3.3 Primer design 
Primers were designed to regions flanking the chosen SNPs’ locations for both PCR 
amplification of gene fragments and SNaPshot primer extension analyses. A total of 
20 outer primer sets for PCR amplification of the target regions and 13 SNaPshot 
primers were designed (figure 3.2-3.7). 
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     3601 ggtgggagca gtaaggactg gtgcaggctc tggtgaaggc cgttgaagac ttcaacgtgg 
     3661 aggcctcctc accgaccctg cctgcctgtg tctcagatct caccaacatc ctggcttcct 
     3721 cgcgaagcta cgccatgctc ctgtttgcct gggagggctg gcacaa C/T gct gcgggcatcc 
     3781 cgctgaaacc gctgtacgag gatttcactg ccctcagcaa tgaagcctac aagcaggacg 
     3841 gtgagcaggc ctctccctgt ccaggaacca cgccaggtgt cctctctcag ctgtctcccc 
     3901 agagtcccag cccagagtca ggcagagcag ctggtatgac aattccagca ggccctgagt 
     3961 ttcccagaaa gtggaggtgg gaccggcctg cacccagtgt gcctggactt tgctgctggc 
     4021 ctgccccacg tggccatcct gctgtcactc ctggccctga tgctcctctt tgcctctggg 
     4081 aacctccagg atctgtttag ctggctgtag ctaattagaa attgtagagt ggcaaccccc 
     4141 aagccaattt tccagctagc tgcagatcca cgggcctcga gccagtggaa gagccgactt 
     4201 acagctgaga ggctgaggtc cgagcctttg gcctgagcta catacctcac ccccacgccc 
     4261 ccaggcttca cagacacggg ggcctactgg cgctcctggt acaactcccc caccttcgag 
     4321 gacgatctgg aacacctcta ccaacagcta gagcccctct acctgaacct ccatgccttc 
     4381 gtccgccgc G/T cactgcatcg ccgatacgga gacagataca tcaacctcag gggaccc atc 
     4441 cctgctcatc tgctgggtaa ggacctggcc tcgcctccac atgagtccca cggaagtgtg 
     4501 ggtcccgagg taggggtggg ggatgtccag ggtaagggaa ggtgggttgt gaccctcaca 
     4561 tctcacatgt gtggggcatc atactgtttg cttcacatgc aggagaccat tcgtgttccc 
     4621 actttacagg tggggaccct gaggcttagg gtcgtgaggg acttagtggt cagagagcta 
     4681 ggggccaaac caaaggctct ggccctgggt ccagtggggg agccatcagc ctagctcatg 
     4741 cccaaggaaa caagcactgt ggccctgcct caggattgag tggctggggc ctggcacagc 
     4801 cagaaatgac agtggcagca tcttgcagcc ccaggacatg tggccctcgg aggagtgtgg 
     4861 gtgggactga tgtgtgagat ttctggccct aagccaggcc tgcagccctt gagggcccca 
     4921 gggtacaggt gccggcccca gggtgccact cagcgatgca tgaagaagca ggcacagcca 
     4981 ggcagggagc caagctgtcc ccttccttcc ttatctagga gacatgtggg cccagagctg 
 
 
 
 
Figure 3.2: Primer design for the rs4298 and rs4303 sequence variants (in pink) within ACE1 
fragment1.  
Forward and reverse primers (highlighted in green) were designed to amplify the genomic 
region harbouring the rs4298 and rs4303 sequence variants (in pink font). The SNaPshot 
interrogation primers used to genotype the variants in subjects from the HCM-affected 
families are highlighted in blue.  
forward primer for PCR 
reverse primer 
for PCR 
SNaPshot primer for 
rs4298 
SNaPshot primer 
for rs4303 
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      841 ggtcccagcg tgagtgtcgc ttctggcatc tgtccttctg gccagcctgt ggtctggcca 
      901 agtgatgtaa ccctcctctc cagcctgtgc acaggcagcc tgggaacagc tccatcccca 
      961 cccctcagct ataaataggg catcgtgacc cggcc G/A gggg aagaagctgc cgttgttctg 
     1021 ggtactacag cagaaggtaa gccgggggcc ccctcagctc cttctcggtc ttgtctctct 
     1081 cagatgtaac tgagctgtgg gctaggagga aaaggccggg aggaggcacg gtgatgactg 
     1141 aaaaacctct cccctctcat aagaccagtc atccggacgc gggctttccc ccactcggtg 
     1201 cccacctggg gtcttacagg aggagctgct cctcctcagc aataggacaa gatggtcagg 
     1261 tcttcctgct tccgctgaga aaagttaggg tcctcaggaa cggagcagac tggtacagga 
     1321 acagagtcat catggccaag agtccaccgg gtcctcttgc catcaggagg aatagcaggg 
     1381 cttgtgcagg aattggggct ggagggaagg gccgggctcg gtcagtctcc agctgggatc 
     1441 cccagagtgg tcaccctacc cctccctcga gacagactgc ctgactgtgt gtcatcaggc 
     1501 tggtcaccat ctccctgaac ctcgatttgc tcacctataa aatggaacta ataacgatgc 
     1561 ctgggctccc tgtctcaggg gctctggtat agctgaagag aactaatata acatgaaagt 
     1621 gctttctaag ctttgggata agctaaaagg cagattccaa ttttattcga gggcagcgta 
     1681 gattggtgct tcagctcgtg gatgacagag tcagggggcc tggttctgag tcctagttct 
     1741 gtctcttccc agctgtgtga cgttgaacaa gtcactggac ctctctgttc ctctgcaaaa 
     1801 cagcatgaac caattcatta actacttctc caggatgcag taggtcccag ggactatcct 
     1861 aggaatgtgg gctgtattag taaacacaac agcgggaacc ctgttccggg gctcacattc 
     1921 acatcagagc aaacagacaa agacgctgga cagaataagt gcataactac atggtacaga 
     1981 gggttataag gagggaaaag gggagctgga tgagagagtt gagagtgccc ggtgtggtgg 
     2041 ggaaagctgc agggtgaaat actgcatcag ggaaacctca gggaaggtga ggactatggt 
     2101 gaggtcagag gggttgatat gagaacagtg ccctgcaaat ggcaggcacc acaggagcat 
     2161 gagccgtcat cttcaccttt agcattcagc ccgggagaag tagggagaca tagaaggggc 
     2221 aggtgctggc caagaggcag gggcaggaga ggagaaggcg gaggggcact cagggcgagg 
     2281 gtgtcaggcc cgccacccca gagcaccatt actcccagga cgcggctgcg tgcagacctg 
 
 
 
Figure 3.3: Primer design for the rs5051 sequence variant (in pink) within AGT fragment 1. 
Forward and reverse primers (highlighted in green) were designed to amplify the genomic 
region harbouring the rs5051 sequence variant (in pink font). The SNaPshot interrogation 
primers used to genotype the variants in subjects from the HCM-affected families are 
highlighted in blue. The sequence above is the anti-sense (reverse), the SNaPshot primer is 
designed for the forward strand. 
 
 
forward primer for PCR SNaPshot primer for rs5051 
on forward strand 
(complement)
reverse primer for PCR 
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     4021 acacgggcat tatggccgtt gggggaggta ggacataatt cagctgatat tggtgcattt 
     4081 tgcacttgga tcatgtagat attttccatg gagctttgaa tccatttctt cttttttttg 
     4141 tagacatgaa tggatttatt ctgggctaaa tggtgacagg gaatattgag acaatgaaag 
     4201 atctggttag atggcactta aaggtcagtt aataaccacc tttcaccctt tgcaaaatga 
     4261 tatttcaggg tatgcggaag cgagcacccc agtctgagat ggctcctgcc ggtgtgagcc 
     4321 tgagggccac catcctctgc ctcctggcct gggctggcct ggctgcaggt gaccgggtgt 
     4381 acatacaccc cttccacctc gtcatccaca atgagagtac ctgtgagcag ctggcaaagg 
     4441 ccaatgccgg gaagcccaaa gaccccacct tcatacctgc tccaattcag gccaagacat 
     4501 cccctgtgga tgaaaaggcc ctacaggacc agctggtgct agtcgctgca aaacttgaca 
     4561 ccgaagacaa gttgagggcc gcaatggtcg ggatgctggc caacttcttg ggcttccgta 
     4621 tatatggcat gcacagtgag ctatggggcg tggtccatgg ggccaccgtc ctctccccaa 
     4681 cggctgtctt tggcaccctg gcctctctct atctgggagc cttggaccac acagctgaca 
     4741 ggctacaggc aatcctgggt gttccttgga aggacaagaa ctgcacctcc cggctggatg 
     4801 cgcacaaggt cctgtctgcc ctgcaggctg tacagggcct gctagtggcc cagggcaggg 
     4861 ctgatagcca ggcccagctg ctgctgtcca C/T ggtggtggg cgtgttcaca gccccaggcc 
     4921 tgcacctgaa gcagccgttt gtgcagggcc tggctctcta tacccctgtg gtcctcccac 
     4981 gctctctgga cttcacagaa ctggatgttg ctgctgagaa gattgacagg ttcatgcagg 
     5041 ctgtgacagg atggaagact ggctgctccc tga C/T gggagc cagtgtggac agcaccctgg 
     5101 ctttcaacac ctacgtccac ttccaaggta aggcaaacct ctctgctggc tctggcccta 
     5161 ggacttagta tccaatgtgt agctgagatc agccagtcag gccttggaga tgggcagggg 
 
 
 
Figure 3.4: Primer design for the rs4762 and rs699 sequence variants (in pink) within AGT 
fragment 2.  
Forward and reverse primers (highlighted in green) were designed to amplify the genomic 
region harbouring the rs4762 and rs699 sequence variants (in pink font). The SNaPshot 
interrogation primers used to genotype the variants in subjects from the HCM-affected 
families are highlighted in blue. 
 
 
 
 
 
    10441 agacacagtg cattatttca gagaatagca tttaaaaatt acccaagtaa cacaccttca 
    10501 atgcagccaa cctaaaaaca gaatgcacca aaggacaacc attcctaggt cctcatcggt 
    10561 aaatcttcta tgtccctcac atagtattgc aaatgaca T/C gaaggattttt attgtaggtt 
    10621 ttgctgaaat tttccccaag ggggaggatg acttagttgg gtgatggggg gagcaaacat 
    10681 ccctgtcgtc agggttgggt gcaaggagca taagcctgcc tggcctctgg gagagccctc 
    10741 actgtgtggc ctggagcctt cctaactgtg c A/G tcatctcc ccaggaccat ccacctgacc 
    10801 atgccccaac tggtgctgca aggatcttat gacctgcagg acctgctcgc ccaggctgag 
    10861 ctgcccgcca ttctgcacac cgagctgaac ctgcaaaaat tgagcaatga ccgcatcagg 
 
 
 
 
Figure 3.5: Primer design for the rs1122575 and rs1926723 sequence variants (in pink) 
within AGT fragment 3.  
Forward and reverse primers (highlighted in green) were designed to amplify the genomic 
region harbouring the rs1122575 and rs1926723 sequence variants (in pink font). The 
SNaPshot interrogation primers used to genotype the variants in subjects from the HCM-
affected families are highlighted in blue. 
 
 
 
 
 
 
 
 
Forward primer for PCR 
SNaPshot primer for rs699 
SNaPshot primer for rs4762 
reverse primer for PCR 
SNaPshot primer for rs1926723 
SNaPshot primer for rs1122575 
reverse primer for PCR 
forward primer for PCR 
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   1 TTAAAATACACAGGTATACATATGACAAAGCAAAGAAGGAAATGTGAGCAGATAGCGCAG 60 
  61 TCCTCGTTTCTGAAATTGGTCCCCTGACTGGGGCTATACCTATTCCATTTCCTCACCCTC 120 
 121 AGCCAGGCAGGTG A/G AGCAAAACTTAAGTCTTGGTGGATCTGAATCTTGATGCTGTGGAGC 180 
 181 TGTCTTACTAGCCCCAGACTACCTGCCTCTCAATTTCTAATTATATCAGTGAAAGCAAAC 240 
 241 AGCTTTGATTTGTTTAAGCCTCTGATTTTTTGGTCTAACTGATGTAAGACCACAAGACAA 300 
 301 GAGTTCTCCAGCTCCGGATTCTCTTCTGTTCTGTTAATGGTGAAATGCCCAGAGAAGAGT 360 
 361 TGCCAACTTTGGCAAATAAAAAATACAGGATTCCAGTTAAATTCAAATTTTAGATAAACA 420 
 421 ACAATTTTTTAGTATTAGTGTGTCCCATTCAATATTTGGACATACTTAACTAAAAAATGA 480 
 
 
 
Figure 3.6: Primer design for the rs1800875 sequence variant (in pink) within CMA fragment 
1. Forward and reverse primers (highlighted in green) were designed to amplify the genomic 
region harbouring the rs1800875 sequence variant (in pink font). The SNaPshot interrogation 
primers used to genotype the variants in subjects from the HCM-affected families are 
highlighted in blue. 
 
 
 
 
 
 
3721 AGCTTGAGGTTATAAAGCAATTCCGTCATCCAAAATATAACACTTCTACTCTTCACCACG 3780 
3781 ATATCATGTTACTAAAGGTGACAACACCTCTCTTCTCCCTTTCCACTTCCCATTCTCCTA 3840 
3841 AGCTTCTCCTTCAGGTCCTCATTGCCCTGAATTTTTCTTAGGACTTGGCTATAACATGAA 3900 
3901 GCTACTCACCCTGTCCCTCCCTGATCACCTCCAACTGTCCAGAGCCCATTTCGAGGACTG 3960 
3961 AC A/G GTCCTTCATTCCCTTCACAGTTGAAGGAGAAAGCCAGCCTGACCCTGGCTGTGGGGA 4020 
4021 CACTCCCCTTCCCATCCCAATTCAACTTTGTCCCACCTGGGAGAATGTGCCGGGTGGCTG 4080 
4081 GCTGGGGAAGAACAGGTGTGTTGAAGCCGGGCTCAGACACTCTGCAAGAGGTGAAGCTGA 4140 
4141 GACTCATGGATCCCCAGGCCTGCAGCCACTTCAGAGACTTTGACCACAATCTTCAGCTGT 4200 
4201 GTGTGGGCAATCCCAGGAAGACAAAATCTGCATTTAAGGTGATCCTCCAACTAGGTTTCC 4260 
 
 
 
Figure 3.7: Primer design for the rs1885108 sequence variant (in pink) within CMA fragment 
2. Forward and reverse primers (highlighted in green) were designed to amplify the genomic 
region harbouring the rs1885108 sequence variant (in pink font). The SNaPshot interrogation 
primers used to genotype the variants in subjects from the HCM-affected families are 
highlighted in blue. 
 
 
 
 
reverse primer for PCR 
forward primer for PCR 
SNaPshot primer for rs1800875 
Reverse primer for PCR 
Forward primer for PCR SNaPshot primer for rs1885108 
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3.4. Polymerase chain reaction (PCR) 
3.4.1. Optimising of PCR conditions 
PCR conditions were optimised to amplify all the fragments of ACE1, CYP11B2, 
AGTR1, AGT, CMA and ACE2 using the outer primers listed in table 2.3 and using 
DNA from the same individuals for each optimisation (see figures 3.8 to 3.13). 
 
 
 
 
 
A) ACE1 fragment 1 
B) ACE1 fragment 2 
            
 
 
 
 
 
  
 
C) ACE1 fragment 3       
 
Figure 3.8: Representative 2% agarose gel showing PCR amplified ACE1 fragments 1, 2 and 
3.  
A) Lane 1 – molecular weight marker ; lanes 2-6 and 8 – ACE1 fragment 1 amplicons of 6 
selected individuals; Lane 7 – negative control (water blank), B) Lane 1 – molecular weight 
marker; lanes 2-10 – ACE1 fragment 2 amplicons of 9 selected individuals; Lane 11 – 
negative control (water blank) and C) Lane 1 – molecular weight marker; lanes 2, 4-10 – 
ACE1 fragment 3 amplicons of  8 selected individuals; Lane 3 – negative control (water 
blank). 
 
 
 
 
 
 
1 2 3 5 6 87 9 10 114
450bp 
1 2 3 87 9 10 114
 
1274bp 1200bp 
500bp 
1198bp 1500bp 
1 4 5 6 7 8 9 10 2 3 
1 4 5 6 7 82 3
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A) CMA fragment 1 
 
 
 
 
 
 
        
 
 
  
 
 
 
 
 
 
B) CMA fragment 2   
 
Figure 3.9: Representative 2% agarose gel showing PCR amplified CMA fragments 1 and 2.  
A) Lane 1 – molecular weight marker; lanes 2-10 – CMA fragment 1 amplicons of 9 selected 
individuals; Lane 11 – negative control (water blank) and B) Lane 1 – molecular weight 
marker; lanes 2-5, 7 and 8 – CMA fragment 2 amplicons of  6 selected individuals; Lane 6 – 
negative control (water blank). 
 
 
 
 
 
 
 
185bp 
200bp 
333bp 
300bp 
1 4 5 6 7 8 9 10 2 3 11 
1 4 5 6 7 8 2 3
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A) AGT fragment 1 
 
 
 
 
 
 
 
 
 
  
B) AGT fragment 2 
 
 
 
 
 
 
 
 
 
 
 
C) AGT fragment 3 
Figure 3.10: Representative 2% agarose gel showing PCR amplified AGT fragments 
1, 2 and 3.  
A) Lane 1 – molecular weight marker ; lanes 2, 5-10 – AGT fragment 1 amplicons of 7 
selected individuals; Lane 3 – unsuccessful PCR amplification; Lane 4 – negative control 
(water blank), B) Lane 1 – molecular weight marker; lanes 2, 3, 5-11 – AGT fragment 2 
amplicons of 8 selected individuals; Lane 4 – negative control (water blank) and C) Lane 1 – 
molecular weight marker; lanes 3-7 – AGT fragment 3 amplicons of  5 selected individuals; 
Lane 2 – negative control (water blank). 
1030bp 
1100bp 
1 4 5 6 7 8 9 2 3 10 
1328bp 1500bp 
332bp 400bp 
1 4 5 6 7 8 9 10 2 3 11 
1 4 5 6 7 2 3
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A) AGTR1 fragment 1 
 
 
 
 
 
 
 
 
 
 
 
 
B) AGTR1 fragment 2 
 
 
 
 
 
 
 
 
 
 
 
C) AGTR1 fragment 3 
 
Figure 3.11: Representative 2% agarose gel showing PCR amplified AGTR1 fragments 1, 2 
and 3.  
A) Lane 1 – molecular weight marker ; lanes 2, 5 -10 – AGTR1 fragment 1 amplicons of 7 
selected individuals; Lanes 3 – unsuccessful PCR amplification; Lane 4 – negative control 
(water blank), B) Lane 1 – molecular weight marker; lanes 2, 3, and 5 – AGTR1 fragment 2 
amplicons of  3 selected individuals; Lane 4 – negative control (water blank) and C) Lane 1 – 
molecular weight marker; lanes 2, 4 and 5 – AGTR1 fragment 3 amplicons of  3 selected 
individuals; Lane 3 – negative control (water blank). 
 
 
 
 
992bp 
1200bp 
1 4 5 6 7 8 9 2 3 10 
1120bp 1000bp 
1141bp 1000bp 
1 4 5 2 3
1 4 5 2 3
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A) CYP11B2 fragment 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) CYP11B2 fragment 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
C) CYP11B2 fragment 4 
 
Figure 3.12: Representative 2% agarose gel showing PCR amplified CYP11B2 fragments 1, 
2, 3 and 4.  
A) Lane 1 – molecular weight marker ; lanes 2-10 – CYP11B2 fragment 1 amplicons of  9 
selected individuals; Lane 11 – negative control (water blank), B) Lane 1 – molecular weight 
marker; lanes 2, 5-10 – CYP11B2 fragment 2 amplicons of  7 selected individuals; Lane 3 – 
no sample loaded; Lane 4 – negative control (water blank) and C) Lane 1 – molecular weight 
marker; lanes 2-10 – CYP11B2 fragment 3 amplicons of  9 selected individuals; Lane 11 – 
negative control (water blank) and D) Lane 1 – molecular weight marker; lanes 2-8 – 
CYP11B2 fragment 4 amplicons of  7 selected individuals; Lane 9 – negative control (water 
blank). Not shown are CYP11B2 fragments 3 and 5 because the SNPs within these fragments 
were not considered for the present study.  
 
 
 
 
177bp 
500bp 
907bp 1200bp 
1011bp 1000bp 
1 4 5 6 7 8 9 2 3 10 
1 4 5 6 7 8 92 3 10 11 
1 4 5 6 7 8 9 2 3
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A) ACE2 fragment 1 
 
 
 
 
 
 
 
B) ACE2 fragment 2 
 
 
 
 
 
 
C) ACE2 fragment 3 
 
       
 
 
 
 
         D) 
 
 
D) ACE2 fragment 4 
 
Figure 3.13: Representative 2% agarose gel showing PCR amplified ACE2 fragments 1, 2, 3 
and 4.  
A) Lane 1 –PCR amplified marker (fragment of 1030bp in size); lanes 2-16 – ACE2 fragment 
1 amplicons of  15 selected individuals; Lane 17 – negative control (water blank), B) Lane 1 – 
molecular weight marker; lanes 2-10 – ACE2 fragment 2 amplicons of  9 selected individuals; 
Lane 11 – negative control (water blank), C) Lane 1 – molecular weight marker; lanes 2-10 – 
ACE2 fragment 3 amplicons of  9 selected individuals; Lane 11 – negative control (water 
blank) and D) Lane 1 – molecular weight marker; lanes 2, 5-10 – ACE2 fragment 4 amplicons 
of 7 selected individuals; Lane 3 – unsuccessful PCR amplification; Lane 4 – negative control 
(water blank). 
 
1044bp 1030bp 
130bp 
200bp 
188bp 200bp 
680bp 
500bp 
1 4 5 6 7 8 92 3 10 11 
1 4 5 6 7 8 92 3 10 11 12 13 14 15 16 17 
1 4 5 6 7 8 92 3 10 11 
1 4 5 6 7 8 9 2 3 10 
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3.5. Genotyping of individuals 
3.5.1. Genotyping ACE1 I/D polymorphism by PCR-based method 
PCR amplification was used to genotype individuals for the insertion/deletion (I/D) 
polymorphism located within the ACE1 gene (figure 3.14). PCR amplification 
generated a 450bp fragment if the D-allele was present or a 737bp fragment if the I-
allele was present, or both, in the case of heterozygotes.  
 
 
 
 
 
 
 
 
 
Figure 3.14: A representative 2% agarose gel of individuals genotyped for ACE1 I/D 
polymorphism. Lane 1 = an individual homozygous for the I-allele, Lane 2 = an individual 
heterozygous with both insertion (I) and deletion (D) alleles present, Lane 3 = an individual 
homozygous for the D-allele and Lane 4 = 100bp Promega marker. 
 
 
3.5.2. SNaPshot primer extension results  
Individuals were genotyped for the two SNPs in ACE1 fragment 1, one SNP each in 
CMA fragment 1 and fragment 2, one SNP in AGT fragment 1 and two SNPs each in 
AGT fragment 2 and fragment 3 using the primer extension technique (Makridakis 
and Reichardt, 2001) (see section 2.5). The alleles were assigned by Genotyper 3.7 
NT software (Applied Biosystems). Figure 3.15 to 3.22 show representative results 
obtained after single base extension reaction and analysis of ACE1 rs4298, rs4303, 
CMA rs1800875 and rs1885108, AGT rs5051, rs4762, rs699 and rs11122575, 
respectively, with Genotyper 3.7 NT software (Applied Biosystems). Not shown is a 
SNaPshot result for AGT rs1926723 as a representative electropherogram was 
unavailable. Only SNPs within CMA were multiplexed. Sixteen samples per 
individual were optimised in single reactions and indicated that different coloured 
peaks occurred at different positions. For AGT, the amplicons containing the 
investigated SNPs within fragments 1, 2 and 3 were designed for multiplexing but 
were done as single reactions. The assigned genotypes at each locus are indicated on 
the figures 3.15 to 3.22. 
450bp 
1 3 42
500bp 
1000bp 
737bp 
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          A                           B 
Figure 3.15: A representative electropherogram of SNP variant analysis of ACE1 rs4298.  
The chromatogram represents analysis of SNaPshot reactions of A) an individual 
homozygous for the C-allele at rs4298, B) an individual heterozygous for the C and T-allele at 
rs4298. Not indicated an individual homozygous for the T-allele at rs4298. 
 
 
 
     
 
      A         B 
Figure 3.16: A representative electropherogram of SNP variant analysis of ACE1 rs4303.  
The chromatogram represents analysis of SNaPshot reactions of A) an individual 
heterozygous for the G and T-alleles at rs4303 and B) an individual homozygous for the G-
allele at rs4303. Not indicated an individual homozygous for the T-allele at rs4303.   
 
 
 
 
 
T-allele 
C-allele 
C-allele 
G-allele 
T-allele
G-allele
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    A                 B      C 
Figure 3.17: A representative electropherogram of SNP variant analysis of CMA rs1800875.  
The chromatogram represents analysis of SNaPshot reactions of A) an individual 
heterozygous for the G and A-alleles at rs1800875, B) an individual homozygous for the A-
alleles at rs1800875 and C) an individual homozygous for the G-alleles at rs1800875. 
 
         
 A             B            C 
Figure 3.18: A representative electropherogram of SNP variant analysis of CMA rs1885108.  
The chromatogram represents analysis of SNaPshot reactions of A) an individual 
heterozygous for the G and A-alleles at rs1885108, B) an individual homozygous for the G-
alleles at rs1885108 and C) an individual homozygous for the A-alleles at rs1885108. 
G-allele
G-allele 
A-allele
A-allele
A-allele 
G-allele
G-allele
A-allele 
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   A            B                   C 
Figure 3.19: A representative electropherogram of SNP variant analysis of AGT rs5051.  
The chromatogram represents analysis of SNaPshot reactions of A) an individual 
heterozygous for the C and T-allele at rs5051, B) an individual homozygous for the C-allele at 
rs5051 and C) an individual homozygous for the T-allele at rs5051. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         A     B             C 
Figure 3.20: A representative electropherogram of SNP variant analysis of AGT rs699.  
The chromatogram represents analysis of SNaPshot reactions of A) an individual 
heterozygous for the C and T-allele at rs699, B) an individual homozygous for the C-allele at 
rs699 and C) an individual homozygous for the T-allele at rs699. 
 
 
 
C-allele
T-allele C-allele
T-allele
T-allele
C-allele
C-allele
T-allele
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          A                   B                 C  
Figure 3.21: A representative electropherogram of SNP variant analysis of AGT rs4762.  
The chromatogram represents analysis of SNaPshot reactions of A) an individual 
heterozygous for the C and T-allele at rs4762, B) an individual homozygous for the C-allele at 
rs4762 and C) an individual homozygous for the T-allele at rs4762. 
 
     
 
 
 
 
 
 
 
 
 
          A                  B 
Figure 3.22: A representative electropherogram of SNP variant analysis of AGT rs11122575.  
The chromatogram represents analysis of SNaPshot reactions of A) an individual 
heterozygous for the C and T-allele at rs11122575, B) an individual homozygous for the T-
allele at rs11122575. Not indicated an individual homozygous for the C-allele at rs11122575.   
C-allele
T-allele
C-allele T-alleleT-allele
T-allele
C-allele
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3.5.3. Allele Specific restriction enzyme analysis 
ACE1/rs4365 polymorphism. 
PCR amplification of ACE1 fragment 3 yielded an 1198bp fragment containing one 
sequence variant, rs4365 (A/G). This fragment contained five invariant AluI restriction 
sites if the A-allele was present and an additional AluI restriction site if the G-allele 
was present.  Thus, AluI digestion yielded seven fragments (332bp, 316bp, 175bp, 
129bp, 120bp, 86bp and 40bp) for the G-allele, while for the A-allele six fragments 
(332bp, 316bp, 261bp, 129bp, 120bp and 40bp) were present (figure 3.23).  
 
 
 
 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
Figure 3.23: ASREA of the ACE1 fragment 3 rs4365 polymorphism.  
A) Representative 12% Polyacrylamide gel showing the fragment sizes generated by AluI 
restriction enzyme digestion of the 1198bp PCR-amplified fragment. Lane 1= 100bp marker, 
Lane 2 = homozygote GG, Lane 3 = heterozygote AG, Lane 4 = homozygote GG, Lane 5 = 
uncut. Not indicated is a homozygote AA subject. The small 40bp fragment was not 
distinguished on this gel. B) Schematic representation of the amplified fragment showing the 
positions of the AluI restriction sites. * = variable restriction enzyme site. The constant 120bp 
fragment co-migrated with the 129bp fragment. 
 
 
 
 
175bp 
1198bp 
86bp 
261bp 
332bp 
316bp 
300bp 
100bp 
1 2 3 4 5
129bp 
*A 
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CYP11B2/rs1799998 (-344C/T), CYP11B2/rs4539 (2713A/G) and CYP11B2/rs3097 
(5937G/A) polymorphisms. 
The three sequence variants, rs1799998, rs4539 and rs3097 identified in amplified 
fragments 1, 2 and 4 of the CYP11B2 (in the promoter, exonic and 3’UTR region, 
figure 3.1D), respectively, each alter a restriction enzyme recognition site.  
 
Genotyping the promoter region -344C/T variant/rs1799998 of CYP11B2 was done by 
digesting the 177bp PCR-amplified fragment 1 containing the polymorphic HaeIII 
site. The presence of the C-allele creates a HaeIII restriction enzyme site yielding two 
fragments of 157bp and 20bp in size after digestion, while the 177bp fragment 
remained intact in the presence of the T-allele (figure 3.24).  
 
PCR amplification of the region containing 2713A/G variant/rs4539 yielded a 907bp 
fragment. The generated amplicon contained only one, polymorphic, Bsu36I 
restriction site. If the G-allele is present restriction enzyme digestion with Bsu36I 
yield two fragments of 823bp and 84bp, while the 907bp fragment remained intact in 
the presence of the A-allele (figure 3.25).  
 
PCR amplification of the region where the 5937G/A variant/rs3097 resides yielded a 
1011bp size fragment containing one invariant NspI restriction site. For the G allele, 
the fragment was cleaved into two fragments of 744bp and 267bp following NspI 
digestion. For the A allele, another NspI restriction site is created and the 744bp 
fragment was further digested into two fragments of 690bp and 54bp, following 
restriction enzyme digestion with NspI (figure 3.26).  
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A) 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
Figure 3.24: ASREA of the CYP11B2 fragment 1 rs1799998 polymorphism.  
A) Representative 12% polyacrylamide gel showing the fragment sizes generated by HaeIII 
restriction enzyme digestion of the 177bp PCR-amplified fragment. Lane 1= 100bp marker, 
Lane 3, 6, 10 = homozygote TT, Lane 2, 4, 5, 7, 8, 9, 11 and 13 = heterozygote TC, Lane 12 = 
homozygote CC, Lane 14 = uncut. The small 20bp fragment was not distinguished on this gel. 
B) Schematic representation of the amplified fragment showing the position of the HaeIII 
restriction site. * = variable restriction enzyme site. 
 
 
 
A) 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
Figure 3.25: ASREA of the CYP11B2 fragment 2 rs4539 polymorphism.  
A) Representative 1.5% agarose gel showing the fragment sizes generated by Bsu36I 
restriction enzyme digestion of the 907bp PCR-amplified fragment. Lane 1= 100bp marker, 
Lane 2 = homozygote AA, Lane 3 = heterozygote GA, Lane 4 = homozygote GG, Lane 5 = 
uncut. The small 84bp fragment was not distinguished on this gel. B) Schematic 
representation of the amplified fragment showing the position of the Bsu36I restriction site. * 
= variable restriction enzyme site. 
500bp 
1 2 3 4 5 
907bp 
823bp 
1100bp 
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A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
Figure 3.26: ASREA of the CYP11B2 fragment 4 rs3097 polymorphism.  
A) Representative 12% polyacrylamide gel showing the fragment sizes generated by NspI 
restriction enzyme digestion of the 1011bp PCR-amplified fragment. Lane 1= 100bp marker, 
Lane 2, 3, 4, 9, 10 and 13 = homozygote GG, Lane 5, 6, 7 and 8 = heterozygote GA, Lane 16 
and 17 = homozygote AA, Lane 22 = uncut. The small 54bp fragment was not distinguished 
on this gel. B) Schematic representation of the amplified fragment showing the positions of 
the NspI restriction sites. * = variable restriction enzyme site. 
 
 
AGTR1/rs2640539 (C/G), AGTR1/rs3772627 (A/G) and AGTR1/rs5182 (573C/T) 
polymorphisms. 
PCR amplification of the region flanking the rs2640539 polymorphism yielded a 
992bp fragment containing a polymorphic MspA1I restriction site. For the G-allele, 
which abolishes the MspA1I site, the 992bp fragment remained undigested, while for 
the C-allele, the creation of an MspA1I site resulted in cleavage of the 992bp 
fragment into two fragments of 609bp and 383bp in size (figure 3.27).  
 
PCR amplification of the region containing the rs3772627 variant yielded an 1120bp 
size fragment containing one invariant Bsah1I restriction enzyme site. For the A-
allele, restriction enzyme digestion of the 1120bp fragment 2 by Bsah1I yielded two 
fragments 697bp and 423bp. For the G-allele, another Bsah1I restriction site is 
267bp 
16 21181314
744bp 
690bp 
1011bp 
800bp 
300bp 
100bp 
12 9642 1151 3 1087 2217 201915
*N 
267bp 690bp 54bp 
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created, consequently the 697bp fragment was cleaved into two fragments of 496bp 
and 201bp in size after digestion with Bsah1I (figure 3.28).  
 
Amplification of the exonic region of AGTR1 in which the rs5182 polymorphism 
resides yielded a 1001bp fragment that contains five invariant MnlI restriction enzyme 
sites. For the T-allele, the 1001bp fragment was cleaved into 422bp, 309bp, 127bp, 
68bp, 47bp and 28bp following digestion with MnlI. The presence of the C-allele 
creates an additional restriction site, consequently, the 422bp fragment was digested 
into two fragments of 325bp and 97bp sizes after digestion with MnlI (figure 3.29).  
 
 
 
   
A)   
  
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
Figure 3.27: ASREA of the AGTR1 fragment 1 rs2640539 polymorphism.  
A) Representative 1.5% agarose gel showing the fragment sizes generated by MspA1I 
restriction enzyme digestion of the 992bp PCR-amplified fragment. Lane 1= homozygote GG, 
Lane 2 = heterozygote CG, Lane 3 = homozygote CC, Lane 4 = uncut, Lane 5 = 100bp 
marker. B) Schematic representation of the amplified fragment showing the position of the 
MspA1I restriction site. * = variable restriction enzyme site. 
 
 
 
 
1 2 3 4 5
992bp 
383bp 
500bp 609bp 
*M 
609bp 383bp 
http://scholar.sun.ac.za
 115
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Figure 3.28: ASREA of the AGTR1 fragment 2 rs3772627 polymorphism.  
A) Representative 1.5% agarose gel showing the fragment sizes generated by Bsah1I 
restriction enzyme digestion of the 1120bp PCR-amplified fragment. Lane 1= 100bp marker, 
Lane 3 and 4 = homozygote AA, Lane 2, 5 and 7 = heterozygote GA, Lanes 6 and 8 = 
homozygote GG, Lane 9 = uncut. B) Schematic representation of the amplified fragment 
showing the positions of the Bsah1I restriction sites. * = variable restriction enzyme site. 
 
A) 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
Figure 3.29: ASREA of the AGTR1 fragment 3 rs5182 polymorphism.  
A) Representative 12% polyacrylamide gel showing the fragment sizes generated by MnlI 
restriction enzyme digestion of the 1001bp PCR-amplified fragment. Lane 1= 100bp marker, 
Lane 2, 3, 13, 15 and 17 = homozygote CC, Lane 4, 5, 6, 7, 8, 9, 14 and 16 = heterozygote 
CT, Lane 11 = homozygote TT, Lane 18 = uncut. Lane 10 = partial digest homozygote CC. 
The smaller 47bp and 28bp fragments could not be distinguished on this gel. B) Schematic 
representation of the amplified fragment showing the positions of the MnlI restriction sites. * 
= variable restriction enzyme site. 
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ACE2/rs1978124 (1075A/G), ACE2/rs2285666 (8790G/A), ACE2/rs879922 
(28330C/G) and ACE2/rs4646179 (C/T) polymorphisms. 
PCR amplification of the various intronic regions of ACE2 in which the above four 
polymorphisms reside generated fragment sizes of 1044bp, 130bp, 188bp and 680bp, 
respectively, which were used to genotype study subjects. The amplicon 1044bp 
contains one polymorphic Sau96I restriction site used for genotyping rs1978124. For 
the G-allele, restriction enzyme digestion with Sau96I yields two fragments of 962bp 
and 82bp, while the 1044bp fragment remains intact in the presence of the A-allele 
(figure 3.30).  
 
The 130bp amplicon contains one polymorphic AluI restriction site used for 
genotyping rs2285666. For the A-allele the 130bp fragment is cleaved into two 
fragments 78bp and 52bp after AluI digestion, while the 130bp fragment remains 
intact in the presence of the G-allele (figure 3.31).  
 
The 188bp PCR amplified fragment contained one polymorphic BfaI restriction site 
that was used to genotype rs879922. For C-allele carriers, the 188bp fragment 
remained intact after digestion with BfaI as no restriction site is present, while the G-
allele creates a BfaI site resulting in the cleavage of the 188bp fragment into two 
fragments of 146bp and 42bp (figure 3.32).  
 
The 680bp amplicon in which rs4646179 resides contains two invariant HpyCH4IV 
restriction enzyme sites. For the T-allele, the 680bp fragment yielded three fragments 
(402bp, 257bp and 21bp) after digestion, while the C-allele creates an additional 
restriction enzyme site, that after cleavage yielded four fragments (402bp, 180bp, 
77bp and 21bp) (figure 3.33).       
 
 
 
 
 
 
 
 
 
 
 
 
http://scholar.sun.ac.za
 117
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Figure 3.30: ASREA of the ACE2 fragment 1 rs1978124 polymorphism.  
A) Representative 1.5% agarose gel showing the fragment sizes generated by Sau96I 
restriction enzyme digestion of the 1044bp PCR-amplified fragment. Lane 1= 100bp marker, 
Lane 2 = homozygote AA, Lane 3 = heterozygote GA, Lane 4 = homozygote GG, Lane 5 = 
uncut. The smaller 82bp fragment could not be distinguished on this gel. B) Schematic 
representation of the amplified fragment showing the position of the Sau96I restriction site. * 
= variable restriction enzyme site. 
 
A) 
 
 
B) 
 
 
 
Figure 3.31: ASREA of the ACE2 fragment 2 rs2285666 polymorphism.  
A) Representative 12% polyacrylamide gel showing the fragment sizes generated by AluI 
restriction enzyme digestion of the 130bp PCR-amplified fragment. Lane 1 = uncut, Lane 2 = 
100bp marker, Lane 3 and 5 = homozygote GG, Lane 4, 6 and 9 = heterozygote GA, Lane 8 = 
homozygote AA. B) Schematic representation of the amplified fragment showing the position 
of the AluI restriction site. * = variable restriction enzyme site. 
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A) 
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Figure 3.32: ASREA of the ACE2 fragment 3 rs879922 polymorphism.  
A) Representative 12% polyacrylamide gel showing the fragment sizes generated by BfaI 
restriction enzyme digestion of the 188bp PCR-amplified fragment. Lane 1= 100bp marker, 
Lane 2 and 4 = homozygote GG, Lane 3 = homozygote CC, Lane 5 = heterozygote GC, Lane 
6 = uncut. B) Schematic representation of the amplified fragment showing the position of the 
BfaI restriction site. * = variable restriction enzyme site. 
 
 
A) 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
Figure 3.33: ASREA of the ACE2 fragment 4 rs4646179 polymorphism.  
A) Representative 1.5% agarose gel showing the fragment sizes generated by HpyCH4IV 
restriction enzyme digestion of the 680bp PCR-amplified fragment. Lane 1= 100bp marker, 
Lane 2 = homozygote TT, Lane 3 = heterozygote CT, Lane 4 = homozygote CC, Lane 5 = 
uncut. The smaller 77bp and 21bp are not resolved on this gel. B) Schematic representation of 
the amplified fragment showing the position of the HpyCH4IV restriction site. * = variable 
restriction enzyme site. 
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3.6. Automated sequence analysis 
To assess the accuracy of SNaPshot analysis, two individuals from each of 16 of the 
22 pedigrees studied were selected for sequence analysis. Pairs of individuals chosen 
were never from the same nuclear family. Thus, the sequence of the regions 
encompassing each SNP genotyped by SNaPshot in ACE1, AGT and CMA were 
recorded in 32 individuals per SNaPshot SNP (representing about 10% of the total 
HCM cohort). Shown are representative sequencing results for individuals in the 
HCM panel for ACE1 fragments 1, CMA fragment 2 and AGT fragments 1 and 3 
(figures 3.34-3.37). A 100% correlation was found between SNaPshot results for 
variants used in this study and automated sequencing results.  
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  A)      B) 
 
 
                
 
  C)      D) 
 
Figure 3.34: A representative sequence analysis of fragment 1 of ACE1 in the HCM panel. 
Chromatogram indicating the partial nucleotide sequences of three individuals in the HCM 
panel with variant patterns. A) Individual 5202 heterozygous (C/T) at rs4298, B) individual 
4778 homozygous (CC) at rs4298, C) individual 4778 homozygous (GG) at rs4303 and D) 
individual 5143 heterozygous (G/T) at rs4303 with the position of the sequence variation 
indicated by an arrow.  
 
                  A      C/T  G   C    T    G                 A     C  G  C   T   G C  G         
                  C    G  C  G   C  A  C                       C    G  C G/T C  A  C      
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Figure 3.35: A representative sequence analysis of fragment 2 of CMA in the HCM panel. 
Chromatogram indicating the partial nucleotide sequences of three individuals in the HCM 
panel with variant patterns. A) Individual 5189 heterozygous (G/A) at rs1885108, B) 
individual 5215 homozygous (GG) at rs1885108 and C) individual 4773 homozygous (AA) at 
rs1885108 with the position of the sequence variation indicated by an arrow.  
 
 
 A)     B)      C) 
                T   G  A C G/AG T  C         C  T  G  A C  G  G  T  C        T  G   A  C A  G   T  C               
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  A)           B)           C) 
  
Figure 3.36: A representative sequence analysis of the reverse strand of AGT fragment 1 in 
the HCM panel.  
Chromatogram indicating the partial nucleotide sequences of three individuals in the HCM 
panel with variant patterns. A) Individual 5295 heterozygous (C/T) at rs5051, B) individual 
898 homozygous (CC) at rs5051 and C) individual 4367 homozygous (TT) at rs5051 with the 
position of the sequence variation indicated by an arrow. * The sequence above is in the 
reverse orientation. 
 
          C  C  C C/TG  G  C           C    C  C   C   G   G  C              C  C   C  T  G   G  C 
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      A)           B) 
     
         C)                       D) 
 
Figure 3.37: A representative sequence analysis of fragment 3 of AGT in the HCM panel. 
Chromatogram indicating the partial nucleotide sequences of three individuals in the HCM 
panel with variant patterns. A) Individual 4773 heterozygous (C/T) at rs11122575, B) 
individual 1148 homozygous (TT) at rs11122575 C) individual 5437 heterozygous (G/A) at 
rs1926723 and D) individual 1148 homozygous (AA) at rs1926723 with the position of the 
sequence variation indicated by an arrow.  
 
 
              A  C A C/T G   A  A                          A  C  A  T   G    A  A  
           T   G    C A/G T    C   A                       T   G   C   A   T   C   A   
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3.7. Statistical analysis 
The genotypic and clinical information was used in the context of the family 
relationships and were analysed statistically by Dr. Lize van der Merwe from the 
MRC biostatistics unit, except for Hardy-Weinberg equilibrium (HWE) testing and 
LD determination with Haploview which were analysed by the author. 
. 
3.7.1. Distribution of variables (Summary statistics) 
PEDSTATS (Abecasis et al., 2002) produced  descriptive statistics for  the six RAAS 
genes and 25 quantitative traits and three composite scores. The graphical summaries 
of the initial exploratory statistics (PEDSTATS) have been formatted on compact disk 
(see back of dissertation). PEDSTATS revealed a mistake in the data; one person with 
mIVSmit of 110mm instead of 11mm which was corrected before continuing with 
statistical analysis. Additionally, this analysis revealed slight skewness and curtosis of 
the data, however, as this could be interpreted to reflect the different groups of 
individuals within the cohorts, data was not transformed. Furthermore, this analysis 
included checks for errors of Mendelian inheritance in the genotype data. These 
genotypes were re-evaluated by revisiting the raw data to monitor database 
transcription errors. Where inheritance errors were not due to transcription mistakes, 
re-genotyping using newly generated PCR products was performed not only for the 
individual in whom the genotype was in question, but for the whole nuclear family 
involved. 
 
3.7.2. Hardy-Weinberg equilibrium (HWE) testing and LD determination 
In pedigree 131 two generations of double first cousins were present, creating 
pedigree loops. Hence, the whole pedigree was excluded for the purposes of HWE 
and LD analysis with Haploview vs3.32. The remaining pedigrees were used for 
HWE testing and LD determination. We did not find any significant deviation from 
the HWE for any of the SNPs. 
 
Pairwise LD was estimated between the markers of each of the six RAAS genes 
(figures 3.38 to 3.43). The LOD score is a measure of confidence in the value of D’. 
A low LOD score corresponds to a low frequency of the polymorphism. In AGT, 
rs1926723 and rs11122575 were in strong LD, and rs699 was in strong LD with 
rs5051, the latter pair creating a haplotype block of 4kb (figure 3.39). None of the 
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SNPs investigated within ACE1, AGTR1, CYP11B2 and ACE2 were in strong LD 
with each other (figures 3.38, 3.40, 3.41 and 3.43). The two SNPs in CMA were also 
in strong LD (figure 3.42) as indicated by the red square.  
 
 
Fig3.38: Plot of LD between ACE1 markers in the HCM cohort. 
D’-values are shown on the squares (%). White squares indicate D’-values < 100% and LOD score<2 
and blue squares indicate D’ =100% and LOD score <2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig3.39: Plot of LD between AGT markers in the HCM cohort. 
Blue squares indicate D’ =100% and LOD score <2, while red squares indicate D’=100% and LOD 
score ≥2. The haplotype block extending from rs699 through rs5051, as determined by the confidence 
intervals method of Gabriels et al. (2002) is indicated in black. 
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Fig3.40: Plot of LD between AGTR1 markers in the HCM cohort. 
D’-values are shown on the squares (%). White squares indicate the D’-values< 100% and LOD 
score<2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig3.41: Plot of LD between CYP11B2 markers in the HCM cohort. 
D’-values are shown on the squares (%). Blue squares indicate D’ =100% and LOD score <2, while the 
pink square shows the D’-values < 100% and LOD score ≥2. 
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Fig3.42: Plot of LD between CMA markers in the HCM cohort.  
The red square indicates D’=100% and LOD score ≥2.   
 
 
Fig3.43: Plot of LD between ACE2 markers in the HCM cohort. 
D’-values are shown on the squares (100%). The white square indicate D’-values< 100% and LOD 
score<2 and the blue squares indicate D’=100% and LOD<2. 
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3.7.3. Population stratification tests 
Table 3.2 contains the p-values for the population stratification tests.  Tests were 
adjusted for all covariates including mutation group. Only three SNPs were non-
informative for testing population stratification and were omitted from table 3.2: 
namely, rs4303 (ACE1), rs1112257 (AGT) and rs1926723 (AGT).  The majority of the 
p-values for the population stratification tests were not statistically significant but for 
some traits, for a few SNPs, highlighted in bold in table 3.2, statistical significance 
was reached. Because association was tested using the orthogonal model, which 
accounts for population stratification, the further results are protected against it.  
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Table 3.2: The p-values for population stratification test for entire cohort, adjusted for mutation groups and all other covariates. 
Trait 
ACE1 AGT AGTR1 CYP11B2 CMA 
rs4340 I/D rs4303 rs4356 rs699 rs4762 rs5051 rs2640539 rs3772627 rs5182 rs1799998 rs4539 rs3097 rs1885108 rs1800875 
LVM 0.8792 0.9446 0.6400 0.8786 0.1829 0.9004 0.4998 0.0240 0.4969 0.9668 0.0494 0.8883 0.6536 0.4122 
mIVS 0.6459 0.2610 0.7202 0.3952 0.0735 0.6791 0.1437 0.0270 0.5386 0.5322 0.1063 0.7411 0.4451 0.5071 
mLVWT 0.6950 0.3243 0.7859 0.2875 0.0789 0.4879 0.1424 0.0161 0.4485 0.5368 0.1104 0.9187 0.4248 0.4464 
mPWT 0.2239 0.8056 0.2336 0.7711 0.7553 0.6056 0.2660 0.4478 0.6856 0.5969 0.1928 0.0231 0.1439 0.4975 
Maron-
Spirito 1.0000 0.7883 0.8157 0.4311 0.0944 0.7066 0.1585 0.0278 0.4859 0.3381 0.0377 0.6201 0.8077 0.4399 
CWTscore 0.9349 0.3806 0.4818 0.4145 0.1659 0.7190 0.1874 0.0468 0.3206 0.6414 0.0560 0.3285 0.8945 0.8071 
Wigle score 0.4038 NI NI NI NI NI NI 0.0177 0.1290 NI NI NI NI NI 
mLVWTmit 0.5992 0.3702 0.9545 0.5067 0.1934 0.8454 0.0170 0.0694 0.6551 0.6771 0.1617 0.8048 0.4140 0.7649 
mIVSTmit 0.0480 0.1585 0.4028 0.1807 0.6557 0.0105 0.0128 0.6273 0.3486 0.5771 0.8966 0.8793 0.7329 0.8404 
pIVSmit 0.8496 0.5228 0.3030 0.5704 0.0281 0.6926 0.0834 0.1907 0.6886 0.9190 0.1018 0.3340 0.5935 0.5723 
aIVSmit 0.3286 0.3038 0.9097 0.4687 0.1361 0.8354 0.0502 0.0444 0.7845 0.6570 0.1581 0.7444 0.3951 0.7839 
AWmit 0.6601 0.5079 0.9665 0.5266 0.3909 0.8286 0.0265 0.0617 0.7126 0.7722 0.0481 0.7054 0.3736 0.7462 
LWmit 0.4424 0.3684 0.5993 0.6562 0.6287 0.9058 0.0168 0.1880 0.2310 0.9709 0.1235 0.1346 0.6578 0.5855 
IWmit 0.4389 0.9494 0.2721 0.3328 0.1549 0.2458 0.0211 0.2922 0.4780 0.7974 0.4647 0.6844 0.3672 0.2871 
PWmit 0.1766 0.7018 0.0551 0.3268 0.9369 0.2405 0.1152 0.4916 0.7347 0.4927 0.0611 0.0264 0.1485 0.7827 
mLVWTpap 0.8455 0.4928 0.8417 0.2753 0.0418 0.4896 0.1795 0.0078 0.2724 0.5098 0.1075 0.5754 0.5151 0.4292 
mIVSpap 0.7751 0.4451 0.7408 0.3452 0.0391 0.6336 0.1284 0.0086 0.3327 0.6728 0.1081 0.4497 0.5728 0.5607 
pIVSpap 0.9354 0.9907 0.9294 0.5361 0.0215 0.7406 0.3070 0.0392 0.4170 0.6890 0.1257 0.4160 0.7112 0.4606 
aIVSpap 0.5622 0.3097 0.7470 0.2482 0.0235 0.5021 0.1371 0.0031 0.4773 0.5348 0.0785 0.4842 0.6691 0.5868 
AWpap 0.5364 0.6637 0.8819 0.3538 0.2075 0.4864 0.7998 0.0277 0.3908 0.3550 0.0279 0.9690 0.6507 0.6259 
LWpap 0.3541 0.9524 0.7323 0.9086 0.6830 0.7991 0.1357 0.1538 0.2453 0.7640 0.3356 0.3005 0.6444 0.7952 
IWpap 0.0819 0.2879 0.1507 0.4282 0.9952 0.2635 0.1053 0.7406 0.1056 0.0470 0.0382 0.0322 0.1601 0.3701 
PWpap 0.1981 0.5649 0.0949 0.3721 0.9180 0.2194 0.4766 0.2708 0.8499 0.0934 0.0722 0.0036 0.0974 0.5910 
mLVWTapx 0.8240 0.1745 0.2980 0.7260 0.1139 0.7591 0.2306 0.0073 0.1814 0.4392 0.1213 0.1842 0.5723 1.0000 
IVSapx 0.9779 0.1369 0.2897 0.6102 0.0570 0.6924 0.3421 0.0073 0.2929 0.4741 0.1091 0.1086 0.8663 0.9422 
AWapx 0.6021 0.3059 0.6555 0.6166 0.2960 0.6676 0.2348 0.0090 0.0361 0.4819 0.0531 0.4723 0.7343 0.7261 
LWapx 0.1568 0.4735 0.6170 0.2820 0.4598 0.3474 0.7589 0.6172 0.3349 0.3516 0.4243 0.0944 0.1082 0.6328 
PWapx 0.4770 0.8365 0.2503 0.8634 0.6223 0.5896 0.3896 0.4888 0.8793 0.9845 0.6238 0.0616 0.2372 0.5696 
 
NI-not informative
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3.7.4. Variance component models: heritability test 
The heritability values of ACE1, AGT, CMA, AGTR1 and CYP11B2 were estimated 
for 25 quantitative traits and three composite scores after adjusting for the effects of 
all the covariates. Table 3.3 contains the estimated percentage variance attributable to 
environment (E) and genetic factors (G) and p-values for a test of heritability.  
 
Heritability tests after adjusting for SBP, DBP, BSA, age, sex, mutation and HR 
showed a strong genetic component for determining mIVS, mLVWT, Maron-Spirito 
score, CWTscore, pIVSmit, AWmit, PWpap, mLVWTpap, pIVSpap, aIVSp, AWpap, 
and IVSapx (table 3.3).   
 
After heritability was assessed for the 28 parameters, only the 16 individual 
hypertrophic traits and one composite score, CWT score, were selected for subsequent 
investigation for association. The rationale for the exclusion of certain parameters is 
given in the discussion (see section 4.4).  
 
3.7.5. Variance component models: environment, polygenes and additive 
component  
Tables 3.4 to 3.7 contain the estimated variance components (the estimated percentage 
variance attributable) for environment, (E), polygenes (G) and specific SNP (major 
gene additive component: A) for the CWT score (table 3.4) and the hypertrophy traits 
at mitral valve (table 3.5), papillary muscles (table 3.6) and apex (table 3.7) after 
adjusting for all covariates. Generally, most of the variance for all 17 traits was 
attributable to environmental effects (between 55 and 100 %). We showed in the 
previous section, table 3.3, that some of the variance is due to a heritable effect, which 
is the combined polygene effect (G) and major gene additive effect (A) of tables 3.4 
to 3.7.  
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Table 3.3: Percentage variance attributable to environment, E, and genetic factors, G, 
and p-values for heritability of 28 echo-measured traits analysed. Tests were adjusted 
for all covariates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trait 
E G p-value 
LVM 70.84 29.16 0.0744 
mIVS 68.62 31.38 0.0094 
mLVWT 69.95 30.05 0.0148 
mPWT 92.02 7.98 0.7121 
Maron-Spirito score 73.08 26.92 0.0534 
CWTscore 67.38 32.62 0.0309 
Wigle score 55.86 44.14 0.9486 
mLVWTmit 72.97 27.03 0.0352 
mIVSTmit 81.76 18.24 0.1803 
pIVSmit 54.30 45.70 0.0009 
aIVSmit 75.33 24.67 0.074 
AWmit 77.72 22.28 0.0458 
LWmit 79.89 20.12 0.1778 
IWmit 88.32 11.68 0.5949 
PWmit 79.36 20.64 0.1312 
mLVWTpap 66.25 33.75 0.0052 
mIVSpap 67.19 32.81 0.0068 
pIVSpap 70.18 29.82 0.0340 
aIVSpap 70.49 29.51 0.0162 
AWpap 67.99 32.01 0.0080 
LWpap 83.21 16.79 0.4534 
IWpap 93.82 6.18 0.7704 
PWpap 65.47 34.53 0.0641 
mLVWTapx 69.55 30.45 0.0577 
 IVSapx 62.72 37.28 0.0144 
AWapx 77.66 22.34 0.1922 
LWapx 82.95 17.05 0.4891 
PWapx 97.84 2.16 0.9336 
http://scholar.sun.ac.za
 132
The ACE1, AGT and CYP11B2 accounted for between 23 and 31% of the variance of 
the CWT score, while the SNPs evaluated in AGTR1 and CMA did not contribute to 
the additive component of variance (table 3.4). 
 
At mitral valve level, the AGT and CYP11B2 accounted for between 15.5 and 21.4% 
of the variance of the pIVS. Most variants in AGT accounted for only a small portion, 
1 to 2%, of the variance of the aIVS trait, although rs4762 within AGT and variants in 
the CMA and CYP11B2 account for between 13.6 and 21.3% of the variance of the 
aIVS trait. For the AWT trait, rs4356 within ACE1 accounted for 19.9% of the 
variance, while polymorphisms within AGTR1 and CMA accounted for between 11.9 
and 20.9% of variance in this trait. ACE1, AGT, AGTR1 and CYP11B2 all contributed 
significantly to variance of the LWmit, between 12.1 and 17.7%, while only ACE1 
and AGT contributed to variance at the IWmit (between 6.8 and 13.9%). Only variants 
in AGT accounted significantly for variance (~13.5%) at the PWmit (table 3.5).    
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Table 3.4: Percentage variance attributable to variance components for cumulative 
wall thickness score (CWT). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations used: E- Environmental effect, G- Polygenic effect and A- Major gene additive effect 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene SNP ID E G A 
ACE1 
rs4340 I/D 72.9   0.0 27.0 
rs4298 72.7   0.0 27.3 
rs4303 72.9   0.0 27.1 
rs4356 72.7   0.0 27.3 
AGT 
rs699 76.7   0.0 23.3 
rs4762 76.2   0.0 23.8 
rs5051 76.6   0.0 23.3 
rs1112257 76.7   0.0 23.3 
rs1926723 76.6   0.0 23.4 
AGTR1 
rs2640539 71.6 28.4   0.0 
rs3772627 71.6 28.4   0.0 
rs5182 71.7 27.7   0.6 
CYP11B2 
rs1799998 69.0   0.0 31.0 
rs4539 71.6   0.0 28.4 
rs3097 71.6   0.0 28.4 
CMA rs1885108 70.4 29.6   0.0 
rs1800875 70.4 29.6   0.0 
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Table 3.5: Percentage variance attributable to variance components at the mitral valve level.  
 
  Mitral valve level 
  interventricular septum thickness wall thickness 
  posterior anterior anterior lateral interior posterior 
Gene SNP ID E G A E G A E G A E G A E G A E G A 
ACE1 
rs4340 I/D 55.1 44.9 0 77.5 22.5 0 78.2 21.8 0 83 0 17 86.1 0 13.9 96.9 15.5   3.4 
rs4298 55.1 44.9 0 77.5 22.5 0 78.2 21.8 0 83.2 0 16.8 86.8 0 13.3 83 16.5   0.5 
rs4303 55.1 44.9 0 77.5 22.5 0 78.2 21.8 0 83.2 0 16.8 86.6 0 13.4 83.3 15.3   1.5 
rs4356 55.0 45.0 0 77.5 22.5 0 80.1 0 19.9 82.3 0 17.7 84.4 0 15.6 82.9 16.8   0.3 
AGT 
rs699 62.8 16.6 20.6 78 20.2   1.8 78.6 17.6   3.8 87.5   0.2 12.3 93.2 0   6.8 86.4   0.1 13.5 
rs4762 61.0 22.4 16.6 81.2   5.2 13.6 79.2 11.5   9.3 87.5 0 12.5 93.2 0   6.8 86.7 0 13.3 
rs5051 62.5 17.8 19.8 77.9 20.6   1.5 78.6 17.6   3.8 87.6 0 12.4 93.2 0   6.8 86.4 0 13.6 
rs1112257 63.1 15.6 21.4 78.2 19.6   2.2 78.6 17.5   3.9 87.5   0.1 12.4 93.2 0   6.8 86.4 0 13.6 
rs1926723 62.9 16.3 20.9 78.2 19.6   2.2 78.6 17.6   3.8 87.5   0.3 12.2 93.2 0   6.8 86.4 0 13.6 
AGTR1 
rs2640539 57.3 42.7 0 79.3 18.4   2.3 79.1 0 20.9 87.5   0.4 12.1 93.5 6.5 0 81.3 18.7 0 
rs3772627 57.3 42.7 0 78.9 21.1 0 79.5 0 20.5 85.9 0 14.2 93.5 6.5 0 81.4 18.6 0 
rs5182 57.3 42.7 0 78.9 21   0.1 81.2 0.3 18.5 85.9 0 14.1 93.5 6.5 0 81.4 18.6 0 
CYP11B2 
rs1799998 61.9 20.7 17.4 78.8 0 21.3 78.7 17.7   3.6 84.4 0 15.6 93.5 6.5 0 81.4 18.6 0 
rs4539 62.4 18.5 19.1 79.9 0 20.1 78.6 21.4 0 83.9 0 16.1 93.5 6.5 0 81.3 18.7 0 
rs3097 61.5 23.0 15.5 80 0 20 78.7 21.3 0 83.8 0 16.2 93.5 6.5 0 81.3 18.7 0 
CMA rs1885108 55.1 44.9 0 77.7   5.3 17.1 78 8.9 13.2 86.1 13.9 0 94.4 5.6 0 82.8 17.2 0 
rs1800875 55.1 44.8   0.2 77.7   5.3 17 78 10.2 11.9 86.1 13.9 0 94.5 5.6 0 82.8 17.2 0 
 
Abbreviations used: E- Environmental effect, G- Polygenic effect and A- Major gene additive effect 
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At papillary muscle level, variants in the ACE1, AGT and CYP11B2, as well as rs1885108 in 
CMA, accounted for between 3.9 and 28.6% of the variance of the pIVSpap trait (table 3.6). 
The ACE1, CYP11B2 and CMA genes accounted for between 8.1 and 27.9% of the variance 
of the aIVSpap trait (table 3.6). The ACE1, AGTR1 and CMA accounted for between 11.7 and 
28.6% of the variance of the aWpap trait (table 3.6). ACE1, AGTR1, CYP11B2 and CMA 
accounted for between 8.4 and 22.7% of the variance of the LWpap trait (table 3.6). Only 
ACE1 and CYP11B2 account for between 4.2 and 12.6% of the variance of the IWpap trait 
but none of the other genes contributed significantly to variance in this trait (table 3.6). 
ACE1, AGT, and rs4539 and rs3097 in CYP11B2 accounted for between 21 and 39.6% of the 
variance of the PWpap trait (table 3.6).  
 
At the apex level, the ACE1, AGT and CYP11B2 accounted for between 27.6 and 35.4% of 
the variance of the IVSapx trait and between 17.6 and 31.1% of the variance of the AWapx 
trait (table 3.7). ACE1, AGTR1 and CYP11B2 variants accounted for between 6.6 and 15.1% 
of the variance of the LWapx trait (table 3.7). The ACE1 accounts for a small portion 6-7% of 
the variance of the LWapx trait (table 3.7). Only ACE1 and CYP11B2 contributed 
significantly to variance of the PWapx trait, accounting for between 10.8 and 17.5% (table 
3.7).  
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Table 3.6: Percentage variance attributable to variance components at the level of the papillary muscles. 
  Level of Papillary muscles 
  interventricular septum thickness wall thickness 
  posterior anterior anterior lateral interior posterior 
Gene SNP ID E G A E G A E G A E G A E G A E G A 
ACE1 
rs4340 I/D 73.5 18.7   7.8 75.8 0 24.2 72   0.1 27.9 78.4 0 21.6 91.9 0   8.1 66.9 0 33.1 
rs4298 73.7 17.5   8.8 75.6 0 24.4 71.4 0 28.6 78.5 0 21.5 92.7 0   7.3 67.8 0 32.2 
rs4303 73.7 18   8.4 75.7 0 24.3 71.8 0 28.2 78.5 0 21.5 92.7 0   7.3 68 0 32.1 
rs4356 72.9 22.2 5 76 0 24 72.6 0 27.4 77.3 0 22.7 87.4 0 12.6 60.4 0 39.6 
AGT 
rs699 77.7 0 22.3 71.4 28.6 0 68.4 31.6 0 89.3 10.7 0 97.8 2.2 0 73.1   5.9 21 
rs4762 77.8 0 22.3 71.6 28   0.4 68.4 31.6 0 89.3 10.7 0 97.7 0     2.3 69.9 0 30.1 
rs5051 77.7 0 22.3 71.4 28.6 0 68.4 31.6 0 89.4 10.7 0 97.8 2.2 0 73.1   5.6 21.3 
rs1112257 77.7 0 22.4 71.4 28.6 0 68.4 31.6 0 89.3 10.7 0 97.8 2.2 0 73.1   5.7 21.2 
rs1926723 77.6 0 22.4 71.4 28.6 0 68.4 31.6 0 89.3 10.7 0 97.8 2.2 0 73.1   5.8 21.2 
AGTR1 
rs2640539 73 27 0 72.1 27.9 0 71.1 17.1 11.7 89.1 0 10.9 96.1 3.9 0 69 31 0 
rs3772627 73 27 0 72.1 27.9 0 71.5 13.8 14.7 87 0 13 96.1 3.9 0 68.9 31.1 0 
rs5182 73 27 0 72.4 26.3   1.3 71.9 12.6 15.6 86.2 0 13.8 96.2 3.8 0 68.9 31.1 0 
CYP11B2 
rs1799998 71.4 0 28.6 72.2 0 27.9 69.1 30.9 0 84.5 0 15.5 95.8 0   4.2 69 31 0 
rs4539 76.1 0 23.9 73.8 0 26.2 69.1 30.9 0 85.9 0 14.2 91.2 0   8.8 71   1.8 27.2 
rs3097 76.3 0 23.7 74.2 0 25.9 69.1 30.9 0 85.6 0 14.4 91.5 0   8.5 71.1   1.8 27.1 
CMA rs1885108 71.5 24.6   3.9 71.4 22.7   5.9 65.3 10.4 24.2 88.6   2.9   8.4 97.8 2.2 0 70.5 29.5 0 
rs1800875 71.5 24.3 0 71.3 20.6   8.1 65.3   9.1 25.7 88.6   1.7   9.7 97.8 2.2 0 70.5 29.5 0 
 
Abbreviations used: E- Environmental effect, G- Polygenic effect and A- Major gene additive effect 
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Table 3.7: Percentage variance attributable to variance components at the level of the 
apex. 
  Level of Apex 
  interventricular wall thickness 
  septum thickness anterior lateral posterior 
Gene SNP ID E G A E G A E G A E G A 
ACE1 
rs4340 
I/D 70.9 0 29.1 69.2 0 30.9 89  4.3   6.7 89 0 11 
rs4298 70.6 0 29.4 68.9 0 31.1 89  4.1   6.9 89.2 0 10.8 
rs4303 70.8 0 29.2 69.1 0 30.9 89  4.7   6.3 89.2 0 10.8 
rs4356 71.1 0 29 70.4 0 29.6 89   4.6   6.4 88.4 0 11.6 
AGT 
rs699 72.4 0 27.6 82.2 0 17.8 89.6 10.4 0 99.9 0.1 0 
rs4762 72.2 0 27.8 82.3 0 17.7 89.6 10.4 0 99.9 0.1 0 
rs5051 72.4 0 27.6 82.2 0 17.8 89.6 10.4 0 100 0 0 
rs1112257 72.4 0 27.6 82.1   0.3 17.6 89.6 10.4 0 100 0 0 
rs1926723 72.3 0 27.7 82.2 0 17.8 89.6 10.4 0 100 0 0 
AGTR1 
rs2640539 65.9 34.2 0 81.8 18.3 0 89.5 3  7.5 98.6 1.4 0 
rs3772627 65.9 34.1 0 81.8 18.2 0 84.9 0 15.1 98.7 1.3 0 
rs5182 65.9 34.2 0 81.7 18.3 0 89.8 9.9   0.3 98.7 1.3 0 
CYP11B2 
rs1799998 64.7 0 35.4 74.4 0 25.6 88.1 0 11.9 82.5 0 17.5 
rs4539 68.8 0 31.2 75.9 0 24.1 90.4 3   6.6 82.6 0 17.4 
rs3097 68.9 0 31.1 76.2 0 23.8 90.5  1.9   7.6 82.8 0 17.3 
CMA rs1885108 64.8 35.2 0 80.4 19.6 0 89.6 10.4 0 99.9 0.1 0 
rs1800875 64.8 35.2 0 80.4 19.6 0 89.6 10.4 0 100 0 0 
Abbreviations used: E- Environmental effect, G- Polygenic effect and A- Major gene additive effect 
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3.7.6. Linkage analysis 
The LOD-scores and p-values for testing linkage of the 17 markers of the five RAAS 
genes to hypertrophy traits are listed in the first two columns of tables 3.8 (for CWT 
score) and 3.9 to 3.24 (for 16 wall thickness parameters). Significant linkage results 
(LOD-scores ≥3, and p < 0.05), which represents strong evidence for linkage, are 
highlighted in bold. The only significant indication for linkage was seen with variants 
in the ACE1 (table 3.20). Specifically, several markers (rs4340, rs4303 and rs4356) in 
ACE1 showed LOD-scores >3 for trait PWpap (table 3.20), while only rs4340, rs4298 
and rs4303 in ACE1 showed LOD-scores >3 for trait AWapx (table 3.22). 
 
3.7.7. Association tests 
Highly significant evidence of association was observed between AGTR1 rs2640539 
and AWmit (p = 0.009) (table 3.11). We estimate that each G-allele decreases AWmit 
by 2.2mm, making it a protective allele.  
 
Evidence of association was observed between CYP11B2 rs3097 and PWmit trait 
under an additive model (p = 0.001) (table 3.14), with the G-allele representing the 
protective allele. Each G-allele is estimated to reduce PWmit by 1.0mm.  
 
Further, significant association was observed between AGTR1 rs3772627 and the 
aIVSpap trait (p = 0.037) (table 3.16). The A-allele of the AGTR1 rs3772627 
polymorphism represents the risk allele with each copy of the A-allele estimated to 
add 1.7mm to aIVSpap thickness. Furthermore, association tests indicated a 
significant association between AGTR1 rs5182 and IWpap trait (p = 0.006) (table 
3.19). Each T-allele of the AGTR1 rs5182 polymorphism is estimated to decrease 
IWpap by 0.6mm making the T-allele a protective allele (table 3.19). Additionally, a 
significant association was observed between AGTR1 rs5182 and the AWapx trait (p 
= 0.046) (table 3.23). Again, the T-allele of the AGTR1 rs5182 polymorphism is 
acting as a protective allele, and is estimated to decrease AWapx by 1.9mm.  
 
Similarly, a significant association was observed between CYP11B2 rs3097 and 
IWpap trait (p = 0.01) (table 3.19). Each G-allele was estimated to decrease IWpap by 
1.0mm, making the G-allele protective for IWpap (table 3.19). A significant 
association was also found between CYP11B2 rs3097 and PWpap under an additive 
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model of association (p = 0.003) (table 3.20), with the G-allele representing the 
protective allele. We estimate that each G-allele decreases PWpap by 2.1mm. 
 
3.7.8 Linkage in the presence of association 
After modeling linkage and association simultaneously, the p-values generated 
suggested that for all the SNPs that showed association with one or more hypertrophy 
traits, viz. rs2640539, rs3772527 and rs5182 in AGTR1, and rs3097 in CYP11B2, 
there was no residual evidence for linkage (p > 0.10) (tables 3.11, 3.14, 3.16, 3.19, 
3.20, 3.23), suggesting that these variants are in strong LD with the respective 
functional susceptibility variants in these two genes.  
 
Conversely, evidence for linkage of ACE1 to hypertrophy parameters (tables 3.20 and 
3.22) are not accounted for by association and suggests that the polymorphisms 
investigated for association are not the functional variants. The results obtained are 
similar to that generated when modeling only linkage indicated in bold in tables 3.20 
and 3.22. The ACE1 locus could be a QTL for hypertrophy development.  
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Table 3.8: Linkage and association values for the cumulative wall thickness (CWT) 
score and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive model 
p-value p-value  
ACE1 
rs4340 I/D 0.844 0.161 0.515 0.237 
rs4298 0.844 0.161 NI NI 
rs4303 0.835 0.161 0.979 0.062 
rs4356 0.810 0.164 0.443 0.230 
AGT 
rs699 0.110 0.400 0.453 0.647 
rs4762 0.161 0.354 0.953 0.433 
rs5051 0.107 0.402 0.805 0.532 
rs1112257 0.113 0.398 NI NI 
rs1926723 0.110 0.400 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.303 1.000 
rs3772627 0.000 1.000 0.320 0.536 
rs5182 0.000 0.984 0.268 1.000 
CYP11B2 
rs1799998 1.447 0.108 0.631 0.090 
rs4539 0.571 0.204 0.516 1.000 
rs3097 0.130 0.197 0.296 0.295 
CMA rs1885108 0.000 1.000 0.889 0.996 
rs1800875 0.000 1.000 0.671 0.815 
Abbreviation used: LPOA-linkage in the presence of association.  NI-not informative. 
 
Table 3.9: Linkage and association values for the posterior interventricular septum 
thickness at level of mitral valve and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.000 1.000 0.204 1.000 
rs4298 0.000 1.000 NI NI 
rs4303 0.000 1.000 0.949 1.000 
rs4356 0.000 1.000 0.573 1.000 
AGT 
rs699 0.032 0.674 0.538 0.733 
rs4762 0.009 0.658 0.610 0.446 
rs5051 0.006 0.684 0.606 0.450 
rs1112257 0.008 0.667 NI NI 
rs1926723 0.032 0.668 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.215 1.000 
rs3772627 0.000 1.000 0.379 1.000 
rs5182 0.000 1.000 0.498 1.000 
CYP11B2 
rs1799998 0.004 0.711 0.135 1.000 
rs4539 0.007 0.674 0.890 1.000 
rs3097 0.002 0.769 0.577 1.000 
CMA rs1885108 0.000 1.000 0.732 1.000 
rs1800875 0.000 1.000 0.345 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
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Table 3.10: Linkage and association values for the anterior interventricular septum 
thickness at level of mitral valve and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.000 1.000 0.226 1.000 
rs4298 0.000 1.000 NI NI 
rs4303 0.000 1.000 0.858 0.355 
rs4356 0.000 1.000 0.296 1.000 
AGT 
rs699 0.000 0.963 0.843 1.000 
rs4762 0.006 0.690 0.917 0.874 
rs5051 0.000 0.984 0.657 1.000 
rs1112257 0.000 0.953 NI NI 
rs1926723 0.000 0.956 NI NI 
AGTR1 
rs2640539 0.000 0.924 0.137 1.000 
rs3772627 0.000 1.000 0.288 0.574 
rs5182 0.000 1.000 0.513 0.989 
CYP11B2 
rs1799998 0.217 0.318 0.672 0.363 
rs4539 0.078 0.437 0.856 1.000 
rs3097 0.089 0.425 0.841 0.883 
CMA rs1885108 0.028 0.550 0.325 1.000 
rs1800875 0.027 0.553 0.636 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
 
Table 3.11: Linkage and association values for the anterior wall thickness at level of 
mitral valve and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.000 1.000 0.528 1.000 
rs4298 0.000 1.000 NI NI 
rs4303 0.000 1.000 0.966 0.485 
rs4356 0.035 0.525 0.228 0.657 
AGT 
rs699 0.000 0.838 0.764 1.000 
rs4762 0.011 0.642 0.802 0.631 
rs5051 0.000 0.838 0.800 1.000 
rs1112257 0.000 0.835 NI NI 
rs1926723 0.000 0.838 NI NI 
AGTR1 
rs2640539 0.414 0.241 0.009 0.687 
rs3772627 0.414 0.240 0.225 0.248 
rs5182 0.104 0.408 0.371 0.682 
CYP11B2 
rs1799998 0.000 0.906 0.576 1.000 
rs4539 0.000 1.000 0.401 1.000 
rs3097 0.000 1.000 0.883 1.000 
CMA rs1885108 0.015 0.607 0.925 1.000 
rs1800875 0.011 0.640 0.705 0.929 
Abbreviation used: LPOA-linkage in the presence of association. Bold highlighting indicates a 
Markov Chain Monte Carlo (MCMC) exact p-value.  
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Table 3.12: Linkage and association values for the lateral wall thickness at level of 
mitral valve and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.414 0.241 0.629 0.582 
rs4298 0.340 0.264 NI NI 
rs4303 0.356 0.258 0.432 0.294 
rs4356 0.658 0.187 0.723 0.448 
AGT 
rs699 0.003 0.727 0.949 1.000 
rs4762 0.006 0.684 0.434 1.000 
rs5051 0.003 0.728 0.855 1.000 
rs1112257 0.004 0.720 NI NI 
rs1926723 0.003 0.725 NI NI 
AGTR1 
rs2640539 0.010 0.643 0.147 1.000 
rs3772627 0.035 0.528 0.266 0.521 
rs5182 0.040 0.513 0.142 0.687 
CYP11B2 
rs1799998 0.086 0.428 0.469 0.970 
rs4539 0.110 0.400 0.255 1.000 
rs3097 0.110 0.400 0.144 0.521 
CMA rs1885108 0.000 1.000 0.523 1.000 
rs1800875 0.000 1.000 0.828 0.992 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
 
 
 
Table 3.13: Linkage and association values for the inferior wall thickness at level of 
mitral valve and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.463 0.227 0.973 0.655 
rs4298 0.373 0.252 NI NI 
rs4303 0.408 0.242 0.709 0.266 
rs4356 0.628 0.193 0.934 0.471 
AGT 
rs699 0.068 0.453 0.470 0.991 
rs4762 0.068 0.453 0.419 0.755 
rs5051 0.068 0.453 0.362 0.990 
rs1112257 0.068 0.453 NI NI 
rs1926723 0.068 0.453 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.348 1.000 
rs3772627 0.000 1.000 0.724 0.997 
rs5182 0.000 1.000 0.100 1.000 
CYP11B2 
rs1799998 0.000 1.000 0.680 1.000 
rs4539 0.000 1.000 0.729 1.000 
rs3097 0.000 1.000 0.533 1.000 
CMA rs1885108 0.000 1.000 0.453 1.000 
rs1800875 0.000 1.000 0.889 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
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Table 3.14: Linkage and association values for the posterior wall thickness at level of 
mitral valve and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.000 0.919 0.918 1.000 
rs4298 0.000 0.985 NI NI 
rs4303 0.000 0.960 0.330 0.527 
rs4356 0.000 1.000 0.942 0.976 
AGT 
rs699 0.059 0.473 0.507 0.938 
rs4762 0.040 0.511 0.522 0.562 
rs5051 0.059 0.473 0.433 1.000 
rs1112257 0.061 0.468 NI NI 
rs1926723 0.061 0.466 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.615 1.000 
rs3772627 0.000 1.000 0.570 1.000 
rs5182 0.000 1.000 0.225 1.000 
CYP11B2 
rs1799998 0.000 1.000 0.715 1.000 
rs4539 0.000 1.000 0.481 1.000 
rs3097 0.000 1.000 0.001 1.000 
CMA rs1885108 0.000 1.000 0.554 1.000 
rs1800875 0.000 1.000 0.673 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
For association tests, bold highlighting indicates a Markov Chain Monte Carlo (MCMC) exact 
p-value 
 
 
Table 3.15: Linkage and association values for the posterior interventricular septum 
thickness at level of papillary muscles and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.001 0.786 0.362 0.429 
rs4298 0.001 0.773 NI NI 
rs4303 0.001 0.777 0.402 0.124 
rs4356 0.000 0.873 0.357 0.901 
AGT 
rs699 0.086 0.429 0.550 0.508 
rs4762 0.078 0.439 0.430 0.598 
rs5051 0.084 0.431 0.706 0.370 
rs1112257 0.086 0.427 NI NI 
rs1926723 0.086 0.429 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.456 1.000 
rs3772627 0.000 1.000 0.226 0.966 
rs5182 0.000 1.000 0.721 1.000 
CYP11B2 
rs1799998 0.801 0.166 0.643 0.140 
rs4539 0.061 0.466 0.925 1.000 
rs3097 0.040 0.514 0.778 1.000 
CMA rs1885108 0.000 0.894 0.788 1.000 
rs1800875 0.000 0.885 0.573 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
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Table 3.16: Linkage and association values for the anterior interventricular 
septum thickness at level of papillary muscles and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.217 0.317 0.336 0.304 
rs4298 0.226 0.312 NI NI 
rs4303 0.222 0.315 0.965 0.044 
rs4356 0.180 0.341 0.554 0.390 
AGT 
rs699 0.000 1.000 0.342 0.968 
rs4762 0.000 1.000 0.353 0.785 
rs5051 0.000 1.000 0.713 0.874 
rs1112257 0.000 1.000 NI NI 
rs1926723 0.000 1.000 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.254 1.000 
rs3772627 0.000 1.000 0.037 0.828 
rs5182 0.000 1.000 0.253 0.976 
CYP11B2 
rs1799998 0.905 0.153 0.809 0.172 
rs4539 0.351 0.259 0.626 1.000 
rs3097 0.334 0.265 0.405 0.581 
CMA rs1885108 0.000 0.847 0.701 1.000 
rs1800875 0.000 0.793 0.574 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
For the asociation test, bold highlighting indicates a Markov Chain Monte Carlo (MCMC) 
exact p-value.   
 
Table 3.17: Linkage and association values for the anterior wall thickness at level 
of papillary muscles and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.249 0.301 0.525 0.271 
rs4298 0.263 0.295 NI NI 
rs4303 0.244 0.303 0.754 0.173 
rs4356 0.254 0.300 0.535 0.319 
AGT 
rs699 0.000 1.000 0.633 1.000 
rs4762 0.000 1.000 0.310 1.000 
rs5051 0.000 1.000 0.943 1.000 
rs1112257 0.000 1.000 NI NI 
rs1926723 0.000 1.000 NI NI 
AGTR1 
rs2640539 0.009 0.653 0.461 0.992 
rs3772627 0.027 0.556 0.258 0.849 
rs5182 0.015 0.607 0.225 0.961 
CYP11B2 
rs1799998 0.000 1.000 0.931 1.000 
rs4539 0.000 1.000 0.407 1.000 
rs3097 0.000 1.000 0.707 0.994 
CMA rs1885108 0.126 0.384 0.545 0.355 
rs1800875 0.150 0.364 0.634 0.523 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
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Table 3.18: Linkage and association values for the lateral wall thickness at level of 
papillary muscles and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 1.120 0.132 0.473 0.563 
rs4298 1.020 0.141 NI NI 
rs4303 1.040 0.139 0.369 0.167 
rs4356 1.160 0.129 0.623 0.299 
AGT 
rs699 0.000 1.000 0.436 0.995 
rs4762 0.000 1.000 0.087 1.000 
rs5051 0.000 1.000 0.294 0.996 
rs1112257 0.000 1.000 NI NI 
rs1926723 0.000 1.000 NI NI 
AGTR1 
rs2640539 0.021 0.579 0.216 0.989 
rs3772627 0.063 0.464 0.852 0.990 
rs5182 0.081 0.436 0.338 0.951 
CYP11B2 
rs1799998 0.153 0.359 0.621 0.555 
rs4539 0.084 0.430 0.858 1.000 
rs3097 0.092 0.420 0.337 1.000 
CMA rs1885108 0.002 0.770 0.505 0.898 
rs1800875 0.003 0.741 0.215 0.989 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
 
 
Table 3.19: Linkage and association values for the inferior wall thickness at level of 
papillary muscles and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.061 0.468 0.171 1.000 
rs4298 0.040 0.510 NI NI 
rs4303 0.044 0.502 0.505 0.988 
rs4356 0.254 0.299 0.723 0.431 
AGT 
rs699 0.000 1.000 0.808 0.988 
rs4762 0.000 0.871 0.399 0.364 
rs5051 0.000 1.000 0.617 0.999 
rs1112257 0.000 1.000 NI NI 
rs1926723 0.000 1.000 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.744 0.996 
rs3772627 0.000 1.000 0.950 1.000 
rs5182 0.000 1.000 0.006 1.000 
CYP11B2 
rs1799998 0.001 0.777 0.434 0.945 
rs4539 0.063 0.462 0.634 1.000 
rs3097 0.052 0.483 0.010 0.722 
CMA rs1885108 0.000 1.000 0.081 0.994 
rs1800875 0.000 1.000 0.681 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
For the asociation test, bold highlighting indicates a Markov Chain Monte Carlo (MCMC) 
exact p-value. 
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Table 3.20: Linkage and association values for the posterior wall thickness at 
level of papillary muscles and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 3.780 0.041 0.458 0.078 
rs4298 3.156 0.051 NI NI 
rs4303 3.290 0.049 0.211 0.131 
rs4356 7.465 0.016 0.517 0.015 
AGT 
rs699 0.089 0.423 0.501 1.000 
rs4762 0.628 0.192 0.365 0.240 
rs5051 0.092 0.419 0.274 1.000 
rs1112257 0.092 0.420 NI NI 
rs1926723 0.089 0.423 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.980 1.000 
rs3772627 0.000 1.000 0.808 1.000 
rs5182 0.000 1.000 0.260 1.000 
CYP11B2 
rs1799998 0.000 1.000 0.902 1.000 
rs4539 0.217 0.318 0.852 1.000 
rs3097 0.209 0.323 0.003 0.584 
CMA rs1885108 0.000 1.000 0.190 1.000 
rs1800875 0.000 1.000 0.639 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
For association tests, bold highlighting indicates a Markov Chain Monte Carlo (MCMC) exact 
p-value. 
 
 
 
Table 3.21: Linkage and association values for the interventricular septum thickness 
at level of apex and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.599 0.197 0.565 0.102 
rs4298 0.578 0.201 NI NI 
rs4303 0.578 0.201 0.698 0.112 
rs4356 0.463 0.227 0.948 0.243 
AGT 
rs699 0.042 0.509 0.689 0.708 
rs4762 0.052 0.486 0.546 0.714 
rs5051 0.040 0.512 0.797 0.460 
rs1112257 0.044 0.505 NI NI 
rs1926723 0.042 0.506 NI NI 
AGTR1 
rs2640539 0.000 0.995 0.373 1.000 
rs3772627 0.000 0.997 0.144 1.000 
rs5182 0.000 1.000 0.234 1.000 
CYP11B2 
rs1799998 2.062 0.079 0.830 0.097 
rs4539 0.445 0.232 0.895 1.000 
rs3097 0.470 0.226 0.148 0.692 
CMA rs1885108 0.000 1.000 0.663 1.000 
rs1800875 0.000 1.000 0.683 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
http://scholar.sun.ac.za
 147
Table 3.22: Linkage and association values for the anterior wall thickness at level of 
apex and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 3.256 0.049 0.783 0.034 
rs4298 3.139 0.051 NI NI 
rs4303 3.172 0.051 0.391 0.059 
rs4356 2.325 0.071 0.490 0.042 
AGT 
rs699 0.002 0.758 0.856 0.523 
rs4762 0.002 0.763 0.742 0.603 
rs5051 0.002 0.756 0.856 0.523 
rs1112257 0.002 0.750 NI NI 
rs1926723 0.002 0.748 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.284 1.000 
rs3772627 0.000 1.000 0.150 1.000 
rs5182 0.000 1.000 0.046 1.000 
CYP11B2 
rs1799998 2.198 0.075 0.870 0.139 
rs4539 1.403 0.111 0.405 1.000 
rs3097 1.359 0.114 0.300 0.215 
CMA rs1885108 0.000 1.000 0.802 1.000 
rs1800875 0.000 1.000 0.171 1.000 
Abbreviation used: LPOA-linkage in the presence of association. NI-not informative. 
For association tests, bold highlighting indicates a Markov Chain Monte Carlo (MCMC) exact 
p-value 
 
 
Table 3.23: Linkage and association values for the lateral wall thickness at level of 
apex and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.001 0.783 0.381 1.000 
rs4298 0.001 0.784 NI NI 
rs4303 0.001 0.796 0.864 1.000 
rs4356 0.000 0.808 0.181 0.995 
AGT 
rs699 0.000 1.000 0.321 1.000 
rs4762 0.000 1.000 0.717 0.995 
rs5051 0.000 1.000 0.489 0.978 
rs1112257 0.000 1.000 NI NI 
rs1926723 0.000 1.000 NI NI 
AGTR1 
rs2640539 0.003 0.726 0.951 0.983 
rs3772627 0.213 0.319 0.743 1.000 
rs5182 0.000 0.993 0.615 1.000 
CYP11B2 
rs1799998 0.071 0.449 0.960 0.993 
rs4539 0.001 0.791 0.834 1.000 
rs3097 0.002 0.760 0.201 1.000 
CMA rs1885108 0.000 1.000 0.223 0.996 
rs1800875 0.000 1.000 0.286 0.994 
Abbreviation used: LPOA-linkage in the presence of association.  NI-not informative. 
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Table 3.24: Linkage and association values for the posterior wall thickness at level of 
apex and each SNP analysed. 
Gene SNP ID 
Linkage Association LPOA 
LOD-
score p-value 
Additive 
model 
p-value 
p-value  
ACE1 
rs4340 I/D 0.091 0.422 0.831 0.978 
rs4298 0.081 0.436 NI NI 
rs4303 0.081 0.430 0.964 1.000 
rs4356 0.098 0.413 0.966 0.487 
AGT 
rs699 0.000 1.000 0.909 1.000 
rs4762 0.000 1.000 0.988 1.000 
rs5051 0.000 1.000 0.701 0.981 
rs1112257 0.000 1.000 NI NI 
rs1926723 0.000 1.000 NI NI 
AGTR1 
rs2640539 0.000 1.000 0.565 1.000 
rs3772627 0.000 1.000 0.926 1.000 
rs5182 0.000 1.000 0.950 1.000 
CYP11B2 
rs1799998 0.844 0.161 0.350 0.068 
rs4539 0.571 0.204 0.462 1.000 
rs3097 0.557 0.206 0.061 0.205 
CMA rs1885108 0.000 1.000 0.621 0.992 
rs1800875 0.000 1.000 0.915 1.000 
Abbreviation used: LPOA-linkage in the presence of association.  NI-not informative. 
 
 
3.7.9. X-linked gene analysis 
Table 3.25 gives the association p-values for the X-linked ACE2 gene. Four markers 
in ACE2 were tested for association and linkage to 16 wall thickness parameters and 
CWT-score. One marker, rs879922, was significantly associated with both pIVSmit (p 
= 0.0047) and LWmit (p = 0.027). None of the other markers investigated in ACE2 
showed significance with any of the 16 quantitative traits and CWT-score investigated 
(p > 0.05) (table 3.25). 
 
The estimated difference in pIVSmit between each rs879922 group and the male C 
hemizygote was: 1.5mm for male G; and for females: 0.2mm for CC, 2.1mm for GC 
and 7.1mm for GG homozygotes. The estimated difference in LWmit between each 
rs879922 group and the male C hemizygote was: 0.6mm for male G; and for females: 
0.1mm for CC, 0.5mm for CG and 5.6mm for GG homozygotes.   
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Table 3.25: Association analysis p-values for each SNP of ACE2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 rs1978124 rs2285666 rs879922 rs4646179 
CWT 0.4739 0.5334 0.3891 0.3184 
pIVSmit 0.6255 0.3772 0.0047 0.2120 
aIVSmit 0.6052 0.7689 0.0934 0.1937 
AWmit 0.1570 0.7324 0.3958 0.6777 
LWmit 0.0792 0.7372 0.0270 0.9524 
IWmit 0.1214 0.2967 0.3950 0.8405 
PWmit 0.6081 0.5182 0.3696 0.4845 
pIVSpap 0.7983 0.6542 0.5393 0.4819 
aIVSpap 0.5186 0.5397 0.2008 0.1541 
AWpap 0.1445 0.4242 0.4443 0.7666 
LWpap 0.4301 0.6901 0.5601 0.7773 
IWpap 0.2090 0.8147 0.8819 0.2672 
PWpap 0.5450 0.6092 0.5658 0.7331 
 IVSapx 0.5347 0.3393 0.1843 0.4517 
AWapx 0.6151 0.4769 0.2767 0.2996 
LWapx 0.8692 0.6777 0.7703 0.7507 
PWapx 0.3755 0.5370 0.0864 0.3618 
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4.1. Previous HCM hypertrophy modifier studies 
Most early studies of hypertrophy modifiers in HCM selected genes involved in cell 
growth and BP control (see section 1.3.1), including genes that encode key-components 
of the RAAS (Marian et al., 2002). Most of these studies were performed in unrelated 
individuals, rather than members of families, and furthermore did not control for 
differences in ethnic background or primary HCM-causing mutations in the cohorts. 
Additionally, many of these studies did not make adjustments for hypertrophy covariates, 
such as age, sex, body size and blood pressure. These factors alone would contribute 
greatly to hypertrophic variability and would obscure the effects of any genetic modifiers. 
However, in 2002, Ortlepp and colleagues investigated the role of RAAS gene variants as 
modifiers of hypertrophy within individuals of a single family carrying the same HCM-
causative mutation. Although, this study controlled for age, sex and the presence of 
hypertension, it did not index LVM to BSA, and showed that genetic polymorphisms in 
the genes encoding components of the RAAS had an influence on the degree of LVH. 
 
4.2. Choice of candidate genes and SNPs 
The present family-based association study implemented a candidate gene approach in 
which an “a priori-based” hypothesis was employed to assess association between a 
genotype and a quantitative trait: genes were chosen because they encode key-
components of the RAAS pathway known to be involved in control of BP and cell 
growth. Additionally, the genomic structure and location of these genes were known, as 
was the function of the encoded products. Wherever possible the SNPs selected for 
investigation were those that had been investigated in previous studies and included those 
with and those without functional data. However, as this study aimed to investigate a 
spread of SNPs throughout the candidate genes, some additional SNPs, not previously 
investigated, were also targeted. These newly chosen polymorphisms had to possess a 
heterozygosity value of 40% or higher to be included in the investigation, to optimize the 
chance of meeting the requirement of the QTDT program for a threshold number of 
informative matings. This approach was used to re-investigate the role of RAAS genes in 
LVH (discussed in sections 1.4.4.1 to 1.4.4.6), attempting to test their role in a more 
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robust manner by addressing the caveats present, but largely/often ignored, in previous 
studies, as described above.  
 
As discussed, the genes that encode components of the RAAS represent attractive 
candidates for susceptibility to LVH development because of their regulatory role in 
control of BP and cell growth. This is further supported by their association with LVH 
(section 4.1). Although the data are intriguing, association studies are subject to several 
shortcomings such as population stratification, phenotypic heterogeneity, numbers of 
markers tested, sample size and statistical power. The following sections will discuss the 
relevance of these pitfalls in more detail.  
 
4.3. Caveats in association studies  
As association studies aim to be susceptibility marker studies to infer risk and/or even 
causality associated with a specific genotype, their reproducibility, or lack thereof, is a 
confounding factor in determining the degree to which results can be used for risk 
stratification because of the occurrence of false positives or negatives. Below, some of 
the causes of false positive and negative findings are discussed. 
 
Population stratification 
Discrepant associations obtained in different case-control studies are often ascribed to 
allelic differences between populations because of divergent genetic background, which 
may arise due to geographical locations of population groups (Cardon and Palmer, 2003). 
Should cryptic substructure exist in a case and/or control group, population stratification 
may result in either a type I error (finding an association when it does not exist) or a type 
II error (finding no association when it does in fact exist) (see section 1.4.3.2 for 
examples). 
 
Statistical power  
The power of a genetic association study is the probability that a true association is 
detected by the test. It reflects the ability of the study to detect true effects and to 
differentiate between the absence of an effect and an inconclusive result. The power for a 
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family-based association test depends on the following factors- the minimum size of the 
effect regarded as clinically or biologically meaningful (a difference might be statistically 
significant, but not scientifically meaningful at all), the variation in the trait being tested, 
the correlations in the trait variables between the members of families, the allele 
frequencies of the polymorphism being tested,  the number of familes, the total number of 
individuals and the significance level selected for the test. Generally, the following will 
increase the power of a specific test: more families, more members per family, less trait 
correlation between family members, detecting a larger effect, less variation in the trait 
being tested and increasing the significance level. The relationship between allele 
frequencies and power is too complicated to generalise. The extent of the effect of these 
factors is interdependent. The only way to calculate the power for a specific test is by 
simulating the distribution of the test statistic (bootstrapping). This is a complicated, 
lengthy and time-consuming process (Diao and Lin et al., 2006; Abecasis et al., 2001). 
Markers that do not show association in pilot studies should not necessarily be ruled out 
but could be retested in follow-up studies using larger sample size, thus with improved 
power, to determine if these markers can truly be excluded as playing a role in disease 
pathogenesis. Meta-analysis is another statistical method employed to overcome small 
sample size in genetic association studies and so to increase study power (Egger et al., 
2002). In meta-analyses, genotypic and phenotypic data from several studies are pooled 
to identify a common main effect, while controlling for study-dependent factors (Glass et 
al., 1976). However, it still has its limitations due to between-study heterogeneity, as a 
result of genotypic, phenotypic and methodological confounders (Gambaro et al., 2000). 
 
Number of markers tested 
Single SNP studies have limitations, as they may fail to capture all the available LD 
information in flanking SNPs - unless they are tag SNPs for the true functional variant (or 
happen to be the functional variant) (Niu et al., 2002). Investigation of all tag SNPs in a 
given gene, and/or haplotype analysis of multiple SNPs spread throughout a gene can 
resolve this problem by combining information of multiple adjacent SNPs into relatively 
more informative multilocus haplotypes. Haplotypes are more informative as they capture 
all the regional LD information, and are therefore considered to be a powerful and robust 
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method for detecting association in complex disorders (Akey et al., 2001; Daly et al., 
2001). 
 
Additional confounding factors in association studies 
Another limitation of association studies is publication bias against negative results 
(Easterbrook et al., 1991). Additionally, an explanation for the lack of a consistent 
relationship between marker and trait could also be that the independent effect of a single 
allele/gene is too small or variable to detect within the subjects presenting with the 
disease. Furthermore, there could also be epistatic effects of one gene with other genes 
within specific individuals that produce a clinical phenotype that is measurable in some, 
but not in other, subjects studied. 
 
4.4. Controlling for confounding factors in the present study 
A number of confounding factors that typically plague association studies were controlled 
for in the present study. Individuals belonging to three cohorts in which founder 
mutations segregated were investigated. Due to the ancestral relatedness within each 
cohort, genetic background noise should be reduced because individuals were more 
closely related, compared to cohorts consisting of the general unrelated population. The 
fact that three distinct cohorts were used was adjusted for by including the mutation 
groups as covariates in the analyses.  
 
Population stratification 
Population stratification was a concern in the present study, because families were either 
of Mixed Ancestry or Caucasian descent. The possible effect of population stratification 
was controlled for throughout the association analyses by using family-based controls and 
by implementing Abecasis’s orthogonal model which protects against population 
stratification (Iles M., 2002). 
 
Power 
We did not estimate the power of any of the tests performed in this study, as it was 
considered to be beyond the scope of this thesis. 
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Phenotype 
In HCM, formal quantification of the degree, and extent, of hypertrophy is difficult 
because of the regional and individual nature of increases in wall thickness. Accordingly, 
a number of parameters were measured, which included composite scores and absolute 
measurements.  
 
Because HCM subjects usually, but not always, present with asymmetrical hypertrophy, 
it is difficult to quantify the extent of hypertrophy for all individuals in a cohort by using 
only one score (Reichek et al., 1983). However, it is not clear which composite score is 
appropriate. Although LVM has often been used as the phenotypic parameter in HCM 
genetic modifier studies (Perkins et al., 2005; Marian et al., 2002), assessment of LVM 
by echocardiography, which assumes that the left ventricle takes on an even geometric 
shape, may not be accurate due to the variable and non-uniform nature of hypertrophy in 
HCM. The Wigle score captures the distribution and extent of hypertrophy on a more 
global scale, but the score is semi-quantitative. On the other hand, the Maron score, 
although quantitative, does not capture the full extent of hypertrophy in all segments of 
the heart. 
 
Thus, in the absence of more accurate calculation of LVM, such as by MRI, it may be 
more appropriate to focus on measurements of those heritable regions of the ventricular 
wall frequently affected by hypertrophy. Such measurements could be used as a range of 
individual wall thickness values, or as composite scores derived from them, in 
quantitative trait analyses. Thus, in statistical data analysis the only composite score used 
was the in-house derived CWT score (see section 2.1), as it is a global, quantitative 
estimate that attempts to capture the total amount of hypertrophy observed in all 16 
segments of the heart muscle. 
 
Compensating for multiple testing 
Performing any association test may result in a false positive finding (Berry et al., 1998). 
If the significance level is 5%, the probability of a false positive finding is 5%. If multiple 
tests are done, all at 5% significance levels, the probability of a false positive finding 
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increases with the number of tests done. Thus some published papers have applied a 
Bonferroni adjustment in an attempt to correct for type I errors (false positive findings) 
introduced by such multiple testing. Bonferroni assumes that tests are statistically 
independent and multiplies each p-value with the number of tests done. So it will only 
produce a significant p-value in circumstances where the p-values were already very 
significant (Bland et al., 1995; Perneger et al., 1998) and therefore put a constraint on the 
statistical power of the study. Perneger et al., (1998) argued that the Bonferroni 
correction is too conservative, because closely-linked markers are not independent and 
genotypes are correlated when familial data is being used. The present study used QTDT 
to calculate empirical p-values for the within-family component of association using a 
Monte-Carlo permutation framework, because it provides a global p-value with a built-in 
adjustment for multiple testing. It is valid for traits with normal or non-normal 
distributions (McIntyre et al., 2001). 
 
4.5. Heritability tests for quantitative traits and composite scores  
Although there are many definitions of heritability, in the present study, heritability was 
calculated by means of variance components analysis, as the proportion of variance in a 
trait attributable to common genes. This provides a broad measure and, as with all 
estimation, in some cases one might estimate significant heritability while the trait might 
not be heritable, while in other instances, the detection of heritability might be obscured 
in a small sample (Elston et al., 2000). This method does not distinguish between a single 
major gene, a few moderately strong genes or numerous polygenes with small effects 
(Thomas D., 2004). Other authors have defined heritability solely for a specific locus 
(Ziegler A and König IR., 2006).  
 
Heritability and evidence of strong familial aggregation in LVM have been shown within 
different population groups, namely, Caucasians (Bielen et al., 1991; Garner et al., 2000; 
Mayosi et al., 2002), African Americans (Kotchen et al., 2000), American Indians (Bella 
et al., 2004) and Caribbean Hispanic families (Juo et al., 2005) and Taiwanese (Chien et 
al., 2006). In the latter study, the authors demonstrated that heritability and major gene 
effects accounted in part for significant familial correlations observed in this population 
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(Chien et al., 2006). Chien and colleagues (2006) provided several reasons for the high 
heritability estimates observed in African Americans in the Kotchen et al., (2000) study, 
suggesting that this might be due to sample selection criteria, for example, ascertaining 
hypertensive siblings, genetic background of these subjects and also expression of a range 
of complex multiple traits in comparison to unmeasured factors. Obviously, these factors 
may also apply to studies performed in other populations groups. 
 
The present study also investigated the heritability of LVM, shown in familial studies to 
have a strong genetic component, but focused on heritability of LVM after adjustment for 
a variety of covariate factors that may influence heart size and structure. Interestingly, the 
findings of the present study are in contrast to previous reports because LVM was not 
significantly heritable in the SA HCM families, although other traits were (table 3.3). 
This may be because previous studies did not adjust for the covariates used in this study; 
alternatively, heritability may have been masked by factors not taken into account in this 
study.  
 
In the present study, strong association p-values were found that did not correspond to 
heritability p-values (tables 3.3, 3.14, 3.16, 3.19, 3.20, 3.23). It was decided not to 
exclude traits that do not show heritability, as it has been suggested by Elston et al., 
(2000) that rare disease traits may have a strong genetic component, and yet give rise to a 
small overall familial correlation. 
 
It should be pointed out that in this study, we analysed raw, untransformed, trait values, 
as the association would subsequently be tested with Markov Chain Monte Carlo 
permutations, which does not require distributional assumptions.  Further, there are many 
different approaches to adjusting or normalising trait values for family-based variance 
component analysis and it was not clear which, if any, would be most appropriate for this 
study (Ziegler A and König I., 2006).  
 
 
 
http://scholar.sun.ac.za
 158
4.6. Estimating and testing heritability 
The heritability of the CWT score was accounted for, in part, by variants in ACE1, AGT 
and CYP11B2 (table 3.4). The genetic component of the pIVSmit trait was accounted for 
by variants in AGTR1, CMA, AGT and CYP11B2, with those in AGT and CYP11B2 
appearing to have stronger effects than those in ACE1, AGTR1 and CMA. The variants in 
the latter three genes did not convert any of the polygenic variance to an additive variance 
component which the two stronger effect genes did (table 3.5). The aIVSmit trait’s 
heritability was contributed to by variants in AGT, CMA and CYP11B2, with variants in 
CMA and CYP11B2 appearing to play a much larger role in the heritability of the 
aIVSmit trait than those in AGT (table 3.5). Variants in CMA and AGTR1 contributed to 
the heritability of the AWmit trait (table 3.5), while heritability of the LWmit trait was in 
part accounted for by variants in ACE1, AGT, AGTR1 and CYP11B2 (table 3.5). The 
IWmit trait’s heritability was accounted for by variants in ACE1 and AGT (table 3.5); 
however, only variants in AGT appeared to account for all the heritability of the PWmit 
trait (table 3.5). 
 
The variants in ACE1, AGT and CYP11B2 contributed to the heritability of the pIVSpap 
trait (table 3.6). Interestingly, variants in AGT and CYP11B2 had a stronger effect by 
converting all the polygenic variance to an additive variance (table 3.6). The variants in 
ACE1, CMA and CYP11B2 each contributed to the heritability of the aIVSpap trait (table 
3.6). Interestingly, variants in ACE1 and CYP11B2 had a stronger effect by converting all 
the polygenic variance to additive variance (table 3.6). The heritability of the aWpap trait 
was accounted for, in part, by variants in ACE1, CMA and AGTR1 (table 3.6). 
Interestingly, variants in ACE1 had a stronger effect compared to CMA and AGTR1 by 
converting all the polygenic variance to additive variance (table 3.6). Additionally, the 
genetic component of the LWpap trait was comprised of variants in ACE1, AGTR1, 
CYP11B2 and CMA (table 3.6). Only variants in ACE1 and CYP11B2 accounted for the 
heritability of the IWpap trait (table 3.6). The markers in CYP11B2, rs4539 and rs3097, 
and ACE1 and AGT accounted for a large proportion of the heritability of the PWpap trait 
(table 3.6). Interestingly, variants in ACE1 appeared to have a stronger effect than those 
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in CYP11B2 and AGT by converting all the polygenic variance to additive variance, 
respectively (table 3.6).  
 
The variants in ACE1, CYP11B2 and AGT accounted for all of the heritability of the 
IVSapx trait (table 3.7). The variants in the latter three genes converted all the polygenic 
variance to additive variance (table 3.7). Additionally, all the heritability of the aWapx 
trait was contributed by variants in ACE1, AGT and CYP11B2 (table 3.7). The markers in 
CYP11B2 (rs2640539) and AGTR1 (rs3772627) and the ACE1 accounted for a small 
proportion of the heritability of the LWapx trait (table 3.7). However, only variants in the 
ACE1 and CYP11B2 accounted for all of the heritability of the pWapx trait (table 3.7).  
 
4.7. Linkage analysis 
In the present study, significant evidence for linkage was found between the ACE1 
rs4340, rs4303 and rs4356 polymorphisms and the PWpap trait (table 3.20). Similarly, 
significant linkage was observed between the ACE1 rs4340 polymorphism and the 
AWapx trait (table 3.22). This suggests that the region in which ACE1 resides either 
contains, or is closely linked to, a functional allele involved in hypertrophy development 
in this segment.  
 
4.8. Association analyses  
4.8.1. ACE1 rs4298, rs4303, rs4340 (I/D) and rs4365 polymorphisms 
The results of the within-family association tests with single markers suggested that none 
of the markers investigated in ACE1 was associated with any of the 17 LVH parameters 
(tables 3.8 to 3.24). However, there was evidence of statistically significant linkage in the 
presence of association to PWpap and AWapx ACE1 SNPs (tables 3.20 and 3.22). This 
result indicates that the linkage data observed are not accounted for by association and 
suggests that these SNPs in themselves are not the susceptibility loci, but are in LD with 
the causal variant.  
 
 
 
http://scholar.sun.ac.za
 160
In LVH 
The ACE1 (I/D) polymorphism has frequently been previously studied in LVH and 
hypertension and the results are discrepant (see section 1.4.4.1). Schunkert et al., (1994) 
suggested the ACE1 locus to be a QTL for determining an individual’s genetic 
susceptibility to LVH, however subsequent studies by Lindpaintner et al., (1996), Wu et 
al., (2000) and Shlyakhto et al., (2001) negated this. This polymorphism was found to be 
associated with LVH and has been reported to correlate with variation in plasma and 
tissue ACE levels (Zhu et al., 2001; Kuznetsova etal., 2004; Saeed et al., 2005). There are 
mixed results for the association studies of the ACE1 I/D polymorphism and LVH; in 
some there are associations between the II genotype and increased LVMI and in others 
the DD genotype is associated with increased LVMI (Kuznetsova etal., 2004). The 
variability of the association results of the ACE1 I/D polymorphism and LVH suggests 
that this polymorphism is not a functional variant but is in LD with a functional variant 
(Ganau et al., 1990), as the actual allele conferring susceptibility or protection of the 
ACE1 I/D polymorphism varies depending on ethnicity and geographical region and may 
be a reflection of the LD structure of the particular population (van Berlo et al., 2003). 
 
In hypertrophy and HCM 
The findings from Yoneya et al., (1995) suggest that the ACE1 DD genotype is associated 
with cardiac hypertrophy in HCM. The findings of Yoneya et al., (1995) suggested that in 
solitary cases of HCM the DD genotype of ACE1 partially determines an individual’s 
genetic disposition for HCM. The main difference between the present study and both the 
Lechin et al., (1995) and Yoneya et al., (1995) studies is the inclusion of a healthy panel 
of related individuals that did not develop hypertrophy (table 2.1). The inclusion of 
phenotypically unaffected individuals gives a better estimate of the influence of the ACE1 
genotype on hypertrophy development. Several other investigators considered the ACE1 
DD genotype an allelic LVH modifier in HCM (Marian et al., 1993; Lechin et al., 1995; 
Tesson et al., 1997; Ortlepp et al., 2002) despite the use of smaller numbers in their study 
and not indexing LVM to BSA, as was done in the present study. Smaller HCM cohort 
studies found overall overrepresentation of the D-allele (Yoneya et al., 1995; Lopez-
Haldon et al., 1999) but did not include family members as controls. Larger studies have 
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shown a LVH-modifying effect of DD-ACE1 while adjusting for covariates such as age, 
sex, weight, height, BSA, BMI and ACE1 genotypes (Lechin et al., 1995; Ortlepp et al., 
2002). However, contrary to the present study, the Lechin et al., (1995) and Ortlepp et al., 
(2002) studies, only investigated single SNPs within individual genes that encode RAAS 
components.  
 
Animal models 
Higaki et al., (2000a) demonstrated that “in vivo” transfection of human ACE1 into rat 
myocardium resulted in elevated cardiac ACE activity, increased left ventricular wall 
thickness and collagen content independent of systemic and haemodynamic effects. 
Furthermore, administration of perindopril (an ACE inhibitor) abolished the cardiac 
hypertrophy observed in the rat hearts (Higaki et al., 2000a). Xiao and colleagues (2004) 
observed in a genetic mouse model with cardiac restricted ACE1 (called ACE 8/8) atrial 
enlargement, cardiac arrhythmia and SCD, but no ventricular hypertrophy or fibrosis, 
indicating that ANGII in the heart is not sufficient to induce LVH or fibrosis.  
 
It is speculated that although no known HCM loci are genetically linked to the ACE1 
locus, ACE1 may be playing the role of a co-acting modifier gene (Pfeufer et al., 1996). 
This implies that the ACE1 DD genotype serves as an indicative marker to assess risk to 
an individual for development of LVH. However, the present association data does not 
support a significant independent role for the ACE1 DD genotype in contributing to the 
development or severity of hypertrophy in the South African HCM population (tables 3.8 
to 3.24). 
 
On the other hand, interestingly, in the present study variants in ACE1 showed linkage to 
two traits (PWpap and AWapx) (table 3.20 and 3.22) but showed no association with 
these particular traits. The reason for this perhaps could be that linkage extends over 
substantial genetic distances, and is therefore suited for long-range mapping, and in the 
present study might be picking up signals of a more distant locus. Association on the 
other hand relies on either the presence of LD between the investigated marker and trait 
locus, or on the marker locus being the trait locus itself and is therefore useful for short 
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range-mapping. If there is linkage, but no association, the marker itself can be discarded 
as having an effect. In the present study, there was therefore no evidence that the I/D 
locus itself influences cardiac hypertrophy after other covariates of hypertrophy had been 
taken into account. 
 
4.8.2. AGT rs5051, rs4762, rs699, rs11122575 and rs1926723 polymorphisms 
The localised expression of AGT occurs within the myocardium and makes it a good 
candidate gene to assess its influence on cardiac growth (Dzau et al., 1987; Baker et al., 
1992; de Mello and Danser, 2000). Consequently, it has been suggested that variants 
within AGT might be potential independent mediators or determinants of LVM. 
Numerous investigators have reported on positive and negative findings regarding the 
relationship between the M235T (rs699) polymorphism and LVM (Kauma et al., 1998; 
Jeng et al., 1999; Staessen et al., 1999). 
 
The M235T (rs699) polymorphism has been shown to be in LD with -6G/A (rs5051), 
with the latter having been shown to influence AGT concentrations (Inoue et al., 1997; 
Paillard et al., 1999). The -6G/A (rs5051) polymorphism, particularly the A-allele, 
influences basal transcription of AGT and stimulate transcription due to receptor binding 
(Zhao et al., 1999). According to Cooper et al., (1998), a key site for the transcriptional 
effect of -20A/C and -6G/A variants might be the adipose tissue because AGT is highly 
expressed within this tissue. The -6G/A (rs5051) polymorphism were shown to be 
associated with plasma AGT concentrations in subjects of African ancestry (Rotimi et al., 
1997).  
 
In the present study, the results of the within-family association tests with single markers 
suggested that the AGT rs5051, rs4762, rs699, rs11122575 and rs1926723 
polymorphisms showed no association with any of the 17 LVH parameters (tables 3.8 to 
3.24). These results are in agreement with a study by Yamada et al., (1997) that found no 
relationship between AGT M235T (rs699) and T174M (rs4762) variants and HCM or 
DCM. In contrast, other studies did reveal a statistically significant association between 
AGT M235T and LVM or LVH (Karjalainen et al., 1999; Tang et al., 2002; Kurland et 
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al., 2002; Ortlepp et al., 2002). Reasons for differences in results between the present 
study and latter mentioned studies could be the use of different ethnic groups and not 
compensating for covariates that determine LVH. 
 
4.8.3. CYP11B2 rs1799998, rs4539 and rs3097 polymorphisms 
The results of the within-family association tests with single markers suggested that the 
CYP11B2 rs3097 polymorphism in exon 9 (3’UTR) was associated with PWmit, IWpap 
and PWpap (tables 3.14, 319 and 3.20). Further statistical analysis of rs3097 revealed that 
subjects homozygous for the G-allele were at a lower risk of developing increased 
PWmit, IWpap and PWpap compared to homozygotes for the A-allele, indicating a 
protective role for the G-allele in LVH susceptibility. The CYP11B2 rs3097 
polymorphism has been previously studied in LVH and has shown association with 
cardiac wall thickness (Mayosi et al., 2003) as well as with hypertension in a study by 
Kumar et al., (2003). Mayosi and colleagues (2003) observed that a haplotype containing 
the minor A-allele of rs3097 polymorphism was associated with increased septal wall 
thickness (SWT) in a panel of Caucasian hypertensive probands. The G-allele of rs3097 
polymorphism was strongly associated with hypertension particularly in females, with the 
GG genotype frequency being three-fold higher in hypertensives compared to 
normotensives (Kumar et al., 2003). The CYP11B2 rs3097 polymorphism is located in 
the 3’UTR and might play a role in mRNA stability (Pesole et al., 2002). 
 
In the present study, the other previously investigated polymorphisms in the promoter 
region (rs1799998) and exon 3 (rs4539) of CYP11B2 showed no association with any of 
the 17 LVH parameters investigated (tables 3.8 to 3.24), while only the rs1799998 
polymorphism did show association with hypertension in the Kumar et al., (2003) study. 
In a different study, the rs4539 (2713 A/G or Arg173Lys) polymorphism was associated 
with stage-2 hypertension in Han-Chinese women (Gu et al., 2004), while Zhu et al., 
(2003) found no association with hypertension in black Afro-Caribbean origin subjects 
from South-West London. The rs4539 polymorphism is suggested to have a negligible 
physiological significance on CYP11B2 transcription as it does not alter enzyme activity 
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“in vitro” and is in LD with the functional -344C/T polymorphism, as discussed below 
(Davies et al., 2003).  
 
Several studies have found an association between CYP11B2 rs1799998 (-344 C/T) 
polymorphism and LV structure and LVM (Kupari et al., 1998; Delles et al., 2001), 
although Schunkert et al., (1998) could not confirm the association in a larger study 
cohort. The current findings are in agreement with the Schunkert et al., (1998) study, as 
no such an association was found between LVH and rs1799998 (-344 C/T) polymorphism 
allele status. The CYP11B2 rs1799998 polymorphism is an attractive choice for 
association studies as it resides at a putative binding site for steroidogenic transcription 
factor (SF-1) (White and Slutker et al., 1995). Additionally, it is associated with a four-
fold increase in SF-1 binding to -344 C-allele carriers and increased aldosterone synthesis 
associated with plasma aldosterone concentrations and urinary aldosterone excretion rates 
(Pojoga et al., 1998; Davies et al., 1999; Paillard et al., 1999).  
 
A reason for the association between the CYP11B2 rs1799998 (-344 C/T) polymorphism 
and hypertension in other studies could be that CYP11B2 is known to influence 
aldosterone production, and thereby blood pressure. This influence may not be directly 
correlated with an influence on hypertrophy, as it has been shown that there is an 
imperfect correlation between BP and LVM (Wachtell et al., 2000). 
 
In vitro, the -344 C-allele binds SF-1 four fold stronger, than the T-allele (White and 
Slutker et al., 1995). Consequently, the C-allele results in there being less SF-1 available 
to bind to other promoter sites and thus might lead to reduced transcription, while the -
344 T-allele increases transcription (Clyne et al., 1997). This polymorphism could be in 
LD with an, as yet, unidentified functional variant near or adjacent to CYP11B2. 
Discrepancies in other studies that investigated hypertension support such a notion 
(Brand et al., 1998; Davies et al., 1999; Matsubara et al., 2001; Russo et al., 2002).  
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Animal model 
Tsybouleva et al., (2004) demonstrated that aldosterone is involved in the cardiac 
phenotype observed in a genetically engineered mouse model with HCM. Blockade of 
mineralocorticoid receptors in a transgenic animal model of human HCM (cTnT-Q92) 
had beneficial effects by reducing myocytic disarray and interstitial fibrosis indicating 
aldosterone is an important molecular link between cardiac phenotype and the HCM 
phenotype (Tsybouleva et al., 2004).  
 
The present CYP11B2 rs3097 data supports a significant independent role for CYP11B2 
in contributing to the development or severity of hypertrophy in the SA HCM population. 
 
4.8.4. CMA rs1800875 and rs1885108 polymorphisms 
The results of the within-family association tests with single markers suggested that none 
of the polymorphisms within CMA was associated with any of the 17 LVH parameters 
investigated.  
 
The present study’s results are in agreement with studies of Pfeufer et al., (1996) and 
Ortlepp et al., (2002), where no independent association was found between CMA 
rs1800875 and LVH in HCM subjects. Similarly, no evidence was found to support a 
possible association between the CMA rs1800875 polymorphism and regression of LVH 
when 157 unrelated Chinese hypertensive patients were treated with the same 
antihypertensive drug benazepril (He et al., 2005). The usual arguments are discussed in 
the He et al., (2005) paper to explain why their observed results are different from the 
studies of Pfeufer et al., (1996) and Gumprecht et al., (2002). Reasons such as the 
different population groups used, genetic heterogeneity, different diagnosis criteria and 
the level of hypertension and LVH were posited. Finally, the dosage of the ACE inhibitor 
(ACEI) and other medicines used could also have contributed to spurious results 
observed between studies where treatment of LVH was investigated. These findings 
indicate that LVH formation/development is a complex process with the possibility of 
various genes interacting to produce a clinical phenotype, for example CMA and other 
genes encoding RAAS products. 
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4.8.5. AGTR1 rs2640539, rs3772627and rs5182 polymorphisms 
The AGTR1 rs2640539 and rs3772627 polymorphisms have not been previously studied 
in LVH or in hypertension, as far as is known. In the present study, the results of the 
within-family association tests with single markers suggested that the AGTR1 rs2640539 
polymorphism in intron 1 is associated with AWmit (table 3.11), and the AGTR1 
rs3772627 polymorphism in intron 2 is associated with aIVSpap (table 3.16). 
Additionally, the association tests with single markers suggested that the AGTR1 rs5182 
polymorphism in exon 3 is associated with IWpap and AWapx (tables 3.19 and 3.23). 
Further statistical analysis of rs2640539 polymorphism revealed that subjects 
homozygous for the G-allele were at a lower risk of developing increased AWmit 
compared to homozygotes for the A-allele, indicating a protective role for the G-allele in 
LVH susceptibility. Moreover, statistical analysis of rs3772627 polymorphism revealed 
that subjects homozygous for the A-allele were at a higher risk of developing increased 
aIVSpap compared to homozygotes for the G-allele, making the A-allele the risk allele. 
Statistical analysis of rs5182 polymorphism revealed that subjects homozygous for the T-
allele were at a lower risk of developing increased IWpap and AWapx compared to 
homozygotes for the C-allele, indicating a protective role for the T-allele of the rs5182 
polymorphism.  
 
The T-allele of the AGTR1 rs5182 (573 C/T) polymorphism was shown to be a protective 
factor for urinary albumin excretion in EHT patients (Chaves et al., 2001). Additionally, 
Chaves et al., (2001) demonstrated evidence of linkage disequilibrium between rs5186 
(1166A/C) and 573C/T polymorphisms. However, Redon and colleagues (2005) found no 
association between rs5182 and rs5186 polymorphisms and BP reduction following 
telmisartan treatment. The present results are in contrast with those of Kupari et al., 
(1994), Lindpaintner et al., (1996) and Hamon et al., (1997) that showed no significant 
influence of AGTR1 genotypes on LVH.  
 
It should be noted that genotyping the rs5182 polymorphism using restriction enzyme 
MnlI generated incongruous results. For technical reasons the fragment sizes differed on 
the gel from the expected digested product sizes generated using the software package 
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DNAMAN. A possible reason for the banding pattern is that the MnlI enzyme has the 
ability to remain associated with the cleaved DNA, thus resulting in DNA band shifting 
during electrophoresis (http://www.fermentas.com/catalog/re/mnli.htm). Sequencing the 
AGTR1 fragment 3 containing the SNP revealed that the correct region of the gene 
containing the SNP of interest was amplified. These discrepancies were also confirmed 
by another laboratory (Dr P. Fernandez, Department of Urology, US), which also found 
that the 325bp and 422bp fragments did not migrate as expected by size. Additionally, no 
disparities between the AGTR1 nucleotide sequence of fragment 3 and the NCBI database 
sequence were observed. After confirming that the different sized fragment on the gels 
was not due to technical errors, and that mobilities were constant, the genotyping of 
rs5182 polymorphism was continued. 
 
The functional significance of the association of the AGTR1 rs5182 polymorphism with 
cardiac hypertrophy remains unknown. This polymorphism is a synonymous substitution 
and does not alter the sense codon 191 (CTC →CTT) that codes for leucine but it can be 
speculated that it is in LD with an unknown polymorphism in AGTR1 or adjacent genes. 
The AGTR1 rs2640539 and rs3772627 polymorphisms are intronic and so far the 
functional significance of these polymorphic alleles is unclear. However, introns may 
contain regulatory elements that affect gene transcription and translation (Ying and Lin et 
al., 2006). Moreover, microRNAs derived from introns (Ying and Lin et al., 2006) have 
the ability to bind mRNA, interfering with transcription, degrading mRNA and thereby 
reducing transcript levels (Sevignani et al., 2006), indicating that intronic polymorphisms 
can also influence gene splicing by affecting a splice donor or acceptor sites. Of course, 
these polymorphisms could also be in LD with other functional variants that affect 
mRNA and protein expression.  
 
Animal models 
In a rat model, it was demonstrated that overexpression of AGTR1 under physiological 
conditions resulted in no change of the cardiac structure, whereas pressure and volume 
overload produced hypertrophic growth in the model (Hoffmann et al., 2001). In a study 
by Harada et al., (1999), AGTR1 subtype a (AGTR1a) specific receptor knockout mice 
http://scholar.sun.ac.za
 168
displayed less LV remodelling and improved survival rates at four weeks after 
myocardial infarction (MI) compared to wild type (WT) MI mice. However, Yoshiyama 
et al., (2005) demonstrated that ACE inhibitors prevent LV remodelling in a non-AGTR1 
mediated mechanism after MI in AGTR1 knockout mice. In experimental animal model 
studies, ACE inhibitors and AGTR1 antagonists induce regression and prevent cardiac 
hypertrophy development in hypertensive animal models (Pfeffer et al., 1982 and 1983; 
Dunn et al., 1984; Nakashima et al., 1984). Harada et al., (1998) demonstrated that 
AGTR1 is not essential for the development of pressure overload-induced cardiac 
hypertrophy in transgenic animal models. Similarly, Katada and colleagues (2005) 
observed elevated cardiac CYP11B2 levels in AGTR1a receptor knockout mice after MI 
inducing cardiac remodelling via ANGII- independent mechanisms.  
 
Tsuchida and colleagues (1998) generated AGTR1 knockout mice by gene target 
disruption creating a null mutation gene. Similarly to homozygous (AGT -/-) knockout 
mice, (AGTR1 subtype a and b specific receptors, are products of different genes) double 
null-zygote mice developed a ventricular septum defect in combination with abnormal 
phenotypes, namely, severe hypotension (low BP), growth retardation, renal arterial wall 
thickening and hypolastic papilla (Tsuchida et al 1998). Paradis et al., (2000) generated 
transgenic mice expressing human AGTR1 under the control of the mouse (α-MHC) 
promoter and observed ventricular hypertrophy and fibrosis in cardiac overexpressed 
AGTR1 (by more than 200 fold) in absence of external stimuli.  
 
4.8.6. ACE2 rs1978124, rs2285666, rs879922 and rs4646179 polymorphisms 
The results of the association tests with single markers suggested that the rs879922 
polymorphism in intron 11 of ACE2 was associated with both pIVSmit and LWmit (table 
3.25). Further statistical analysis of rs879922 (28330C/G) polymorphism revealed that 
subjects homozygous for the G-allele were at an increased risk of developing increased 
pIVSmit compared to homozygotes for the C-allele, indicating a dominant role for the G-
allele in LVH susceptibility. Similarly, further statistical analysis of rs879922 
polymorphism revealed that subjects homozygous for the G-allele were at an increased 
risk of developing increased LWmit compared to homozygotes for the C-allele, 
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indicating a recessive role for the G-allele in LVH susceptibility. However, the 
previously investigated polymorphisms rs1978124, rs2285666 and rs4646179 of ACE2 
showed no association with any of the 17 LVH parameters investigated in the current 
study. 
 
The present study’s results are similar to findings by Lieb et al., (2006) where an 
independent association was found between the rs879922 polymorphism (the G-allele) 
and LVMI, SWT and LVH. Lieb and coworker’s (2006) results were found in male 
subjects with HCM, while our positive association results were only found in women. 
The association observed in women should be verified by haplotype analysis. In contrast, 
Benjafield et al., (2004) found no evidence of association between the rs879922 
polymorphism and EHT in Australian populations. Whether the ACE2 rs879922 intronic 
polymorphism has any functional significance is yet to be determined, and thus the 
explanation for the described association can only be speculative. One explanation for the 
association could be that the intronic polymorphism is in LD with a functional 
polymorphism, either within ACE2 or an adjacent gene that is associated with LVH 
development. The preliminary data should be seen as experimental evidence suggestive 
of the role of ACE2 as a modifier of cardiac structure and function.  
 
Animal models 
In response to pressure overload, mice that lacked ACE2 developed cardiac hypertrophy 
and dilatation compared to WT mice (Yamamoto et al., 2000). Furthermore, treatment 
with candesartan (an AGTR1 subtype receptor blocker) resulted in the reduction of the 
hypertrophic response and suppression of MAP kinase in ACE2 knockout mice 
(Yamamoto et al., 2000). Furthermore, Crackower et al., (2002) showed that ACE2 is 
involved in the regulation of cardiac structure and function in ACE2 knockout mice 
generated by target gene disruption. However, in ACE2 null mutant mice the BP levels 
were high compared to WT mice, while the cardiac structure and function was normal 
(Gurley et al., 2006). They suggest that ACE2 is an important regulator of BP but not of 
cardiac structure and function.  
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4.9. Limitations of the present study  
The default association test used by QTDT assumes that the trait values, after adjusting 
for all covariates, will have normal distributions inside genotype groups. It is not possible 
to test this assumption, which must be valid for each combination of trait and 
polymorphism tested. That is why it was decided to use QTDT’s permutation tests, which 
are valid for any quantitative variable, and also protect against multiple testing, to test the 
significance of those combinations yielding significant p-values with default QTDT 
association tests. An alternative would have been to transform the trait values to an 
overall normal distribution. This would make it equally difficult to confirm normal 
distributions of adjusted trait values inside genotype groups; there is no recommended 
single approach (Ziegler A and König IR., 2006).  
 
The particular genes and SNPs chosen in this study might have contributed to the 
negative findings obtained. A selection of SNPs spread through the candidate genes was 
targeted; these included those previously reported to be associated with HCM phenotypes 
in other populations, as well as SNPs chosen in this study. It is not known whether these 
SNPs represent tag SNPs in the population studied, and thus it remains unclear what 
extent of variation within each candidate gene was captured by these SNPs. 
 
In the absence of knowledge of tag SNPs, it may be useful to attempt to capture the 
variation in each candidate gene by analysis of haplotypes constructed for the 
investigated SNPs. The investigator was not aware of a program which could construct 
most probable haplotypes in general pedigrees and either analyse these haplotypes for 
association, or export them in a suitable format for analysis in a separate program. 
However, an upgraded version of the program UNPHASED is allegedly proposed to be 
able to do this, but due to time constraints this was not investigated. 
 
Furthermore, it is speculated that a combination of alleles at different loci may act in 
unison to produce a much stronger effect on the clinical phenotype of a condition (Souery 
et al., 2001). These effects, called epistatic interactions, may be a potential reason for the 
failure to replicate association studies. It is quite likely that components of the RAAS 
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system interact epistatically (Ortlepp et al., 2002; Perkins et al., 2005). The RAAS 
cascade is a hormonal system with several components, each interacting to produce 
independent or synergistic effects and thus it is prudent to investigate not one component 
on its own, but several together. Time constraints did not allow the investigation of 
epistatic effects or of additional components of the RAAS, as the focus was on those that 
have been frequently investigated for a role in LVH in the literature. 
 
Additionally, as others suggested, failure to replicate positive association studies could be 
due to statistical issues such as reduced power, correcting for multiple testing, procedural 
issues involving population stratification and differences in diagnostic procedures and 
sample ascertainment. Association studies in the general population are prone to spurious 
results because of genetic heterogeneity of a population. Thus specific studies should be 
repeated in different populations to ensure that any association of a gene with a disease is 
pathogenically significant (Komiya et al., 2000).  
 
Each of the genotyping techniques used in this study has its advantages and 
disadvantages. SNaPshot analysis of a large number of SNPs in many subjects is costly; 
and although multiplexing will reduce costs considerably, optimising conditions can be 
technically challenging. Additionally, there may be a lack of correlation between 
SNaPshot and sequencing data, as shown for the two SNPs, rs4342 and rs3434, in 
fragment 2 of ACE1. There were discrepancies when the data generated by SNaPshot and 
sequencing were compared in 10% of the samples (see section 3.6). Whereas ASREA is 
presently cheaper than SNaPshot analysis, it is manual and time-consuming. A potential 
limitation to this technique is the generation of partial digests, if the restriction enzyme 
does not completely cleave the diagnostic site, for example because of the presence of 
inhibitors, inactive enzyme or other technical conditions. This will obviously confound 
interpretation of genotype and lead to errors. In the present study, this was circumvented 
wherever possible, by designing amplicons with additional invariant restriction enzyme 
sites (section 3.5.3 pg 114, AGTR1 fragment 2 rs3772627 polymorphism). 
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4.10. New resources for association studies  
HapMap project 
The human genome differs by approximately 0.1% between individuals (one variant per 
1000 nucleotide bases on average), with an estimated 10 million SNPs contributing to 
90% of the variation (Li et al., 1991; Wang et al., 1998; Cargill et al., 1999; Halushka et 
al., 1999). Thus, with current technology, genotyping all the SNPs within the genome is 
not feasible, due to cost and labour intensity. As an alternative, the use of HapMap data 
will reduce genotyping workload by targeting SNPs that show association and tag SNPs 
that capture linkage information. Genotyping one SNP in a haplotype block will provide 
enough information about the remainder of the common SNPs in that region. It is thus 
feasible to only investigate or type a few of the tag SNPs in a gene to represent other 
common haplotypes in the region. 
 
At the commencement of the present study, the HapMap project data was in its infancy, 
and the current wealth of SNP data for these candidate genes was not available. 
Additionally, it was uncertain whether HapMap tag SNPs documented for other 
populations will be relevant for the South African HCM cohort. However, the results of a 
study by Willer et al., (2006) demonstrated that selecting tag SNPs for individuals from 
Finland using the CEPH Utah samples from the HapMap database provided useful 
information, as a strong correlation was observed between the two samples. This study 
indicated that the HapMap database may be a useful tool for selecting tag SNPs for 
association studies, beyond the populations from which they were sampled (Willer et al., 
2006), although it could be argued that the Finish population and the CEPH Utah 
population would be expected to be genetically fairly similar. Moreover, a study by 
Service et al., (2007) confirmed that HapMap tag SNPs performed well in several 
population isolates that differed significantly from HapMap samples in levels of LD or 
SNP allele frequency. The study by Service and colleagues (2007) examined 12 
populations (CAU-Caucasian reference sample from the Human Variation Panel of the 
Coriell Institute, FIP-Finland nationwide, FIC-Northern Finland Birth cohort, ERF-a 
village in South Western Netherlands, NFL-Newfoundland, FIK-Finnish subisolate of 
Kuusamo, ASH-Ashkenazi, SAR-Province of Nuoro in Sardinia, SAF-Afrikaner, CR-
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Central Valley of Costa Rica, AZO-Azores, ANT-Antioquia), populations not included in 
the HapMap. However, most individuals in the present study were of Mixed Ancestry 
(Coloured individuals from the Western Cape), a population with roots in the Khoi-San, 
European, African and Malaysian populations. Thus, it remains uncertain which 
HAPMAP tag SNPs to target, as tag SNPs and tagged haplotypes do differ to some extent 
between HAPMAP populations. 
 
By chance, some of the SNPs chosen in the present study were HapMap tag SNPs (ACE1 
rs4343 in CEU population, CMA rs1885108 in CEU and Yoruba population, AGT rs699 
in CEU, CYP11B2 rs3097 in CEU, AGTR1 rs5182 in CEU, ACE2 rs4646179 in CEU). 
Although tag SNPs was not used as a selection priority in the present study, it would add 
value to future studies. As for the present study, certain tag SNPs did show association 
with particular traits, but CYP11B2 rs3097 captured no other SNPs in the CEU, AGTR1 
rs5182 captured no other SNPs in the CEU population and ACE2 rs879922 had no 
available data from HapMap database, thus providing no additional information on how 
much of the relevant gene regions had been covered.  
 
4.11. Future research  
The present study yielded interesting preliminary results that need to be followed up with 
additional gene variants in RAAS-associated genes. For example, more polymorphisms 
in a gene that contain HapMap tag SNPs should be screened in order to capture all the 
information within a whole gene. Additionally, LD tests and functional assays on the 
SNPs investigated need to be employed to verify associations observed. Prospective 
studies should measure the levels of AGTR1, CYP11B2 and ACE2 in HCM patients, 
which could add better value to the study. From the statistical results, it is difficult to 
draw conclusions as to whether ACE1, CMA and AGT are modifiers of the HCM 
phenotype because of the lack of statistically significant associations found. Genes that 
did not show association should not be excluded but be re-examined in other population 
groups. Although, previous association studies looked at the same genes investigated in 
this study, perhaps other novel genes may play a much larger role in the pathogenesis of 
this condition. Future research should include haplotype analysis, which might also make 
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an existing association more credible and clearer and should also be extended to 
candidate genes which showed no association in the current study.  
 
The present research forms part of a larger, ongoing research endeavour to elucidate the 
molecular mechanisms of LVH development in South African HCM families. 
Identification of HCM-modifying genes will not only give insight into the phenotypic 
variability among South African HCM patients, but also the molecular causes of diseases, 
such as hypertension, of which LVH is a feature. In future, these results might contribute 
to the development of new drug targets for reducing cardiac hypertrophy in the general 
population.  
 
4.12. Conclusions 
The present study failed to show significant linkage between any candidate markers 
within AGT, AGTR1, CYP11B2 and CMA and any of the 16 traits and the CWT-score 
studied. However, significant associations were found between some of these traits and 
candidate markers within AGTR1, CYP11B2 and markers within ACE2, while findings 
for association for ACE1, AGT and CMA were all statistically non-significant. The main 
findings of the present study are that some CYP11B2, AGTR1 and ACE2 polymorphisms 
are associated with LVH in patients with HCM, independent of covariates such as blood 
pressure. This study provides simultaneous evidence of linkage in the absence and 
presence of association, confirming that ACE1, but not the ACE I/D polymorphism per 
se, is a QTL for LVH development. The preliminary data should also be seen as 
experimental evidence suggestive of the role for AGTR1, CYP11B2 and ACE2 as 
modifiers of cardiac structure. 
 
The present study followed a strict design and included a larger sample size compared to 
many other studies, thus it may more accurately indicate the mechanisms involved at a 
molecular level in the development of LVH. In future, these results might have beneficial 
pharmacogenetics applications to aid new drug development.  
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APPENDIX I 
BUFFERS, MARKERS AND SOLUTIONS  
1. BUFFERS 
1.1. CELL LYSIS 
 Sucrose (Merck, RSA)       0.32M 
 Triton-X-100 (Sigma, RSA)       1% 
 MgCl2 (Merck, RSA)        5mM 
 Tris-HCl (Merck, RSA)       10mM 
 H2O          1L 
 
1.2. DNA EXTRACTION BUFFER 
NaCl (Meck, RSA)        0.1M 
Tris-HCl         0.01M 
EDTA (pH 8) (Merck, RSA)                 0.025M 
SDS (Sigma, RSA)        0.5% 
Proteinase K (Sigma, RSA)              0.1mg/ml 
 
1.3. TBE-BUFFER (10X stock) 
Tris-HCl         0.89M 
Boric Acid (Whitehead, Scientific, RSA)     0.89M 
Na2EDTA (pH 8)         20mM 
 
1.4. SB-BUFFER (20X stock) 
 di-sodium tetraborate decahydrate (Merck, RSA)      38.137g/mol 
 H2O          1L 
 
1.5. WASH BUFFER 
Tris-EDTA Buffer        10mM 
Absolute ethanol        48ml 
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1.6. ELUTION BUFFER 
Tris-HCl (pH 8)        10mM 
Autoclaved ddH2O        50μl 
 
2. MOLECULAR WEIGHT MARKER  
2.1. LAMBDA PST1  
Bacteriophage Lambda DNA (250μg) (Promega, USA)   100μl 
Buffer M (Boerhinger Mannheim, GmbH)     15μl 
PstI (Boerhinger Mannheim, GmbH)      11μl 
H2O          32μl 
Incubate at 37 oC for 2 hours followed by heat inactivation at 65oC for 5 minutes. 
Load 4μl onto 2% Agarose gel. 
 
2.2. 100 bp DNA ladder (Promega, USA)     4μl 
 
3. SOLUTIONS 
3.1. SOLUTIONS FOR POLYACRYLAMIDE GELS 
3.1.1 40% Acrylamide/ 0.8% BIS (ready to use) stock solution for polyacrylamide gels 
supplied by Merck (37:5:1) 
 
3.1.2. 10% AMMONIUMPERSULPHATE (APS) 
 APS          2g 
 H2O          20ml 
 
3.2. SOLUTIONS FOR SILVER STAINING 
3.2.1. 0.1% AgNO3 (Solution B) 
 AgNO3         1g 
 H2O          1L 
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3.2.2. DEVELOPING SOLUTION (Solution C) 
NaOH (Merck, RSA)        15g 
NaBH4 (Whitehead, Scientific, RSA)      0.1g 
Formaldehyde (Merck, RSA)       4ml 
H2O          1L 
 
4.  GELS 
4.1. AGAROSE GEL SOLUTIONS 
Concentration 1.5% 2% 3% 
Agarose (g) 1.5 2 3 
1X TBE stock 
(ml) 100 100 100 
or    
1X SB stock 
(ml) 100 100 100 
Melt agarose in microwave oven until completely dissolved, let cool for 3’ and add 5μl Ethidium 
Bromide. 
 
4.2. 12% POLYACRYLAMIDE GEL 
 40% Acrylamide-Bis (ready to use) solution     3ml 
 10X TBE         1ml 
 Distilled H2O         6ml 
 APS          80ml 
 TEMED         30ml 
 
5. LOADING DYES 
5.1. BROMOPHENOL BLUE 
 Bromophenol blue (Merck, RSA)     0.2% (w/v) 
 Glycerol (Merck, RSA)      50% 
 Tris (pH 8)        10mM 
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6.  Glossary of terms used: 
 Endocrine system = A system of glands that release their secretions 
 (peptide/hormones) directly into the circulatory system and produces its’ effects 
 on target organs located at a distance. 
 Paracrine system = After secretion, the peptide acts on its’ receptors located on 
 adjacent cells.   
 Autocrine system = After secretion, the peptide acts on its’ own receptors. 
 
7. SNaPshot analysis  
7.1. 50CM CAPILLARY CUSTOMADE RUN MODULE CONDITIONS 
  Parameter name Value Range 
1 Run temp 60 int 18 - 65 oC 
2 Cap fill volume 46 int 1-200 steps 
3 Current tolerance 100 int 1-100μAmps 
4 Run current 100 int 1-100μAmps 
5 Voltage tollerance 0.6 float 0.25-2 kVolts 
6 Pre run voltage 15 float 1-15 kVolts 
7 Pre run time 60 int 1-1000sec 
8 Injection voltage 2 float 1-15 kVolts 
9 Injection time 15 int 1-600sec 
10 Run voltage 15 float 0-15 kVolts 
11 Number of steps 10 int 1-100nk 
12 Voltage step interval 20 int 1-60sec 
13 Data delay time 200 int 1-3600sec 
14 Run time 1900 int 300-14000sec 
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8. Summary of echocardiographic traits measured at three levels and composite 
score. 
Abbreviations used: overall, at three levels and composite scores. 
Overall measures:  
LVM-left ventricle mass 
mIVS-maximum interventricular septum thickness 
mLVWT-maximum left ventricle wall thickness  
mPWT-maximum posterior wall thickness 
 
AT mitral valve level:  
mLVWTmit-maximum left ventricle wall thickness at level of mitral valve 
mIVSmit-maximum interventricular septum thickness at level of mitral valve 
pIVSmit-posterior interventricular septum thickness at level of mitral valve 
aIVSmit-anterior interventricular septum thickness at level of mitral valve  
AWmit-anterior wall thickness at level of mitral valve 
LWmit-lateral wall thickness at level of mitral valve  
IWmit-inferior wall thickness at level of mitral valve  
PWmit-posterior wall thickness at level of mitral valve 
 
At level of papillary muscle:  
mLVWTpap-maximum left ventricle wall thickness at level of papillary muscles 
mIVSp-maximum interventricular septum thickness at level of papillary muscles 
pIVSpap-posterior interventricular septum thickness at level of papillary muscles  
aIVSpap-anterior interventricular septum thickness at level of papillary muscles  
AWpap-anterior wall thickness at level of papillary muscles  
LWpap-lateral wall thickness at level of papillary muscles  
IWpap-inferior wall thickness at level of papillary muscles  
PWpap-posterior wall thickness at level of papillary muscles 
 
At level of apex:  
mLVWTapx-maximum left ventricle wall thickness at level of apex  
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IVSapx-interventricular septum thickness at level of apex  
AWapx-anterior wall thickness at level of apex 
LWapx-lateral wall thickness at level of apex  
PWapx-posterior wall thickness at level of apex  
 
Composite score:  
CWTscore-cumulative wall thickness score 
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Addendum I 
A representative example of a portion of a pedigree file for selected families showing 
covariates, three composite scores, five left ventricle wall thickness measurements and 
the genotype code for AGTR1 rs2640539. 
http://scholar.sun.ac.za
family indiv id father id mother id sex age mutation BSA (m2) Syst BP diast BP HR bpm Maron-Spirito score CWT score Wigle score post IVSmit ant IVSmit ant wallmit lat wallmit inf wallmit AGTR1 rs2640539
F101 1 3 4 1 67 T797 2.0 130.0 80.0 65.0 X 261.4 7.0 11.5 16.4 14.0 9.1 8.0 1 2
F101 2 7 8 2 55 T797 X 120.0 80.0 44.0 37.7 134.3 X X X X X X 0 0
F101 3 0 0 1 X X X X X X X X X X X X X X 0 0
F101 4 0 0 2 X X X X X X X X X X X X X X 0 0
F101 5 0 0 1 X X X X X X X X X X X X X X 0 0
F101 6 5 4 2 53 1 1.9 160.0 90.0 60.0 38.2 191.9 X 9.4 9.0 10.8 8.0 8.3 1 1
F101 7 0 0 1 X X X X X X X X X X X X X X 0 0
F101 8 0 0 2 X X X X X X X X X X X X X X 0 0
F101 9 1 2 2 X T797 X X X X X X X X X X X X 0 0
F101 10 0 0 1 X X X X X X X X X X X X X X 0 0
F101 11 10 9 1 22 1 2.0 120.0 80.0 55.0 43.4 213.1 X 11.2 10.3 10.8 9.3 8.6 1 1
F101 12 10 9 2 22 T797 1.8 100.0 60.0 80.0 118.8 398.4 10.0 25.0 32.2 21.4 12.9 7.8 1 1
F101 13 1 2 1 X T797 X X X X X X X X X X X X 0 0
F101 14 0 0 2 X X X X X X X X X X X X X X 0 0
F101 15 13 14 1 X X X X X X X X X X X X X X 0 0
F101 16 1 2 1 42 T797 2.5 X X 90.0 X X X 15.5 15.5 X X X 1 1
F101 17 0 0 2 X X X X X X X X X X X X X X 0 0
F101 18 16 17 2 19 1 2.1 100.0 70.0 85.0 31.4 185.1 X 7.1 6.6 8.6 7.6 7.6 1 1
F101 19 16 17 2 X T797 X X X X X X X X X X X X 1 1
F101 20 1 2 1 37 T797 2.5 130.0 90.0 90.0 95.5 386.7 10.0 21.4 32.3 20.2 19.4 11.6 2 2
F101 21 7 8 2 62 1 1.6 180.0 120.0 70.0 48.5 234.0 X 14.3 11.8 13.5 9.0 8.4 1 2
F101 22 7 8 2 59 T797 1.5 100.0 70.0 60.0 36.1 210.7 X 8.6 8.1 11.1 9.6 8.5 1 1
F101 23 0 0 1 X X X X X X X X X X X X X X 0 0
F101 24 23 22 2 36 T797 1.8 100.0 70.0 60.0 35.6 199.6 X 7.6 9.5 9.0 8.0 7.6 1 1
F101 25 23 22 1 31 1 2.2 130.0 85.0 70.0 37.2 204.5 X 8.1 9.5 8.4 8.0 7.4 1 1
F101 26 23 22 2 26 1 1.6 90.0 60.0 65.0 25.1 169.9 X 6.0 6.7 5.6 6.7 5.9 1 2
F101 27 7 8 2 45 T797 X 150.0 90.0 80.0 X X X X X X X X 1 1
F101 28 0 0 1 X X X X X X X X X X X X X X 0 0
F101 29 28 27 2 37 1 X X X X X X X X X X X X 1 1
F101 30 28 27 2 34 1 X X X X X X X X X X X X 1 1
F101 31 7 8 2 46 1 X X X X X X X X X X X X 1 1
F103 1 0 0 2 61 1 X X X X X X X X X X X X 1 1
F103 2 0 0 1 X X X X X X X X X X X X X X 0 0
F103 3 2 1 1 42 W92 1.5 160.0 80.0 85.0 74.8 312.5 6.0 17.4 22.0 22.4 17.4 13.0 1 1
F103 4 0 0 2 X X X X X X X X X X X X X X 0 0
F103 5 3 4 2 22 1 1.6 115.0 70.0 77.0 29.5 198.2 X 8.1 7.7 10.3 5.8 5.4 1 1
F103 6 0 0 2 X X X X X X X X X X X X X X 0 0
F103 7 3 6 2 19 W92 1.6 110.0 80.0 74.0 40.2 227.8 X 10.8 10.3 11.4 7.5 5.7 1 1
F103 8 3 4 2 23 1 1.7 120.0 70.0 67.0 35.9 213.0 X 9.6 9.1 8.8 8.2 8.0 1 1
F104 1 0 0 2 70 T797 X X X X X X X X X X X X 1 1
F104 2 0 0 1 X X X X X X X X X X X X X X 0 0
F104 3 0 0 1 X X X X X X X X X X X X X X 0 0
F104 4 3 1 1 X X X X X X X X X X X X X X 0 0
F104 5 0 0 2 X X X X X X X X X X X X X X 0 0
F104 6 2 1 1 56 T797 1.7 180.0 100.0 57.0 111.1 434.1 10.0 24.5 32.7 24.2 15.2 10.8 1 2
F104 7 2 1 1 55 1 X X X X X X X X X X X X 1 1
F104 8 2 1 1 X T797 X X X X X X X X X X X X 1 1
F104 9 2 1 2 47 1 1.8 150.0 90.0 80.0 49.3 266.4 X 11.4 13.8 12.7 9.4 8.6 0 0
F104 10 2 1 2 43 1 1.9 120.0 80.0 60.0 37.4 232.6 X 8.4 8.9 9.5 9.8 7.5 1 2
F104 11 2 1 2 41 T797 1.3 110.0 70.0 70.0 42.6 244.5 X 9.8 11.7 11.5 8.6 7.4 1 2
F104 12 0 0 1 X 1 X X X X X X X X X X X X 1 1
F104 13 12 11 2 18 T797 X X X X X X X X X X X X 1 2
F104 14 0 0 2 X X X X X X X X X X X X X X 0 0
F104 15 8 14 2 29 1 2.0 120.0 80.0 75.0 38.4 236.4 X 10.5 9.1 8.8 7.8 8.4 1 2
F104 16 8 14 2 24 T797 1.9 120.0 80.0 65.0 36.4 238.8 X 9.8 10.1 9.0 8.6 7.0 1 2
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